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ABSTRACT 
SYNTHESIS AND INTERFACIAL BEHAVIOR OF FUNCTIONAL 
AMPHIPHILIC GRAFT COPOLYMERS PREPARED BY RING-OPENING 
METATHESIS POLYMERIZATION 
 
FEBRUARY 2009 
 
KURT E. BREITENKAMP II, B.S., UNIVERSITY OF SOUTHERN MISSISSIPPI 
 
M.S., UNIVERSITY OF MASSACHUSETTS-AMHERST 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS-AMHERST 
 
Directed by: Professor Todd S. Emrick 
 
 
This thesis describes the synthesis and application of a new series of amphiphilic 
graft copolymers with a hydrophobic polyolefin backbone and pendent hydrophilic 
poly(ethylene glycol) (PEG) grafts.  These copolymers are synthesized by ruthenium 
benzylidene-catalyzed ring-opening metathesis polymerization (ROMP) of PEG-
functionalized cyclic olefin macromonomers to afford polycyclooctene-graft-PEG 
(PCOE-g-PEG) copolymers with a number of tunable features, such as PEG graft density 
and length, crystallinity, and amphiphilicity.   Macromonomers of this type were 
prepared first by coupling chemistry using commercially available PEG monomethyl 
ether derivatives and a carboxylic acid-functionalized cycloctene.  In a second approach, 
macromonomers possessing a variety of PEG lengths were prepared by anionic 
polymerization of ethylene oxide initiated by cyclooctene alkoxide.  This methodology 
affords a number of benefits compared to coupling chemistry including an expanded PEG 
molecular weight range, improved hydrolytic stability of the PEG-polycyclooctene 
linkage, and a reactive hydroxyl end-group functionality for optional attachment of 
biomolecules and probes.  
viii 
The amphiphilic nature of these graft copolymers was exploited in oil-water 
interfacial assembly, and the unsaturation present in the polycyclooctene backbone was 
utilized in covalent cross-linking reactions to afford hollow polymer capsules.  In one 
approach, a bis-cyclooctene PEG derivative was synthesized and co-assembled with 
PCOE-g-PEG at the oil-water interface.  Upon addition of a ruthenium benzylidene 
catalyst, a cross-linked polymer shell is formed through ring-opening cross-metathesis 
between the bis-cyclooctene cross-linker and the residual olefins in the graft copolymer.  
By incorporating a fluorescent-labeled cyclooctene into the graft copolymer, both oil-
water interfacial segregation and effective cross-linking were confirmed using confocal 
laser scanning microscopy (CLSM).  In a second approach, reactive functionality capable 
of chemical cross-linking was incorporated directly into the polymer backbone by 
synthesis and copolymerization of phenyl azide and acyl hydrazine-functional 
cyclooctene derivatives.  Upon assembly, these reactive polymers were cross-linked by 
photolysis (in the phenyl azide case) or by addition of glutaraldehyde (in the acyl 
hydrazine case) to form mechanically robust polymer capsules with tunable degradability 
(i.e. non-degradable or pH-dependent degradability).  This process permits the 
preparation of both oil-in-water and water-in-oil capsules, thus enabling the 
encapsulation of hydrophobic or hydrophilic reagents in the capsule core.  Furthermore, 
the assemblies can be sized from tens of microns to the 150 nm - 1 µm size range by 
either membrane extrusion or ultrasonication techniques.  These novel capsules may be 
well-suited for a number of controlled release applications, where the transport of 
encapsulated compounds can be regulated by factors such as cross-link density, 
hydrolytic stability, and environmental triggers such as changes in pH. 
ix 
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CHAPTER 1 
SYNTHETIC POLYMERS FOR ENCAPSULATION AND DELIVERY 
1.1 The Role of Synthetic Polymers in Drug Delivery 
Advances in modern medicine for the treatment of human illness continue to 
improve the length and quality of human life.  While new therapeutic agents play a major 
role in these advances, drug delivery strategies also represent key components of 
successful treatments.  Synthetic polymers are important for implementing delivery 
strategies and hold significant promise for enhancing the therapeutic benefits of current 
and future drugs.
1
 While polymer-based drug delivery systems provide a means to 
improve the bioavailability, safety, and efficacy of drug therapy, several important 
problems are currently under investigation.   For example, a number of strategies are 
being developed to improve the controlled nature of therapeutic delivery to include long 
time periods, predetermined time intervals, and response to physiological changes.
2-4
  In 
addition, functional polymer materials are being designed to provide targeted drug 
delivery mechanisms with a specificity that simultaneously promotes healing and 
diminishes unwanted side effects.
5
 
 Since the introduction of polymer-based drug delivery principles by Ringsdorf 
and coworkers,
6,7 
polymer therapeutics have expanded considerably in scope and are now 
poised to revolutionize medical treatment protocols.  Synthetic polymers have been 
important for implementing delivery strategies currently used in the clinic and will 
continue to be significant in designing drug delivery systems in the future.  Figure 1.1 
illustrates several different polymer-based systems that are currently being utilized for 
therapeutic delivery.  In one approach, drugs can be attached directly to a polymer 
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backbone (i.e. polymer-drug conjugation) to improve their solubility and greatly improve 
their pharmacokinetic profiles.
8
  Recent polymer-drug conjugation techniques make use 
of branched polymer architectures (e.g. star, graft and dendritic) which dramatically 
increase drug payloads and allow for the attachment of bioactive functionality such as 
cell targeting groups or cell permeation enhancers.  Polymers also serve as key building 
blocks in the production of encapsulating delivery systems such as polymer 
microparticles, micelles, and capsules which can be tailored, through appropriate 
chemistries, to control the release of the therapeutic at the site of disease and/or over long 
time periods (e.g. from hours to days) following administration.  
 
Figure 1.1  Polymer architectures and encapsulation techniques for therapeutic 
delivery 
 
 
Polymeric drug delivery systems offer great flexibility with regard to their 
chemistry and physical properties and have been tailored to suit a number of different 
therapeutic applications.  While polymeric delivery systems possess unique attributes, 
they also share many common requirements such as biocompatibility (e.g. low toxicity 
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and immunogenicity) and the ability to control the release of therapeutics over time 
and/or in response to physiological changes.  The development of future polymer-based 
delivery systems will capitalize on many of these existing technologies and focus on 1) 
expanding the range of drugs that can be formulated and administered, 2) targeting drug 
release at the diseased site or inside diseased cells using physiological triggers, and 3) 
developing delivery systems with cell-targeting moieties, such as antibodies, peptides, 
and aptamers that actively bind to diseased cells and tissue.  The objective of such efforts 
is to concentrate drug delivery at the site of disease, thus improving drug efficacy while 
reducing toxic side effects.  To produce such advanced delivery systems, a shifted 
interest from conventional, off-the-shelf polymer materials to the rational design and 
synthesis of new, multi-functional polymers is anticipated.  
1.1.1 Conjugation of Polymers to Drugs and Delivery Systems 
One of first significant demonstrations of synthetic polymer drug delivery was 
reported in 1977 when Abuchowski and coworkers described the covalent linking of 
poly(ethylene glycol) (PEG) to bovine serum albumin (BSA) (shown in Figure 1.2A).
9,10
  
Following conjugation, a dramatic reduction in immunogenicity was observed in the 
PEG-conjugated BSA compared to the unmodified protein, and this “PEGylation” 
strategy was quickly applied to other therapeutic proteins that were previously unusable 
due to their immunological toxicity.
11,12  
Since these early discoveries, many studies have 
validated PEGylation of small molecule drugs and biomolecules for improving water-
solubility of the drug and extending in vivo circulation time by slowing the metabolism 
and renal clearance of the conjugated therapeutic.
13  
PEGylation has been particularly 
successful for protein- and gene-based conjugations as the non-conjugated versions are 
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highly immunogenic and susceptible to rapid in vivo degradation following 
administration.  In fact, several PEGylated protein drugs have been approved in the U.S., 
with additional PEGylated therapeutics currently undergoing clinical trials.
14 
As in the case of protein therapeutics, the attachment of poly(ethylene glycol) to 
drug delivery systems has also been shown to improve in vivo stability and extend 
circulation times.  For example, liposomes emerged in the 1970’s as a potentially 
revolutionary method of delivering therapeutics, but their clinical implementation was 
slowed by their poor stability in vivo and rapid clearance from the bloodstream by the 
reticuloendothelial system (RES).  The incorporation of PEG into liposomes using 
PEGylated phospholipids (shown in Figure 1.2B) addressed many of these shortcomings 
and led to the development of Stealth? liposomal technology which has been utilized in 
several delivery systems for cancer treatment such as Doxil
15 
and Myocet.
16
 
 
Figure 1.2  Examples of polymer-based drug delivery systems in use today 
 
 
While PEGylation is typically limited to conjugation reactions involving the PEG 
chain-ends, a number of new conjugate systems, based on well-defined polymer 
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architectures, are emerging in which drugs are attached pendent to the polymer backbone 
or as the chain-ends of branched polymers and dendrimers.  These systems offer 
enhanced drug payload per molecule and also improve the blood solubility, circulation 
time, and efficacy of small molecule drugs.  For example, poly(N-(2-
hydroxypropyl)methacrylamide) (HPMA) drug conjugates, illustrated in Figure 1.2C, 
were reported by Duncan and coworkers and have shown good promise in clinical 
trials.
17  
The covalent coupling of chemotherapy drugs such as doxorubicin (DOX) and 
paclitaxel to these HPMA copolymers resulted in increased uptake into tumor cells 
relative to non-conjugated DOX, an observation attributed to the enhanced permeability 
and retention (EPR) effect.
18,19
  The EPR effect results from the disorganized nature of 
the tumor vasculature which leads to an increased permeability to polymer 
therapeutics.
20,21 
 Poor lymphatic drainage in the tissue allows drug retention at the tumor 
site.  The EPR effect is a unique feature of polymer-based therapeutics, which arises from 
increased blood circulation times of the polymer-drug conjugate relative to their non-
conjugated analogues. 
The manipulation and control of polymer architecture offers exciting 
opportunities in drug delivery.  Conjugates based on branched polymer architectures are 
particularly interesting, as these polymers possess 1) multiple chain-ends for drug 
attachment, and 2) the potential for engineering degradation sites and cell targeting 
moieties into the structure.
22-25  
In this context, dendritic polymers are unique, as their 
highly branched structure leads to a large number of chain-ends for drug attachment.  In 
addition, the uniform molecular weight distribution of dendrimers, reminiscent of 
proteins, makes them special relative to conventional linear polymers, providing a well-
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characterized molecular platform that is appealing for medical applications.  Fréchet and 
coworkers are among the leaders in designing dendrimers for drug delivery and have 
reported several examples of water-soluble, polyester-based dendrimer-DOX 
conjugates.
26,27  
These conjugates are modular by design and can be equipped with higher 
drug payloads than linear polymer-drug conjugates, as well as chain-end solubilizing 
groups and cell-targeting moieties.  The utility of dendrimer-DOX conjugates was 
demonstrated through in vitro models, which showed dramatically increased serum half-
life compared to free DOX, as well as anti-proliferation effects in cancer cells.  In 
preliminary in vivo studies, dendrimer-drug conjugates were well-tolerated in mice, and 
showed no accumulation in liver, heart, or lung tissue.
28
 
1.1.2 Encapsulation and Release Strategies using Polymeric Delivery Systems 
Another therapeutic delivery approach involves the encapsulation and release of 
drugs within a synthetic polymer matrix or membrane.  Delivery methods based on this 
approach are well-suited for controlled release applications, in which the encapsulating 
polymer is designed to release the encapsulated drug over some time period or in 
response to changing pH, ionic strength, or temperature.  Precisely regulating drug 
release following injection aids in producing more effective therapies while also reducing 
the possibilities of under- and overdosing.  An additional feature of controlled-delivery 
systems is a reduction in dosing frequency which often improves patient compliance with 
the treatment. 
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1.1.2.1 Delivery Systems Based on Polymer Microspheres  
The use of biodegradable polymers such as aliphatic polyesters (e.g. polylactide
29
 
and poly(lactide-co-glycolide)),
30 
polyorthoesters,
31 
and polyanhydrides
32
 for 
microsphere-based delivery systems has been studied widely.  The advantage of such 
polymers is their degradation into biocompatible molecules that can be metabolized 
readily and excreted.  In addition, microsphere degradation and subsequent release rates 
can be tuned through appropriate control of polymer synthesis and composition.  Drug-
loaded microspheres can be prepared by emulsion
33
 or spray-drying
34
 techniques which 
permit the encapsulation of a wide range of therapeutics including small molecule drugs 
and proteins.  Drug release from degradable polymer microspheres is controlled by two 
separate mechanisms.  As shown in Figure 1.3A, the drug can be released by simple 
diffusion (i.e. through pores or between polymer chains).  Degradation of the polymer 
matrix over time, shown in Figure 1.3B, also stimulates drug release in a time-dependent 
manner.  Microparticles based on degradable polymers have led to several clinically used 
therapeutics including injectable formulations such as Lupron Depot for prostate cancer 
and endometriosis treatment,
35 
 and inhalable forms of insulin
36
 (e.g. Exubera) for 
diabetes treatment. 
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Figure 1.3  Illustration of drug release mechanisms from polymer microspheres 
 
 
In addition to biodegradable polymer microspheres, other controlled release 
strategies have been developed which offer many advanced features beyond simply 
controlling release rates over time.  For example, Peppas and coworkers have synthesized 
polymer micro- and nanospheres using poly(methacrylic acid)-graft-poly(ethylene 
glycol) (PMAA-g-PEG) copolymers that control drug release based on changes in the 
physiological environment.
37,38 
 These materials have proven suitable for oral delivery 
systems since the drug is effectively encapsulated at low pH values in the stomach and 
rapidly released at higher pH values encountered in the gastrointestinal tract.  As shown 
in Figure 1.3C, PMAA and PEG segments complex in strongly acidic environments to 
form collapsed networks with very small inter-chain distances between polymers.  Inter-
polymer complexation within the spheres limits therapeutic release until the carrier 
reaches the gastrointestinal tract, where the pH is elevated to approximately 6 or higher.  
The increase in pH reverses complexation, which allows the particles to swell and release 
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their contents.
39,40  
Using pH-responsive delivery systems, formulations of proteins and 
small molecule drugs have been developed, including an oral dosage form of insulin,
41,42 
which has proven to be an effective alternative to traditional injectable diabetes therapies. 
1.1.2.2 Encapsulation Systems Based on Block Copolymer Assembly 
An emerging effort in polymer therapeutics centers on drug encapsulation using 
polymer assemblies.  Both block copolymers and functional polymers of complex 
architectures can be used as precursors to micro- and nanoscale drug delivery vehicles.  
For example, amphiphilic triblock copolymers known as Pluronics,
®
 composed of 
poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide), are the 
polymers of choice for a number of researchers working on polymer therapeutics.  In 
water, these amphiphilic copolymers assemble by multimolecular micellization when 
present in solution above the critical micelle concentration (CMC).  As shown in Figure 
1.4 (top), the hydrophobic poly(propylene oxide) block collapses to form the micellar 
core, while the hydrophilic PEG blocks form a peripheral corona.  These core-shell 
polymer micelles have been used to encapsulate small molecule drugs, polypeptides, and 
polynucleotides.
43-45
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Figure 1.4  Aqueous assembly of amphiphilic triblock and diblock copolymers 
 
 
A variety of amphiphilic diblock copolymers self-assemble in aqueous solution to 
form nano- and micron-sized structures, with applications ranging from drug 
encapsulation to artificial viruses and cells.
46  
While PEG is most often used as the 
hydrophilic segment, a variety of hydrophobic core-forming blocks can be used, 
providing a means to tune features such as drug loading, stability, and release 
characteristics.
46-48  
Figure 1.4 (bottom) illustrates a PEG-b-poly(?-caprolactone) (PEG-b-
PCL) diblock copolymer, where the PCL core encapsulates and solubilizes hydrophobic 
compounds such as indomethacin
49
 and DOX.
50
  Eisenberg and coworkers used PEG-b-
PCL copolymers to demonstrate in vitro delivery of organic dyes to intracellular 
compartments.
51  
Issues to address for present and future development of block 
copolymer drug delivery vehicles include 1) improved stability of the assembly upon 
dilution in the bloodstream, 2) higher drug payload, and 3) improved targeting by 
integration of cell-seeking functionality into these structures.  Wooley and coworkers are 
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among the research groups addressing these issues through novel synthesis, for example 
by covalently cross-linking a poly(acrylic acid) (PAA) micellar corona about a poly(?-
caprolactone) core to form shell-cross-linked nanoparticles (SCNs).
52  
The cross-linking 
imparts stability to the nanostructures, and removal of the polyester core by hydrolysis 
significantly increases the encapsulation volume.   
In an effort to produce improved cancer-targeting treatments, several groups have 
reported the development of stimuli-responsive, drug-loaded polymer micelles that 
respond to environmental pH changes.
53,54
  Acid-sensitive delivery systems designed to 
target drug release inside cancerous tissues and cells are of clear clinical interest since 
these carriers limit harmful side effects and can also bypass many of the cellular 
mechanisms responsible for multi-drug resistance.
55,56
  In one example, Kataoka and 
coworkers synthesized PEG-b-poly(aspartic acid) with pendent doxorubicin linked via 
pH-sensitive hydrazone groups.
57
  This polymer micelle-conjugate hybrid retains DOX in 
the blood (pH 7.4) but rapidly liberates DOX upon hydrazone hydrolysis in the late-early 
endosome (pH ~ 5.0 - 6.0).  Other pH gradients exist within solid tumors due to elevated 
glycolytic rates and lactic acid production compared to healthy cells.  These factors, 
along with poor lymphatic drainage present in cancerous tissue result in an excess of 
lactic acid and a subtle pH gradient between the blood and the solid tumor 
microenvironment (pH 6.0 - 7.0).
58 
 Fréchet and coworkers have developed PEG-
dendrimer micelles which possess acid-sensitive acetal functionality on the dendrimer 
periphery to exploit such pH gradients.
59
  When the dendritic portion is protected with a 
hydrophobic acetal moiety, the copolymers assemble in water with the dendrimer portion 
forming the micelle core and the PEG creating the micelle corona.  In acidic 
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environments, such as those encountered in solid tumors, the acetal functionality is 
hydrolyzed rapidly, exposing the hydroxyl functionality in the micelle core leading to 
micelle dissociation and drug release.  Thus far, pH-responsive micelles based on this 
acetal protecting scheme have been utilized to encapsulate small-molecule 
chemotherapeutics such as doxorubicin.  It is anticipated that pH sensitive delivery 
systems, coupled with the EPR effect, could represent an effective method for limiting 
drug release to solid tumors and may potentially lead to future clinical successes.  
1.1.2.3 Polymer Capsules as Drug Delivery Platforms 
Capsules and vesicles derived from polymer-based materials are well-suited for 
many delivery applications because of their mechanical stability and tunable chemistries 
that can provide control over degradation rates, charge, and cross-linking.  Like polymer 
microspheres, capsules made from polymeric materials can be designed to release active 
agents over defined time periods, or in response to environmental changes.   Capsules are 
distinguished by a characteristic hollow core with a polymeric membrane that can be 
utilized for the release of an encapsulated agent.   
A number of methods exist to produce hollow polymer capsules.
60
  A well-studied 
method of capsule production employs oil-water emulsion techniques in conjunction with 
interfacial polymerization reactions on the droplet surface.   For example, capsules have 
been produced by the interfacial condensation polymerization of oil-soluble carboxylic 
acid chlorides and water-soluble di- and tri-amines to form hollow capsules with 
nanometer to micron-thick polyamide shells.
61  
Free radical polymerization techniques 
such as emulsion and suspension polymerization can also produce hollow capsules with 
micron-thick polymer shells when the polymer is immiscible with the dispersed and 
  13 
continuous phases.
62,63  
The production of polymer capsules using these synthetic 
methodologies requires harsh reaction conditions (e.g. high temperature and highly 
reactive reagents such as acid chlorides and free radical initiators) that can compromise 
sensitive, encapsulated agents.  In most cases, interfacial and emulsion polymerization 
techniques are also difficult to control with regards to capsule size, wall thickness, and 
wall uniformity, all of which are critical design parameters in controlled release systems.  
To circumvent these problems, there has been growing interest in producing 
polymer capsules using precisely controlled assembly techniques.  Several examples of 
capsules produced using a self-assembly approach are illustrated in Figure 1.5.  These 
include micron-sized capsules prepared by layer-by-layer (LbL) deposition of 
polyelectrolytes onto a sacrificial liquid
64
 or colloidal core (Figure 1.5A),
65
  the 
interfacial assembly of polymers and/or colloidal particles (Figure 1.5B),
66 
and 
polymersomes produced through aqueous self-assembly of diblock copolymers (Figure 
1.5C).
67,68  
Many of these polymer capsules can be further functionalized with cell 
targeting groups or diagnostic agents and then cross-linked to improve overall stability. 
Such systems can be designed for dual use applications whereby drugs and contrast 
agents can be incorporated into a single delivery system.  For example, Gaponik and 
coworkers have reported new methods for producing LbL capsules which incorporate 
fluorescent quantum dots.
69  
Preliminary in vitro studies using human cancer cells have 
demonstrated effective cell uptake and fluorescence response of the capsules, and the 
development of systems such as this may hold future promise for simultaneous diagnosis 
and treatment of cancer.  
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Figure 1.5  Examples of polymer micro- and nanocapsules 
 
To date, most capsules produced using assembly techniques possess diameters of 
greater than one micron.  Future developments in capsule production for in vivo 
applications will likely focus on generating capsules on the nanometer size scale.  The 
advantages of nanoscale delivery systems are numerous and include tumor-selective 
delivery resulting from the EPR effect and reduced clearance from the bloodstream by 
the RES and other biological pathways.  Polymersomes, for example, can be sized from 
the multi-micron scale down to 100 nm or less by extrusion through a track-etch 
membrane, a technique first used with liposomes.
70  
In another approach, illustrated in 
Figure 1.5D, Möhwald and coworkers developed nanometer sized capsules by radial 
growth and cross-linking of polymers from degradable nanocrystal templates.  Following 
core-removal, hollow nanocapsules with a very well defined diameter and wall thickness 
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were produced.
71  
Many of these approaches to produce hollow polymer capsules will be 
discussed further in Chapter 3. 
1.2 Thesis Outline 
This thesis describes the synthesis and application of a new series of amphiphilic 
graft copolymers with a hydrophobic polyolefin backbone and pendent hydrophilic PEG 
grafts.  As discussed in Chapter 2, these copolymers are synthesized by ruthenium 
benzylidene-catalyzed ring-opening metathesis polymerization (ROMP) of PEG-
functionalized cyclic olefin macromonomers to afford polycyclooctene-graft-PEG 
(PCOE-g-PEG) copolymers with a number of tunable features, such as PEG graft density 
and length, crystallinity, and amphiphilicity.   Macromonomers of this type were 
prepared first by coupling chemistry using commercially available PEG monomethyl 
ether derivatives and a carboxylic acid-functionalized cyclooctene.  In a second approach, 
macromonomers possessing a variety of PEG lengths were prepared by anionic 
polymerization of ethylene oxide initiated by cyclooctene alkoxide.  This methodology 
affords a number of benefits compared to coupling chemistry including an expanded PEG 
molecular weight range, improved hydrolytic stability of the PEG-polycyclooctene 
linkage, and a reactive hydroxyl end-group functionality for optional attachment of 
biomolecules and probes.  For example, in a few steps, the reactive hydroxyl end-group 
was converted to carboxylic acid functionality and used in solid-phase chemistry to 
synthesize a PEG-functional cyclic olefin with a terminal RGD-containing oligopeptide.  
This unique macromonomer was subsequently copolymerized to produce graft 
copolymers with both pendent PEG and oligopeptide functionality.  The ability to tune 
PEG molecular weight and density and to incorporate bio-functionality may be 
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particularly useful when preparing polymer capsules for delivery applications, as well as 
in implantable biomaterials made from unsaturated PCOE graft copolymers or 
hydrogenated polyethylene-based graft copolymers.   
As described in Chapter 3, the amphiphilic nature of these graft copolymers was 
exploited in oil-water interfacial assembly, and the unsaturation present in the 
polycyclooctene backbone was utilized in covalent cross-linking reactions to afford 
hollow polymer capsules.  In one approach, a bis-cyclooctene PEG derivative was 
synthesized and co-assembled with PCOE-g-PEG at the oil-water interface.  Upon 
addition of a ruthenium benzylidene catalyst, a cross-linked polymer shell is formed 
through ring-opening cross-metathesis between the bis-cyclooctene cross-linker and the 
residual olefins in the graft copolymer.  By incorporating a fluorescent-labeled 
cyclooctene into the graft copolymer, both oil-water interfacial segregation and effective 
cross-linking were confirmed using confocal laser scanning microscopy (CLSM).  In a 
second approach, reactive functionality capable of chemical cross-linking is incorporated 
directly into the polymer backbone by synthesis and copolymerization of phenyl azide 
and acyl hydrazine-functional cyclooctene derivatives.  Upon assembly, these reactive 
polymers can be cross-linked by photolysis (in the phenyl azide case) or by addition of 
glutaraldehyde (in the acyl hydrazine case) to form mechanically robust polymer capsules 
with tunable degradability (i.e. non-degradable or pH-dependent degradability).  This 
simple interfacial assembly and cross-linking approach to produce capsules is particularly 
attractive when compared to more widely used methods such as LbL assembly which 
requires a multi-step assembly and removal of the core.  This process also permits the 
preparation of both oil-in-water and water-in-oil capsules, thus enabling the 
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encapsulation of hydrophobic or hydrophilic reagents in the capsule core.  These novel 
capsules may be well-suited for a number of controlled release applications, where the 
transport of encapsulated compounds can be regulated by factors such as cross-link 
density, hydrolytic stability, and environmental triggers such as pH and temperature. 
The application of phenyl azide-containing PCOE-g-PEG copolymers as coatings 
for commercially available poly(vinylidene fluoride) ultrafiltration (PVDF-UF) 
membranes is described in Chapter 4.  The structure and tunable nature of these graft 
copolymers, in terms of PEG graft density and cross-linkable functionality, make it 
particularly applicable for enhancing the properties of existing polymer membranes with 
regards to membrane fouling.  Photo-cross-linking of the graft copolymer coating makes 
them resistant to delamination from the underlying membrane, which in turn reduces 
fouling of the membrane when compared to uncoated PVDF-UF membranes. 
Chapter 5 describes the synthesis of a ruthenium benzylidene metathesis catalyst 
made amphiphilic by ligand exchange of Grubbs’ Generation II catalyst with PEG-
substituted pyridine ligands.  The PEG-substituted catalyst represents a unique 
combination of the enhanced reactivity given by a N-heterocyclic carbene (NHC) ligand 
and the amphiphilicity imparted by PEGylation.  The catalyst is soluble in both organic 
and aqueous solvents and effectively polymerizes cyclic olefins in both dichloromethane 
and water.  In dichloromethane, polymers with low PDIs are obtained, suggesting a 
controlled or ‘‘living’’ polymerization similar to the 3-bromopyridine-substituted 
Grubbs’ Generation III catalyst.  The polymerization of cyclic olefins in water proceeds 
rapidly but without the fine molecular weight control observed in the dichloromethane 
case.  
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CHAPTER 2 
SYNTHESIS OF PEG-FUNCTIONALIZED CYCLIC OLEFINS AND PEG-
GRAFTED POLYOLEFINS 
2.1 Polymer Architectures 
Advances in synthetic polymer chemistry have led to a number of diverse 
polymer architectures that have dramatically expanded the range and scope of polymer 
properties and their applications.  Well-defined polymers possessing two or more 
chemically-linked polymeric components as well as a number of branched polymer 
architectures are now accessible using a variety of currently available polymerization 
techniques.  The advent of these chemically sophisticated polymers has thus enabled the 
development of highly advanced materials with tunable macro-, micro-, and nanoscale 
features.
1
  Through chemical tailoring of composition and architecture, polymeric self-
assembly, both in the bulk and solution, can now be controlled with extraordinary levels 
of precision.   Polymer self-assembly has evolved to the level of being a viable tool to 
prepare materials for a wide array of applications in electronics,
2 
alternative energy 
sources,
3 
and biotechnology.
4
 
By synthetically tailoring polymer composition, molecular weight, branching, and 
functionality, polymer architectures, and their resulting material properties, can be tuned 
to suit an expanding number of applications.  Several examples of polymer architectures 
commonly encountered in modern polymer chemistry are illustrated in Figure 2.1.  
Unlike linear homopolymers, which are often limited in chemical tunability and 
functionalization capacity, polymers based on block, star, graft, and dendritic 
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architectures are appealing since their properties can be varied through the incorporation 
of numerous polymer segments and functional chain-ends. 
 
Figure 2.1  Examples of several common polymer architectures  
 
 
In biotechnology, many of these polymer architectures are well-suited for a 
number of applications where the synergistic blending of properties imparted by one or 
more different polymer or biological components can enhance properties such as 
biocompatibility, mechanical strength, or responsiveness to physiological stimuli.  The 
design of synthetic biomaterials based on block, star, and dendritic copolymers has 
accelerated tremendously during the past decade with many new materials emerging for 
applications in drug delivery,
5 
implantation,
6 
and tissue regeneration.
7  
For example, block 
and graft copolymers that utilize water-soluble polymers such as poly(ethylene glycol) 
(PEG) in conjunction with biodegradable polymers such as aliphatic polyesters,
8 
poly(ortho esters),
9 
and polyamino acids
10
 have been utilized extensively for the delivery 
of hydrophobic drugs
11
 as well as structural materials for cartilage and muscular repair.
12  
Further functionalization of these synthetic polymers with biological ligands (e.g. 
streptavidin/biotin, peptides, polysaccharides) has been shown to greatly improve 
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biocompatibility and/or illicit desirable interactions between the material and biological 
components (e.g. cells, proteins, antibodies, etc.).
13-15  
Many of these advanced 
biomaterials offer a number of advantages over traditional materials and may potentially 
lead to future clinical products for disease diagnosis and/or treatment.  
Like block and star copolymers, graft copolymers also possess multiple polymer 
components and in many cases can contain higher quantities of chemical functionality 
with a wider range of tunable properties through control of the pendent grafts.  These 
features present a number of obvious advantages when designing synthetic biomaterials 
such as the ability to incorporate numerous pendent grafts that can enhance water 
solubility or elicit biological functions.  
Graft copolymers can be prepared by several synthetic methods such as post-
polymerization grafting approaches and direct polymerization of macromonomers as 
shown in Figure 2.2.   Post-polymerization “grafting-to” methods utilize reactive 
functionality on the polymer backbone for covalent attachment of pendent polymer 
grafts.
16-18  
In the “grafting-from” method, the polymerization of additional monomers is 
initiated from functionality present on the polymer backbone.
19,20  
These synthetic 
methods are often not ideal since post-polymerization reactions suffer from limitations 
such as poor grafting efficiency as well as numerous side-reactions that may result in the 
presence of homopolymer contaminants or cross-linking.   
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Figure 2.2  Synthetic methodologies commonly used to prepare graft copolymers 
 
 
In contrast to post-polymerization grafting reactions, the polymerization of 
macromonomers represents a more convenient and effective method of synthesizing graft 
copolymers since pendent grafts are incorporated directly through polymerization or 
copolymerization of the macromonomer itself.
21,22
  Thus, better control over graft density 
is possible, and if complete macromonomer conversion is achieved, the removal of 
homopolymer contaminants can be avoided.  By varying the concentration of 
macromonomer with respect to other comonomers, physical properties such as 
crystallinity, mechanical strength, and solubility can be tuned considerably.   Graft 
copolymers have been synthesized by a number of polymerization chemistries.   Recent 
examples include the ring-opening metathesis polymerization (ROMP) of norbornene 
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macromonomers containing polystyrene (PS) and PEG-b-PS grafts prepared by Gnanou 
and coworkers,
23,24 
PEG-grafted polyolefins prepared by acyclic diene metathesis 
(ADMET) polymerization of PEG-functional a,?-dienes,25 and poly(methyl 
methacrylate) functionalized with integrin-binding RGD (arginine-glycine-aspartic acid) 
oligopeptides prepared by free radical polymerization.
26
 
2.1.1 Olefin Metathesis and the Synthesis of Polyolefin Graft Copolymers by ROMP 
In recent years, olefin metathesis reactions (shown in Figure 2.3A) have emerged 
as powerful tools for C-C bond formation in organic and polymer synthesis.  In organic 
synthesis, ring-closing metathesis (RCM) and cross-metathesis (CM) reactions represent 
effective methods for the preparation of complex organic molecules that are difficult to 
prepare by other methods.
27-29 
 In polymer synthesis, ROMP
30-32
 and ADMET
33,34
 offer 
convenient routes to functionalized polyolefins not attainable by conventional olefin 
polymerization methods (e.g. Ziegler-Natta and metallocene-based catalysis). 
 
Figure 2.3  A) Examples of olefin metathesis reactions utilized in organic and 
polymer chemistry, B) mechanism of olefin metathesis 
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Olefin metathesis is achieved through interconversion of an olefin and a metal 
alkylidene catalyst as illustrated in Figure 2.3B.  This “scrambling” of double bonds is 
believed to proceed through a metallo-cycloobutane intermediate by alternating 
cycloadditions and cycloreversions.
  
Early metathesis catalyst systems based on transition 
metals salts of titanium, tungsten, and ruthenium were only capable of performing a 
limited scope of metathesis reactions and possessed low catalytic activity.
35,36  
These 
limitations, along with deeper insights into the metathesis reaction mechanism,
37 
inspired 
the development of highly active, structurally well-defined organometallic metathesis 
catalysts.   One of the first such catalysts to gain widespread acceptance was 
(NAr)(OR’)2Mo=CHR (Ar = 2,6-Pr
i
2-C6H3, R = CMe2-Ph, and R’ = C(CH3)(CF3)2) 
developed by Schrock and coworkers.
38  
This catalyst displayed unprecedented reactivity 
towards olefins but was also sensitive to oxygen, water, and many polar functionalities 
that prevented its widespread use.  Subsequent discoveries of well-defined, functional 
group tolerant ruthenium catalysts
39-41
 by Grubbs and coworkers (shown in Figure 2.4) 
have resulted in the widespread adoption of the metathesis reaction in organic and 
polymer synthesis.  In particular, state-of-the-art ruthenium benzylidene catalysts II and 
III possess similar or better olefin reactivity as compared to earlier molybdenum-based 
catalysts, are relatively stable to air and water, and are compatible with most polar 
organic functionality.  Grubbs, Schrock, and Chauvin were awarded the 2005 Nobel Prize 
in Chemistry for the development of these well-defined metal alkylidene catalysts and the 
elucidation of the olefin metathesis mechanism. 
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Figure 2.4  Ruthenium benzylidene catalysts commonly used in olefin metathesis 
 
 
The unprecedented functional group tolerance of new Ru-based catalysts has 
permitted the ROMP of cyclic olefins containing a multitude of polar functionalities, 
including many with applications in biology.
 
 Prior syntheses of cyclic olefin 
macromonomers with biologically significant functionality have been performed 
exclusively on substituted norbornene derivatives.  For example, polynorbornene with 
poly(ethylene glycol) grafts was prepared by Gnanou and coworkers,
42 
oligopeptide 
functional polynorbornene was prepared by Grubbs and coworkers,
43 
and saccharide-
bearing polynorbornenes were prepared by Kiessling and coworkers.
44 
 The effectiveness 
of norbornene polymerization is attributed to its high ring strain (27.2 kcal/mol
 45
)
 
which 
allows for living polymerization with Schrock-type molybdenum catalysts
38,46
 and by 
Grubbs’ Generation I and III ruthenium catalysts.
39,41,47
   
2.2 Synthesis of Polycyclooctene Graft Copolymers 
In contrast to polynorbornene-based copolymers, graft copolymers synthesized 
from low-strain monocyclic olefin (e.g. cyclopentene (6.8 kcal/mol
 48
), cis-cyclooctene 
(7.4 kcal/mol
 48
),
 
and cyclooctadiene (13.3 kcal/mol
 48
)) macromonomers have not been 
exploited due to slower rates of initiation and facile secondary metathesis reactions that 
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have led to only a few reports of their controlled polymerization.
49,50
  Nevertheless, 
polymers and copolymers synthesized from monocyclic macromonomers are of interest 
since hydrogenation of the unsaturated backbone gives graft copolymers of polyethylene 
(PE), a polymer widely utilized due to its inherently robust and tunable mechanical 
properties.  The incorporation of hydrophilic grafts such as PEG and oligopeptides could 
represent a convenient method to improve the biocompatibility of PE-like polymers, 
which are used as structural and implantable materials in, for example, joint 
replacements,
51 
and ocular applications.
52
   
PEG-grafted polyolefins are also of interest because of their inherent amphiphilic 
properties, imparted by the combination of a hydrophobic polymer backbone and 
hydrophilic PEG grafts.  These unique copolymers have been shown to segregate to the 
oil-water interface and can stabilize polymer particles for weeks to months.  For example, 
Gnanou and workers utilized a PEG-grafted norbornene macromonomer as a reactive 
surfactant in the dispersion and emulsion polymerization of norbornene and 
cyclooctadiene.
53  
They demonstrated that the incorporation of PEG grafts into the 
copolymer was a key parameter in obtaining stable polymer particles with consistent size 
and morphology. 
This thesis describes the first recorded efforts to synthesize and characterize 
polycyclooctene-graft-poly(ethylene glycol) (PCOE-g-PEG) copolymers.  Several 
potential applications for PCOE-g-PEG graft copolymers were envisioned at the outset of 
the project.  As previously discussed, the synthesis and hydrogenation of PCOE-g-PEG 
copolymers yields polyethylene-g-PEG (PE-g-PEG), a semi-crystalline polymer with 
tunable hydrophilicity based on the number and length of PEG grafts.  In addition, the 
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amphiphilic nature of these graft copolymers provided a potential route for assembly at 
the oil-water interface.  The residual olefins in the polycyclooctene backbone proved 
useful for post-polymerization cross-linking reactions at the oil-water interface.  It was 
later found that these unsaturated PCOE-g-PEG copolymers were excellent candidates for 
use as anti-fouling coatings for commercial water purification membranes.  The low glass 
transition temperature of the PCOE backbone, which imparts suitable film forming 
properties, and the hydrophilic PEG grafts, which minimize membrane surface fouling, 
were key elements in this project. 
2.3 Synthesis of PEGylated Cyclooctene Macromonomers 
2.3.1 Synthesis of Ester-linked PEG-functional Cyclooctene Macromonomers  
The initial strategy to prepare PEG-substituted cyclooctene macromonomers 
involved a two-step synthetic procedure starting from 5-hydroxy-1-cyclooctene (1)
54 
as 
illustrated in Scheme 2.1.  Ring-opening of succinic anhydride by 1 in the presence of 4-
dimethylaminopyridine (DMAP) gave the corresponding carboxylic acid 2.  This was 
followed by esterification with PEG-monomethyl ethers under dicyclohexylcarbodiimide 
(DCC) coupling conditions.  While this provided an efficient route to preparing 
PEGylated cyclooctene macromonomers, initial polymerization chemistry with catalyst I 
led to rapid gelation and intractable materials.  The contamination of commercially 
available mPEGs with appreciable quantities of PEG diol gave a mixture of mono- and 
bis-functionalized cyclooctene macromonomers.  The presence of bis-cyclooctenes in the 
polymerization led to cross-linking of the graft copolymers by a ring-opening cross-
metathesis mechanism.  For mPEG molecular weights less than 1000 g/mol, PEG diol 
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was removed by column chromatography over silica gel, eluting with 
chloroform/acetone/methanol mixtures.    
 
Scheme 2.1  Synthesis of PEGylated cyclooctene macromonomers by carbodiimide 
coupling of mPEGs to 2 
 
 
Using carbodiimide coupling, macromonomers 3 and 4 were prepared with 
column-purified mPEGs possessing molecular weights of approximately 750 and 1000 
g/mol, respectively.  The coupling strategy proved quite convenient, as it allowed 
attachment of PEG without the need for anionic polymerization of ethylene oxide.  In 
addition, this synthetic route introduces an ester linkage, which could be potentially 
exploited in controlled-release applications.  The 
1
H NMR spectrum of macromonomer 4 
in CDCl3 consists of olefinic resonances at ? 5.65 ppm and resonances for the protons of 
the succinic anhydride linker centered at ? 2.65 ppm.  A broad signal centered at ? 3.70 
ppm reflects interior methylene protons of PEG, while a singlet at ? 3.38 ppm reflects the 
methoxy end-group. 
13
C NMR spectroscopy (CDCl3) proved useful to confirm the 
absence of residual mPEG (removed by extraction in water) and contains a diagnostic 
methylene signal at ? 61.9 ppm (H3CO-PEG-CH2-OH).  Figure 2.5 shows gel permeation 
chromatography (GPC) overlays of 3, 4 and mPEG starting materials, where 
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macromonomers 3 and 4 exhibit low PDI values (shown in Table 2.1) that are in accord 
with those of the mPEG starting materials. 
 
Figure 2.5  Gel permeation chromatograms of macromonomers 3 and 4 and mPEG 
starting materials 
 
 
Table 2.1  Molecular weight and PDI estimation for macromonomers 3 and 4 and 
mPEG starting materials 
 
 
2.3.2 Synthesis of Ether-linked PEG-functional Cyclooctene Macromonomers 
While carbodiimide coupling of carboxylic acid-functional cyclooctenes and 
commercially available mPEGs proved suitable for the synthesis of low molecular weight 
PEGylated cyclooctene macromonomers, a number of limitations motivated us to seek 
additional synthetic methods to prepare PEG-functional macromonomers.  For example, 
the ester linkage that connects the cyclooctene and PEG moieties is subject to hydrolysis 
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over time, which would be detrimental for long-term applications in aqueous 
environments.  Applications for polyolefin-g-PEG copolymers such as long-term 
therapeutic encapsulation and release, as well as water purification membrane coatings, 
require stable PEG linkages to maintain water-solubility, protein resistance, and anti-
fouling properties.  This motivated the exploration of additional synthetic pathways to 
produce macromonomers where the cyclooctene is connected to the PEG graft via a 
hydrolytically-stable ether linkage.  
Initial attempts to synthesize ether-linked macromonomers involved the coupling 
of 1 with mPEG-mesylates (5) of low molecular weight to produce macromonomer 6 as 
shown in Scheme 2.2.  Initially, the reaction was performed in THF, but the sodium 
alkoxide of 1 was only moderately solvent in THF at concentrations greater than 0.1 M, 
which led to low yields of 6.  In contrast, when dimethylformamide (DMF) was used as 
the reaction solvent, complete reaction of the mPEG-mesylate was observed after stirring 
for 16 hours at room temperature.  This was confirmed by 
1
H NMR spectroscopy in 
CDCl3, which showed an absence of methyl proton resonances at ? 3.01 ppm, attributed 
to the mPEG-mesylate end-group.  New resonances at ? 5.52 ppm and ? 1.32 - 2.30 ppm, 
corresponding to the olefinic and aliphatic resonances of cyclooctene, respectively, were 
also observed.  However, additional resonances at ? 6.40 ppm and ? 4.10 ppm were 
observed in the spectrum and attributed to the presence of vinyl ether-functionalized PEG 
7, a by-product of the competing elimination reaction (E2).  By comparing the peak 
integration of olefinic protons at ? 5.52 ppm to vinyl protons at ? 6.40 ppm, the yield of 
the E2 by-product was found to be approximately 10%.  Vinyl ethers, such as ethyl vinyl 
ether, are commonly utilized to terminate the ROMP of cyclic olefins and even small 
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concentrations of vinyl ether PEG inhibited the polymerization of macromonomer 6.  
Unfortunately, column chromatography and other solid phase extraction techniques were 
ineffective at removing the vinyl ether by-product from the macromonomer. 
Scheme 2.2  Synthesis of ether-linked PEG macromonomer 6 by coupling of 1 and 
mPEG mesylate 5 
 
 
The removal of the vinyl ether by-product 7 from macromonomer 6 proved 
challenging and several additional factors also limited the use of coupling chemistry to 
produce ether-linked macromonomers.  For example, the removal of diol contaminants 
from the mPEG starting material by column chromatography becomes progressively 
more difficult as the mPEG molecular weight exceeds approximately 1000 g/mol (ca. 25 
repeat units).  Thus, preparing monosubstituted PEG derivatives and macromonomers 
from higher molecular weight mPEGs proved difficult.  Furthermore, the utilization of 
mPEGs, which possesses an unreactive methyl terminus precludes the preparation of 
bifunctional PEG derivatives. 
For the reasons outlined above, the living, anionic polymerization of ethylene 
oxide (EO), initiated by cyclooctene alkoxides, offers an attractive synthetic route to the 
desired macromonomer.  The construction of a stainless-steel polymerization manifold, 
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detailed by Coughlin and coworkers,
55 
provided a viable system in which EO, a toxic 
gaseous monomer, could be transferred safely from the lecture bottle to the reaction flask, 
thus significantly reducing the risk of exposure.  Using this manifold, ether-linked PEG 
macromonomers were prepared by anionic polymerization of ethylene oxide initiated by 
1 (shown as 8, 9, and 10 in Scheme 2.3) on the 1 - 30 gram scale.  In a typical 
polymerization, a 1.0 M solution of 1 in THF was introduced to an air-free reaction flask 
containing anhydrous THF using standard Schlenk techniques and subsequently 
deprotonated with an organic base such as potassium naphthalenide or triphenylmethyl 
potassium.  The solution containing the potassium alkoxide of 1 was then connected to 
the manifold, where a measured volume of condensed EO (-78 
o
C) was slowly warmed to 
room temperature and transferred as a gas to the stirring initiator solution at 0 
o
C.  The 
polymerization was conducted in a sealed, argon-filled reaction vessel at room 
temperature for 16 hours, and the macromonomer was purified by repetitive precipitation 
into diethyl ether or by column chromatography using chloroform/methanol mixtures. 
 
Scheme 2.3  Synthesis of ether-linked PEG macromonomers by anionic ring-
opening polymerization of ethylene oxide initiated by the potassium alkoxide of 1  
 
 
In addition to improved hydrolytic stability, the living polymerization of ethylene 
oxide permits the synthesis of macromonomers with a wide range of PEG molecular 
weights by simply varying the monomer-to-initiator ratio.  GPC traces of 
  35 
macromonomers 8 - 10 (25, 50 and 100 EO units, respectively) in THF are shown in 
Figure 2.6 and molecular weight estimates are detailed in Table 2.2.  Using this approach, 
macromonomers with PEG molecular weights ranging from 1100 g/mol (25 EO units) to 
4400 g/mol (100 EO units) and PDI values less than 1.10 were produced with excellent 
control of PEG molecular weight.  
1
H NMR analysis of macromonomers 8, 9, and 10 in 
d6-DMSO showed resonances at ? 5.58 ppm arising from olefinic protons of the 
cyclooctene initiator as well as a broad peak centered at ? 3.60 ppm corresponding to 
methylene protons of the PEG backbone.  In d6-DMSO, the hydroxyl proton of the PEG 
terminus (COE-PEG-OH) is visible as a triplet centered at ? 4.55 ppm. 
 
Figure 2.6  GPC chromatograms of ether-linked macromonomers 8, 9, and 10 
prepared by anionic polymerization of ethylene oxide 
 
 
Table 2.2  Molecular weight and PDI estimation for macromonomers 8 - 10 
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2.3.3 End-functionalization of Ether-linked Macromonomers 9 with an RGD-
containing Oligopeptide 
The anionic polymerization of EO initiated by 1 provides an ideal synthetic 
pathway to produce macromonomers with a very broad range of well-defined PEG 
molecular weights.  In addition to these benefits, EO polymerization also provides 
heterobifunctional PEG macromonomers that possess a terminal hydroxyl group for 
further attachment of targeting groups, drugs, or fluorescent labels.  The attachment of 
cell targeting groups at the macromonomer terminus is advantageous for drug delivery 
and biomaterials applications since the peptide should be readily accessible to cellular 
receptors on targeted cells.  By comparison, the copolymerization of a cyclooctene-
functionalized oligopeptide would place the targeting group close the polycyclooctene 
backbone, and thus, the pendent PEG grafts might sterically shield the desired cellular 
interactions.  As an initial proof-of-concept, macromonomer 9 was functionalized with an 
oligopeptide containing the ?V?3-integrin binding motif, RGD.  RGD-containing 
oligopeptides have been widely utilized in a number of biotechnology applications, 
including, for example, active targeting of drug delivery systems to rapidly proliferating 
endothelium around cancerous tissue
56
  and the promotion of cell attachment to a variety 
of biomaterial scaffolds.
57
  
To accomplish this, a PEG-functional macromonomer possessing terminal 
carboxylic acid-functionality was prepared and coupled directly to an RGD-containing 
oligopeptide prepared by solid phase synthesis (SPS) by Ph.D. candidate Rebecca 
Breitenkamp in the Emrick group.  The initial synthetic route to carboxylic-acid 
functionalized macromonomers involved end-capping the “living” PEG alkoxide of 9 
with t-butyl bromoacetate as shown in Scheme 2.4A.  Using rigorously purified reagents 
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and Schlenk techniques, macromonomer 11 was prepared in 89% yield and with near 
quantitative functionalization of the alkoxide end-group.  This was confirmed by 
1
H 
NMR spectroscopy of 11 in d6-DMSO which showed the absence of the hydroxyl proton 
resonance at ? 4.55 ppm and new resonances at ? 3.98 ppm and ?1.47 ppm corresponding 
to acetate and t-butyl protons, respectively.  However, GPC analysis of 11 and 
deprotected macromonomer 12 showed a bimodal molecular weight distribution, 
indicative of substantial quantities of the dimer of macromonomer 12, presumably 
resulting from coupling through both the acetate and ester moieties.   
 
Scheme 2.4  Synthetic routes to carboxylic acid-functional PEG macromonomers 12 
and 15 
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To circumvent this problem, a multi-step synthetic route to the carboxylic acid-
functional macromonomer was pursued starting from hydroxyl-functional 
macromonomer 9 as shown in Scheme 2.4B.   In the first step, the hydroxyl functionality 
of 9 was converted to the corresponding azide (13) through base-catalyzed reaction with 
methanesulfonyl chloride and subsequent substitution using sodium azide in refluxing 
ethanol.  
1
H NMR spectroscopy of 13 in d6-DMSO showed complete functionalization of 
the hydroxyl functionality as illustrated by the absence of resonances at ? 4.55 ppm and ? 
3.00 ppm, corresponding to hydroxyl and mesylate protons, respectively.  The presence 
of the terminal azide was confirmed by ATR-FTIR spectroscopy, which showed a 
significant absorbance at 2095 cm
-1
.  The azide of macromonomer 13 was subsequently 
converted to a primary amine (14) by Staudinger reduction with triphenylphosphine and 
water.  Complete reduction of the azide was confirmed by the disappearance of the 
absorbance at 2095 cm
-1 
in the IR spectrum and appearance of a new resonance at ? 2.60 
ppm in the 
1
H NMR spectrum (d6-DMSO), attributed to the methylene protons ? to the 
terminal amine.  In the final step, amine 14 was utilized in the ring-opening reaction of 
succinic anhydride to yield carboxylic acid-functionalized macromonomer 15.  
1
H NMR 
spectroscopy of 15 in d6-DMSO showed unique resonances at ? 12.07 ppm and ? 2.50 
ppm corresponding to the carboxylic acid and succinic acid linker, respectively.  GPC 
analysis in THF showed a single peak with Mn of 2500 g/mol with a PDI of 1.12 
(referenced against PEG standards). By employing this series of highly efficient 
reactions, macromonomer 15 was prepared with very high purity and with minimal 
purification required.  The overall yield for this three step synthetic conversion was 
approximately 50%.  
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To synthesize the oligopeptide-functional macromonomer, a resin-bound GRGDS 
oligopeptide was prepared (by Rebecca Breitenkamp) using solid-phase peptide synthesis 
and standard Fmoc protection/deprotection chemistries.  Each amino acid was coupled 
sequentially using 1-hydroxybenzotriazole (HOBt) and HBTU starting from a Ser(t-but)-
loaded, 2-chlorotrityl resin.  Following Fmoc removal from the N-terminal glycine 
residue with piperidine, a solution of macromonomer 15 in DMF was coupled to the 
oligopeptide using HBTU/HOBt as illustrated in Scheme 2.5.  The coupling reaction with 
15 was carried out twice for 3 hours in an effort to maximize coupling efficiency of this 
large macromolecule.  After repeated washing of the resin with DMF and 
dichloromethane, the GRGDS-functional macromonomer was cleaved from the resin 
using trifluoroethanol.  The 2-chlorotrityl resin permits the cleavage of 16 without 
removing the Pbf (arginine) and t-butyl protecting groups (glutamic acid and serine) of 
the oligopeptide.  This is key since primary amine functionality on the arginine residue 
binds to ruthenium benzylidene catalysts, which would prevent ROMP of unprotected 16.  
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Scheme 2.5  Synthesis of GRGDS-functional macromonomer 16 by solid phase 
coupling chemistry 
 
 
1
H NMR analysis of crude 16 shows the presence of PEG resonances at ? 3.50 
ppm and oligopeptide resonances arising from amide protons ranging from ? 7.5 – 8.5 
ppm.  Resonances corresponding to protons of the t-butyl protecting groups of Ser and 
Glu and the amide backbone were also observed at ? 1.10 ppm and ? 7.80 – 8.30 ppm, 
respectively.  However, GPC analysis of the crude product in THF showed multiple 
peaks with molecular weight values less than 1000 g/mol.  This was attributed to the 
presence of free GRGDS oligopeptide that was not coupled to macromonomer 15.  The 
uncoupled oligopeptide, insoluble in water, was removed by filtration.  GPC analysis of 
purified 16 in THF showed a single peak with Mp corresponding to 2500 g/mol with a 
PDI of 1.13 (referenced against PEG standards).  Matrix-assisted laser 
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desorption/ionization (MALDI) mass spectrometry, shown in Figure 2.7, revealed a 
relatively narrow distribution of peaks centered at 3261 Da which corresponds to 
GRGDS-functionalized macromonomer 16 (calcd. 3259 Da) with a second distribution of 
peaks corresponding to the K
+
 charged analogues. 
 
Figure 2.7  MALDI analysis of GRGDS-functional macromonomer 16 
2.4  Synthesis of Polycyclooctene-g-PEG Copolymers 
2.4.1  Copolymerization of Ester-linked Macromonomers 3 and 4 
Macromonomers 3 and 4 were copolymerized with cyclooctene in the presence of 
bis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride (catalyst I), or the 
mono-1,3-dimesitylimidazolidine-2-ylidene derivative (catalyst II), as illustrated in 
Scheme 2.6.  Typical experiments employed about 0.42 mmol of macromonomer and 
0.42 mmol to 3.80 mmol of cyclooctene.  Catalysts were introduced to the 
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macromonomer/cyclooctene mixtures as solutions in dry dichloromethane and then 
removed after polymerization by termination with ethyl vinyl ether. The polymerizations 
were carried out under a variety of concentrations and temperatures that dictate the 
course of the reaction.  Our initial polymerization attempts were conducted at room 
temperature using catalyst I.  While these conditions achieved considerable molecular 
weights and conversion (>75 %) in about 16 hrs, the products possessed multi-modal 
molecular weight distributions.  In contrast, when polymerizations were carried out at 45 
o
C and ca. 2.0 M, a noticeable change in reaction viscosity was observed within 15-30 
minutes in the case of catalyst I, and in seconds using catalyst II.  
 
Scheme 2.6  Synthesis of PCOE-g-PEG by ROMP of macromonomer 4 
 
 
Copolymers 18 - 23 in Table 2.3 represent copolymerizations of macromonomer 4 
and cyclooctene (17) using catalyst I.  The extent of macromonomer incorporation into 
the copolymer was determined by 
1
H NMR spectroscopy by integration of olefinic 
protons of residual macromonomer (? 5.65 ppm) against the methyne proton of the graft 
point (i.e., RCH(OR')R).  In all cases, approximately 60 - 70% of the starting 
macromonomer used became incorporated into the polymer product.  Molecular weight 
estimation by GPC in DMF showed a decrease in Mn of the copolymers from 
approximately 330,000 g/mol (Mn) to 180,000 g/mol upon increasing cyclooctene ratios 
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from 0.5 to 0.9 (relative to macromonomer), respectively.  The extent of low molecular 
weight by-products decreased as well.  This suggests that while macromonomer 
conversion is relatively efficient, at higher macromonomer concentrations there is a 
barrier at the oligomeric stage, possibly due to cyclization.
58-60
  
Monomer-to-catalyst ratios were investigated for these copolymerizations, as 
shown for copolymers 22 and 23 of Table 2.3.  As expected, lower monomer-to-catalyst 
ratios gave lower molecular weight copolymers in a shorter period of time.  For example, 
50:50 copolymerizations using monomer-to-catalyst ratios of 500:1 (copolymer 18) and 
100:1 (copolymer 23) gave products with Mn of 330 kDa and 140 kDa.  Lower monomer-
to-catalyst ratios also resulted in a decrease in low molecular weight oligomers, as 
observed by more nearly uni-modal GPC chromatograms.  Similar syntheses using 
catalyst II are shown as copolymers 24 – 26 of Table 2.3, where nearly complete 
conversion of macromonomer 4 was observed.  The increased activity of this catalyst is 
demonstrated by the excellent macromonomer incorporation achieved, even at lower 
concentrations (1.0 M).  Figure 2.8 overlays chromatograms of copolymers 18 and 24, 
prepared using catalysts I and II, respectively and otherwise identical reaction conditions 
(500:1 monomer-to-catalyst; 2.0 M in dichloromethane).  In the case of copolymer 24, 
where catalyst II was used, the presence of low molecular weight cyclized oligomers is 
reduced dramatically and reasonably narrow polydispersities are observed.  Similar 
results were obtained when polymerizations were conducted at lower monomer 
concentrations (copolymers 25 and 26). 
 
 
 
  44 
Table 2.3  Characteristics of ester-linked PCOE-g-PEG copolymers 18 - 26 prepared 
using ruthenium benzylidene catalysts I and II 
 
 
Figure 2.8  GPC chromatograms of copolymers 18 and 24 (in DMF) prepared using 
ruthenium benzylidene catalysts I and II, respectively 
2.4.2 Copolymerization of Ether-linked Macromonomers 8 - 10 
Copolymerizations of ether-linked macromonomers 8 - 10 showed similar 
physical characteristics to graft copolymers of 3 and 4 when polymerized with catalysts I 
and II.   However, many applications for PCOE-g-PEG copolymers required the long-
term hydrolytic stability imparted by the ether linkage.  Thus, macromonomers 8 – 10 
were extensively used in polymer capsule synthesis and membrane applications described 
in Chapters 3 and 4, respectively.   
a[M] = 2.0 mol/L, 40 oC in CH2Cl2, 
bfmacro= feed ratio of macromonomer relative to cyclooctene, 
cFmacro = fraction of 
macromonomer incorporated into polymer, determined by 1H NMR, dDetermined by GPC in DMF vs. polystyrene 
standards. 
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Recently, Grubbs and coworkers reported a third generation catalyst (catalyst III), 
which replaces tricyclohexylphosphine ligands of II with the more labile 3-
bromopyridine ligands.  This catalyst displays enhanced metathesis activity when 
compared to I and II and enables a faster, living polymerization of norbornene and 
oxanorbornene derivatives relative to I.  Thus, catalyst III was utilized for the 
polymerization of macromonomers 8 – 10.  In this case, complete macromonomer 
conversion was obtained using much lower concentrations of this highly active catalyst.  
While monomer-to-catalyst ratios of 250:1 or 500:1 are typically employed for catalysts I 
and II, full macromonomer conversion was achieved with monomer-to-catalyst III ratios 
up to 10,000:1.  1-Hexene, an acyclic chain transfer agent, is added to these 
polymerizations to control the molecular weight.
61,62
  By simply varying the monomer-to-
chain transfer agent ratio, the molecular weight of the graft copolymer can be effectively 
tuned.   The ability to utilize very high monomer-to-catalyst ratios is particularly 
important when preparing PCOE-g-PEG copolymers in multi-gram quantities since only 
small concentrations of these expensive catalysts are needed for effective polymerization. 
As shown in Scheme 2.7, copolymers 27 – 29, with ether-linked PEG grafts, were 
synthesized using catalyst III and a monomer-to-catalyst ratio of 250:1.  1-Hexene was 
employed at a monomer-to-chain transfer agent ratio of 150:1.  These particular PCOE-g-
PEG copolymers were synthesized to study the effect of graft length on the crystallization 
properties of hydrogenated PE-g-PEG copolymers.  For this reason, the macromonomer 
content in the polymerization feed of copolymers 27 – 29 was held constant at 8 mol % 
and the macromonomer PEG length was varied from 25 to 100 repeat units.  
Polymerizations were carried out in a similar fashion as those described for copolymers 
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18 – 26 with the exception that the reactions were carried out at room temperature.  The 
higher activity of catalyst III versus catalyst II permits the full conversion PEGylated 
macromonomers at lower temperatures in shorter time periods. 
1
H NMR analysis of 
copolymers 27 – 29 performed in CDCl3 showed an absence of cyclic olefin resonances 
at ? 5.65 ppm and new olefinic resonances of the PCOE backbone at ? 5.36 ppm, 
indicating complete conversion of the macromonomer.  Integration of the methyne proton 
of the PEG graft point (RCH(OR')R, 3.25 ppm) versus olefinic proton resonances in the 
PCOE backbone (? 5.36 ppm) provides an estimation of the number of grafts per polymer 
chain.  Based on these ratios, it was calculated that approximately 8 PEG grafts were 
present per 100 cyclooctene repeat units for all three copolymers as shown in Table 2.4.   
GPC analysis of PCOE-g-PEG copolymers with low PEG contents, such as copolymers 
27 – 29, must be performed in CHCl3 due to the limited solubility of PCOE backbone in 
common solvents for GPC, such as THF and DMF.  Copolymers 27 and 28 with PEG 
graft lengths of 25 and 50 repeat units, respectively, possessed estimated molecular 
weight values of approximately 24,000 g/mol.  Copolymer 29 showed significantly 
higher estimated molecular weights of 48 kDa, presumably due to the significantly longer 
PEG grafts (100 EO repeats).  PDI values for the three polymers were approximately 2, 
as predicted when utilizing monofunctional chain transfer agents.
63
 
 
 
Scheme 2.7  Synthesis of PCOE-g-PEG copolymers 27 – 29 by ROMP of ether-
linked macromonomers 8 – 10 
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Table 2.4  Characteristics of ether-linked PCOE-g-PEG copolymers 27-29  
 
 
The PCOE-g-PEG copolymers described above are amphiphilic and soluble in a 
range of organic solvents (MeOH, acetone, CH2Cl2, CHCl3, THF, DMF, and toluene) at 
all percentages of macromonomer incorporation.  Polymers with PEG grafts of 2000 
g/mol or longer (i.e. copolymers 28 and 29) were precipitated into diethyl ether.  Hexane 
proved suitable for precipitation of graft copolymers with shorter PEG lengths (i.e. 
copolymers 18 – 27).  With the exception of copolymer 21, copolymers 18 – 26 all 
readily form aqueous solutions.  These amphiphilic copolymers stabilize oil-in-water 
emulsions for hours to days, depending on macromonomer content.  In general, the 
unsaturated PCOE-based copolymers have limited shelf life, due to their propensity to 
undergo oxidative cross-linking of the olefinic backbone.  However, it was found that 
polycyclooctene copolymers containing high weight percentages of PEG (> 75 wt %) 
showed minimal cross-linking over several weeks, presumably due to the lower 
concentration of olefins present in these samples.  For copolymers with low PEG content 
(< 50 wt %), the introduction of 1 wt % 2,6-di-tert-butyl-p-cresol (BHT) during 
precipitation and storage in the freezer (-20 
o
C) proved useful for prolonging the polymer 
shelf life.  
2.4.3 Copolymerization of GRGDS-functional Macromonomer 16 
To test the feasibility of incorporating oligopeptides into PCOE-g-PEG 
copolymers, GRGDS-substituted macromonomer 16 was copolymerized with 
a[M] = 1.5 mol/L, 25 oC in CH2Cl2, 
bfmacro= feed ratio of macromonomer relative to cyclooctene, 
cFmacro = fraction of 
macromonomer incorporated into polymer, determined by 1H NMR, dDetermined by GPC in CHCl3 vs. polystyrene 
standards. 
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cyclooctene (17) and macromonomer 9 using catalyst III at room temperature.  For this 
initial demonstration, 5 mol % of 16 was introduced into the monomer feed with 75 mol 
% of 17 and 20 mol % of 9 as shown in Scheme 2.8.  This amount of 16 in the monomer 
feed was chosen based on numerous studies which indicate that only low incorporations 
of targeting ligands are needed to facilitate interactions with cellular receptors for drug 
delivery
64
 or to stimulate cellular adhesion and proliferation.
65,66
 
 
Scheme 2.8  Synthesis of GRGDS-containing PCOE-g-PEG copolymer 30 by ROMP 
of peptide-functional macromonomer 16 
 
 
Due to the limited solubility of 16 in pure dichloromethane, a small amount of 
trifluoroethanol (0.1 mL) was added to give a homogeneous solution for the 
polymerization.  ROMP in solvent mixtures containing trifluoroethanol has been reported 
previously by our group,
67
 and others,
68
 and was found in this case to permit the ROMP 
of 16 in yields greater than 90%.  Following termination with ethyl vinyl ether and 
precipitation into diethyl ether, 
1
H NMR spectroscopy of copolymer 30 in d6-DMSO 
revealed an absence of cyclic olefin resonances at ? 5.65 ppm, indicating complete 
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conversion of macromonomers 16 and 9.  Unique resonances corresponding to the 
protected GRGDS oligopeptide at ? 7.90 – 8.10 ppm (-NH-C(O)- peptide backbone 
resonances), ? 4.20 ppm ((-C(O)-CH(R)-NH- peptide backbone resonances), and ? 1.10 
ppm (Asp(t-but) and Ser(t-but) resonances) also verified incorporation of macromonomer 
16.  The molecular weight of copolymer 30 was estimated to be 77,000 g/mol by GPC 
analysis in THF versus polystyrene standards with a PDI of 2.9.  In addition, GPC 
analysis of 30 using UV detection showed a strong absorbance at 254 nm, indicative of 
the aromatic Pbf protecting group of the incorporated GRGDS oligopeptide.  By 
comparison, PCOE-g-PEG copolymers without pendent oligopeptides (e.g. copolymers 
18 – 29) show minimal UV absorbance at this wavelength.  
2.5 Hydrogenation of PCOE-g-PEG Copolymers to PE-g-PEG 
The unsaturated polycyclooctene-g-PEG copolymers were hydrogenated using p-
toluenesulfonhydrazide
54
 to give the saturated analogs with PE backbones as shown in 
Scheme 2.9.  This chemical transformation resulted in dramatic differences in solubility 
and crystallinity, with variations depending on macromonomer content.  Hydrogenated 
products with low macromonomer content, such as copolymers 20a and 21a, were 
completely insoluble at room temperature, while copolymer 19a was soluble in polar 
solvents.  Copolymer 20a, with the highest macromonomer content studied here, 
remained water-soluble after hydrogenation.  Differential scanning calorimetry (DSC) 
analysis confirmed the increasing crystallinity of these copolymers with decreasing 
macromonomer incorporation.  As shown in Figure 2.9, two endotherms at 8 
o
C and 115 
o
C for copolymer 21a were observed and correspond to melting transitions of the PEG 
grafts and PE backbone, respectively.  
1
H NMR spectroscopy and GPC analysis were 
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used to further confirm the structure of these hydrogenated products.  The 
1
H NMR 
spectrum of copolymer 19a in CDCl3, for example, showed no signals in the olefinic 
region and showed resonances that reflect the methyne proton of the graft point, the 
succinic anhydride linker, and the methyl ether end-group of the PEG graft, all in accord 
with the expected structure.  GPC analysis (in trichlorobenzene at 135 °C) of copolymer 
21a showed only small changes in molecular weight (using multiple angle laser light 
scattering detection) from its unsaturated precursor.   
 
Scheme 2.9  Synthesis of PE-g-PEG by hydrogenation of PCOE-g-PEG 
 
 
Figure 2.9  DSC chromatogram of copolymer 21a, A) PEG Tm= 8.7 
o
C, B) PE 
Tm=115.1 
o
C 
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Extensive thermal and X-ray scattering studies of ether-linked, hydrogenated PE-
g-PEG copolymers 27a – 29a with varying PEG chain lengths were performed in 
collaborative efforts with Prof. Sanjeeva Murthy at Rutgers University.  A detailed report 
of these experiments and their results has been published.
69
 
2.6 Summary and Outlook 
In summary, novel PEG-substituted cyclooctene macromonomers were 
synthesized and integrated into graft copolymers by ring-opening metathesis 
polymerization using ruthenium benzylidene catalysts I, II and III.  Macromonomers 3 
and 4 were prepared by coupling chemistry using commercially available mPEG 
derivatives.  These monomers present a hydrolytically-degradable ester linkage between 
the PEG graft and PCOE backbone.  Hydrolytically-stable PCOE-g-PEG copolymers 
were also prepared using ether-linked macromonomers 8 – 10, made by ring-opening 
anionic polymerization of ethylene oxide using cyclooctene-based initiator 1.  The 
synthesis of macromonomers by direct polymerization of ethylene oxide presents a 
number of advantages including the ability to synthesize macromonomers with a wide 
range of PEG molecular weights and the potential for end-functionalization with 
oligopeptides, drugs, dyes, or other biological functionality.  
These unique graft copolymers offer many tunable features based on extent of 
macromonomer incorporation, including a wide range of organic and aqueous solubility, 
crystallinity, and ability to function as macromolecular surfactants.  The polymerization 
of cyclooctene-based macromonomers is also a viable method towards novel 
polyethylene-g-PEG copolymers through hydrogenation of the polycyclooctene 
backbone.  These PEG-functional polyolefins are expected to present many possibilities 
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for the synthesis of novel macromolecules with controlled hydrophilicity and 
biofunctionality for potential applications in delivery, implant, and bio-medical coating 
applications.   
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CHAPTER 3 
PREPARATION OF POLYMER CAPSULES BY SELF-ASSEMBLY AND 
CROSS-LINKING OF POLYCYCLOOCTENE-GRAFT-PEG COPOLYMERS 
3.1 Polymer Capsules for Encapsulation and Release Applications 
Encapsulation and release strategies impact a wide range of technologies, 
particularly those which involve the controlled release of pharmaceuticals, flavors, 
fragrances, and agricultural agents.
1
  Capsules and vesicles derived from polymer-based 
materials are well-suited for these applications because of their mechanical stability and 
tunable chemistries that can provide control over degradation rates, ionic charge, and 
cross-linking.
2
  Such chemical strategies can be utilized to tailor the release rates of 
encapsulated agents over defined time periods, or in response to environmental changes.  
Polymer capsules are distinguished by their hollow nature with a polymer-based 
shell that acts as a membrane to control diffusion of encapsulated species.  This contrasts 
other solid, polymer microparticles prepared using degradable materials where drug 
release is controlled by diffusion and degradation of the polymer matrix.  Polymer-based 
capsules have been prepared by a number of techniques.  Classical methods of capsule 
preparation involve interfacial polycondensation utilizing complementary monomers (e.g. 
multifunctional carboxylic acid chlorides and amines) in a two-phase suspension system 
(e.g. chloroform and water) where each monomer is soluble in one of the two liquid 
phases.
3  
To produce capsules, the resulting polymer formed at the fluid-fluid interface is 
insoluble in either phase and precipitates at the interface to form a membrane, ranging 
from nanometers (nm) to microns (μm) in thickness, which encapsulates the droplets.  
The encapsulated droplet can then be utilized as a reservoir for the controlled release of 
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active agents.  Capsule production methods that utilize free-radical polymerization of 
vinyl monomers have been developed as well.  For example, Stöver and coworkers 
demonstrated that the suspension copolymerization of methyl methacrylate (MMA) and 
poly(ethylene glycol) monomethacrylate (PEGMA) produces hollow capsules with 
micron-thick membranes when the feed ratio of PEGMA is sufficiently high (>15 mol %) 
and a cross-linker such as diethylene glycol dimethacrylate is added to the 
polymerization.
4
  They hypothesized that the hydrophilicity imparted by PEGMA 
resulted in an amphiphilic copolymer which assembles and is subsequently cross-linked 
at the oil-water interface.  Polymer capsules with diameters of approximately 100 nm and 
wall thicknesses ranging from 20 – 50 nm have been prepared by Landfester and 
coworkers using free-radical miniemulsion techniques.
5  
In this case, the free-radical 
polymerization of methyl methacrylate or styrene was performed in an excess of a 
hexadecane using ultrasonication to produce the miniemulsion.  Although the monomers 
are soluble in the hydrophobic phase, the polymer that is subsequently formed is 
immiscible and precipitates to form a shell around surrounding the hexadecane droplet. 
In most cases, interfacial polymerization techniques produce polymer capsules 
with poor control of membrane thickness and inconsistencies in obtaining reproducible 
capsule morphologies.  More recent strategies utilize the self-assembly of polymeric 
building blocks to produce capsules with well-defined diameters, wall thickness, and 
permeability.
6
  For example, amphiphilic diblock copolymers with precisely controlled 
volume fractions (ƒ) of hydrophobic and hydrophilic components can produce hollow 
capsules, termed polymersomes, when hydrated in water.  In general, diblock copolymers 
with large hydrophilic block lengths (ƒ >50%) produce spherical micelles in water with 
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diameters on the order of 20 - 200 nm.  However, when the hydrophilic block constitutes 
a volume fraction of 25%>ƒ>40%, polymersomes are formed upon electroformation
6
 or 
hydration in water.
7  
These hollow structures possess a polymeric bilayer shell that is 
analogues to phospholipid-based liposomes.  The molecular weight and conformational 
freedom of the polymeric bilayer, however, make these vesicles inherently more 
mechanically robust and ten times less permeable to water than liposomes, and these 
unique attributes make polymersomes particularly promising in drug delivery.  For 
example, Discher and coworkers have utilized polymersomes formed from poly(ethylene 
glycol)-b-poly(L-lactic acid) (PEG-b-PLA) and PEG-b-poly(?-caprolactone) to 
encapsulate drugs such as doxorubicin and paclitaxel.
8
  They demonstrated that a higher 
maximum tolerated dose (MTD) and increased tumor localization could be achieved in 
tumor-bearing mice with polymersome-encapsulated drugs when compared to the 
unencapsulated drugs.  
Recently, Weitz and coworkers introduced a new method of preparing 
polymersomes from PEG-b-PLA copolymers by utilizing a microfluidic approach.  Using 
block copolymer-stabilized double emulsion as templates, they showed that 
monodisperse polymersomes were produced upon evaporation of the organic solvent.
9  
Using this approach, they encapsulated a hydrophilic fluorescent dye and demonstrated 
its triggered release by osmotic shock of the polymersomes.  Using the double emulsion 
method, they also found that polymersomes could be formed from a wide range of 
diblock copolymer compositions.  This represents a major advantage over the previously 
discussed polymersome production methods that utilize hydration
 
or electroformation
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since this technique does not require precise control over of the hydrophobic and 
hydrophilic copolymer components. 
The structural integrity of polymersomes can be further enhanced through 
chemical cross-linking strategies, made possible by using reactive block copolymers.  For 
example, Meier and coworkers cross-linked polymersomes prepared from poly(2-
methyloxazoline)-b-poly(dimethylsiloxane)-b-poly(2-methyloxazoline) ABA copolymers 
which were functionalized with acrylate moieties on the polymer chain-ends.
10  
UV-
induced polymerization gave polymer capsules that were shape-persistent after drying.   
These vesicles were found suitable for the encapsulation of small-molecule dyes such as 
sulforhodamine B and proteins such as avidin.
11
  Using a similar approach, Bates and 
coworkers produced elastic capsules by free-radical cross-linking of unsaturated 
polybutadiene-b-PEG copolymers.
12  
They showed that the cross-linked capsules were 
stable in both water and chloroform and also demonstrated the effective encapsulation 
and retention of sucrose inside the polymer capsules, suggesting that defect-free capsules 
could be prepared by this method.  
Weitz and coworkers have pioneered the fabrication of capsules by oil-water 
interfacial assembly of micron-sized colloidal particles.  The particles assemble at the 
interface due to the substantially reduced particle-oil and particle-water surface energies 
compared to the oil-water surface energy.
13  
Mechanically robust capsules are then 
formed by either sintering the assembled polymer particles or by co-assembly of cationic 
polyelectrolytes such as poly(L-lysine) (PLL).
 
 The use of excess PLL is advantageous 
since these capsules can be subsequently inflated or deflated by changes in osmotic 
pressure resulting from encapsulated polyelectrolyte.
14  
Environmental stimuli that alter 
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the osmotic pressure of the capsule (e.g. salt concentration, pH, solvent) may offer an 
effective trigger for the release of encapsulated agents. 
The layer-by-layer (LbL) assembly of polyelectrolytes onto a sacrificial colloidal 
core is another commonly utilized method to produce polymer capsules.
15  
In this 
approach, oppositely charged polyelectrolytes (e.g. poly(vinylpyrrolidone) (PVP) and 
poly(methacrylic acid) (PMAA)) are adsorbed onto degradable templates in a stepwise 
fashion to generate layers of oppositely charged polymers. The templating core, which is 
typically composed of colloidal particles of silica, polystyrene, or melamine 
formaldehyde resin, is then subsequently removed by dissolution to form the hollow 
capsules.  By varying the number of polyelectrolyte layers, the thickness of the capsule 
membrane can be tuned, with values typically ranging from 5 – 20 nanometers.
16
  Due to 
the extremely thin nature of the capsule wall, capsule prepared by the LbL are generally 
permeable to small molecules but can retain macromolecules in the capsule core.  For 
example, Möhwald and coworkers demonstrated the sustained release of fluorescein, a 
small molecule dye, from LbL capsules made from alternating layers of poly(styrene 
sulfonate) (PSS) and poly(allylamine hydrochloride) (PAH).  In this study, the 
encapsulated dye was completely released from the capsules with a membrane thickness 
of 20 nm after only 10 minutes.
17
  However, they showed that PSS with molecular 
weights greater than 4200 g/mol were not permeable and could be retained within the 
capsule interior.
18
    
The ionic interactions that stabilize LbL capsules are inherently reversible by 
varying the ionic strength and pH of the capsule environment.  Thus, poor capsule 
stability or dissolution is often observed at physiological conditions, a key limitation for 
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their use as a drug delivery system.  Several groups have attempted to address this 
stability issue by covalent cross-linking of LbL capsules.  In one approach, Advincula 
and coworkers incorporated benzophenone-functionalized PAH into LbL capsules.  
Following stepwise deposition and template dissolution, the layers were cross-linked by 
irradiation with UV light to covalently stabilize the capsule structure.
19
  Using this 
approach, they showed that a hydrophilic dye, Rhodamine B, could be effectively loaded 
into the capsules prior to cross-linking and its release could be varied from approximately 
10 to 20 minutes through variation in cross-link density.  Caruso and coworkers prepared 
thiol-functionalized PMAA which was incorporated into LbL capsules with PVP and 
subsequently oxidized to form disulfide cross-links.
20  
These capsules were stable to 
simulated physiological conditions and could be utilized for the encapsulation and 
triggered release of the protein, Transferrin.  In this case, triggered capsule degradation 
and release of Transferrin was observed after treatment with dithiothreitol (DTT), a thiol-
disulfide exchange agent. 
Recently, there has been a considerable interest in producing polymer capsules 
with diameters less than 1 micron for nanotechnology applications such as targeted drug 
delivery and high-resolution electronic inks.  Currently, LbL techniques cannot be easily 
extended to produce sub-micron capsules due to difficulties arising from aggregation of 
the colloidal particles at practical reaction concentrations.  To overcome this limitation, 
nano-sized polymer capsules have been prepared by a number of methods using inorganic 
nanoparticles as templates.
 21
 Feldheim and coworkers were among the first to utilize 
such an approach by employing olefin metathesis chemistry to cross-link multi-
functional, alkene-covered gold nanoparticles.  Following metathesis cross-linking, 
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chemical etching of the nanoparticle template with a mixture of potassium cyanide 
(KCN) and K3[Fe(CN)6] afforded polymer capsules with diameters of approximately 10 
nm.  In another approach, Möhwald and coworkers used atom transfer radical 
polymerization (ATRP) to radially polymerize 2-(dimethylamino)ethyl methacrylate 
(DMA) from gold nanoparticles with 2-bromo-2-methylpropionyloxy-functionalized thiol 
ligands.
22  
Polymer capsules were then formed by cross-linking the polyDMA with 1,2-
bis(2-iodoethoxy)ethane (BIE) and subsequent etching of the nanoparticle template with 
KCN.  The nanocapsules were loaded with Rhodamine 6G but complete dye release was 
observed after only a few minutes, suggesting that small molecule diffusion is rapid 
across the thin polymer membrane (approx. 5 – 20 nm). 
Recently, Caruso and workers demonstrated a new approach to produce sub-
micron polymer capsules by adsorption and cross-linking of polyelectrolytes (e.g. PAH 
or poly(L-glutamic acid) (PGA)) in the mesoporous shells of solid core/mesoporous shell 
(SC/MS) templates.
23
  SC/MS templates with diameters of approximately 280 - 400 nm 
were prepared and mixed with solutions of either PAH, PLL, or PGA to form 
polyelectrolyte-infiltrated templates.  In the case of PAH and PLL-infiltrated SC/MS 
templates, polymer cross-linking was carried out using glutaraldehyde or 3,3?-
dithiopropionimidate dihydrochloride.  For PGA-infiltrated templates, cystamine was 
used for cross-linking.  Following SC/MS template removal with hydrofluoric acid, 
hollow capsules with membrane thicknesses of approximately 15 - 45 nm were obtained, 
with thicknesses dependant on the molecular weight of the polyelectrolyte.   The authors 
also demonstrated that this technique could be extended to the infiltration of doxorubicin-
functional PGA conjugates (PGA-DOX), thereby creating chemotherapeutic-loaded 
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capsules for drug delivery applications.  Under simulated conditions found in the 
bloodstream, they observed negligible release of DOX from the capsule but observed 
rapid release of the drug in a simulated lysosomal environment (pH 5.8 with 10 mM 
carboxypeptidase).  In LIM1215 human colorectal tumor cells, PGA-DOX loaded 
capsules demonstrated similar cell toxicity when compared to free DOX suggesting its 
potential use in chemotherapeutic applications. 
3.2 Polymer Capsules Prepared by Interfacial Assembly and Cross-linking of 
PCOE-g-PEG copolymers 
While many of the previously described assembly techniques are effective in 
producing well-defined polymer capsules, a major drawback of these methods is the 
multiple processing steps that are required for their production.  For example, LbL 
assembly and other templating techniques require a multi-step adsorption process 
followed by a dissolution step.  The preparation of polymersomes is often very tedious, 
requiring time-consuming hydration steps and the use of block copolymer building 
blocks with precise ratios of hydrophobic and hydrophilic components.  In contrast to 
these approaches, this chapter describes a novel method to produce micron-sized capsules 
using oil-water interfacial assembly and subsequent cross-linking of amphiphilic graft 
copolymers at the interface.  In early experiments, the polycyclooctene-g-poly(ethylene 
glycol) (PCOE-g-PEG) copolymers described in Chapter 2 were observed to segregate to 
the toluene-water interface.   We exploited this interfacial activity in conjunction with 
novel covalent cross-linking chemistries to develop a rapid route to produce robust, 
polymer capsules.  In the first approach, we describe capsules that are cross-linked by a 
ring-opening cross-metathesis mechanism using a bis-cyclooctene PEG derivative in 
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combination with a ruthenium benzylidene catalyst.  The second strategy involves the 
integration of phenyl azide or acyl hydrazine moieties into the polycyclooctene backbone 
which permits rapid UV cross-linking (in the case of phenyl azide) or glutaraldehyde 
cross-linking (in the acyl hydrazine case) at the oil-water interface.  In all cases, cross-
linking of the assemblies imparts mechanical integrity to the hollow capsules as 
confirmed by confocal laser scanning microscopy (CLSM), atomic force microscopy 
(AFM), and scanning electron microscopy (SEM).  This relatively simple strategy 
requires only a few steps to produce hollow capsules, and oil-in-water assembly can be 
utilized for the encapsulation of hydrophobic molecules, such as neutral doxorubicin and 
Coumarin 153.  These novel capsules may be well-suited for controlled release therapies, 
where the transport of drugs and/or drug conjugates can be regulated by factors such as 
the composition of capsule oil phase, capsule cross-link density, and encapsulant size and 
solubility.  In addition, the choice of cross-linking chemistry (amide-linked phenyl azide, 
ester-linked phenyl azide, or hydrazone) should allow for tunable capsule degradation 
through pH-dependent hydrolysis.  
3.2.1 Polymer Capsules Prepared by Ring-opening Cross-Metathesis at the Oil-
water Interface 
Amphiphilic polymers are particularly useful for mediating interfaces, as 
demonstrated by their history of applications as polymeric surfactants.
24  
While 
amphiphilic block copolymers and polyelectrolytes have been well-studied, amphiphilic 
graft copolymers have received comparatively little attention.  The novel PCOE-g-PEG 
copolymers described herein are inherently amphiphilic and dissolve in many organic 
solvents and water.  These copolymers are also interfacially active, stabilizing oil-in-
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water emulsions for hours to days or more, depending on macromonomer content, thus 
prompting further exploration into encapsulation and release applications.  Like other 
surfactant stabilized emulsions, oil-in-water assemblies formed from PCOE-g-PEG 
copolymers were destroyed upon drying or introduction of a common solvent such as 
methanol, ethanol, or acetone.  To enhance the structural stability for encapsulation 
applications, covalent cross-linking strategies that utilize polymer backbone functionality 
were developed.  It was anticipated that capsule cross-linking would not only provide 
structural stability to the polymer capsules but also provide a polymer membrane that 
could be chemically tuned to control diffusion and release of encapsulated agents.  For 
example, ester-containing cross-links hydrolyze in aqueous solution while amide-
containing cross-links are stable in water.  Thus, the extent of cross-linking combined 
with variation of the cross-linking chemistry, provides opportunities for controlling 
diffusion across the membrane.  
Although a number of cross-linking chemistries are accessible through the 
polyolefin backbone, a ring-opening cross-metathesis approach using bis-cyclooctene 
PEG was initially chosen to generate the desired cross-linking.  Ring-opening cross-
metathesis is an extremely useful methodology in small molecule synthesis
25
 and can be 
performed under mild conditions that do not disrupt the polymer assembly.  To 
accomplish the cross-linking, a bis-cyclooctene PEG cross-linker 31 was prepared by 
reaction of two equivalents of carboxylic acid functionalized cyclooctene 2 and ?,?-PEG 
diol under carbodiimide coupling conditions as shown in Scheme 3.1. These bis-
functionalized molecules are, like the graft copolymers, interfacially active.  This is key 
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to the cross-linking strategy since only small quantities of the bis-cyclooctene are needed 
to achieve effective cross-linking of the polymer assembly. 
 
Scheme 3.1  Synthesis of bis-cyclooctene cross-linker 31 by carbodiimide coupling of 
2 and PEG diol  
 
 
Figure 3.1 depicts the segregation of PCOE-g-PEG copolymers to the oil-water 
interface and cross-linking with bis-cyclooctenyl PEG and a ruthenium benzylidene 
catalyst to generate capsules with cross-linked membranes.  Experimentally, the hollow 
polymer capsules were prepared by combining graft copolymer 25 (0.25 wt %) with bis-
cyclooctene cross-linker 31 (2 wt %) in toluene.  Grubbs’ Generation II catalyst (catalyst 
II) was then added to the solution, and the mixture is added to water.  This heterogeneous 
mixture was shaken for 15 minutes to produce cross-linked capsules with sufficiently 
robust membranes.  Catalysts I and III were also tested in interfacial metathesis cross-
linking but reaction kinetics were found to be too slow in the case of catalyst I and too 
fast for catalyst III to cleanly form cross-linked capsules. 
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Figure 3.1  Schematic illustration of interfacial assembly of polycyclooctene-g-PEG 
and cross-linking by ring-opening cross-metathesis with bis-cyclooctene 31 
 
 
The capsules possess diameters in the micron-size range and can easily be 
visualized by optical microscopy.  However, the spatial distribution of polymer in the 
assembly (i.e. oil phase, aqueous phase, or interface) could not be determined by optical 
microscopy.  The polymer was also not amenable to fluorescence microscopy due to the 
lack of fluorescence emission from the as-prepared copolymers.   Thus, we prepared a 
fluorescent cyclooctene derivative 32 through esterification of 5-hydroxy-1-cyclooctene 
(1) with Rhodamine B as shown in Scheme 3.2, and integrated this new monomer into 
  67 
the amphiphilic graft copolymer by copolymerization with cyclooctene and the PEG-
functional cyclooctene macromonomer.  The functional group tolerance of catalyst II was 
essential for the preparation of this fluorescent polyolefin.   
 
 
Scheme 3.2  Synthesis of fluorescent-labeled cyclooctene 32 by coupling of 1 and 
Rhodamine B 
 
 
Confocal laser scanning microscopy (CLSM) images of the fluorescent 
amphiphilic graft copolymer in oil-in-water biphasic systems (shown in Figure 3.2A) 
reveals a strong preference of the graft copolymer for the interface, as indicated by the 
emission at 556 nm at the equator of an oil droplet in water while a very weak 
fluorescence was observed in both the toluene-filled droplet core and the aqueous phase.  
The integration of the fluorescent probe into the polyolefin backbone also permitted 
further investigation of the capsule morphology, mechanical integrity, and size 
distribution.  Using confocal microscopy, a three-dimensional reconstruction of the 
capsules was assembled (Figure 3.2B) to illustrate their spherical nature and complete 
coverage by the polymer.  Figure 3.2C demonstrates the robust nature of the interfacial 
cross-linking reaction.  In this experiment, the two-phase oil/water mixture used to create 
the assembly is replaced with ethanol, a mutually good solvent for both phases.  In this 
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case, the capsules do not dissolve away and the collapsed, cross-linked membrane can be 
isolated and visualized clearly.   
 
Figure 3.2 Confocal laser scanning microscopy of fluorescent-labeled graft 
copolymer capsules, A) cross-sectional slice, B) 3-D projection image of polymer-
covered capsules, C) collapsed capsule after introduction of ethanol 
 
 
Figure 3.3A illustrates a representative confocal micrograph showing cross-
sectional slices of several fluorescent-labeled capsules following preparation by hand 
shaking the oil-water mixture.  Capsules produced by this method typically possess 
diameters ranging from 20 – 50 μm with an average diameter of approximately 30 μm.  
AFM analysis was also performed on a dried capsule to qualitatively determine the 
thickness of the capsule membrane.  A representative AFM micrograph, shown in Figure 
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3.3B, suggests the presence of a very thin polymer membrane (approx. 10 – 20 nm) on 
the droplet surface.  
 
Figure 3.3  A) Confocal micrograph of cross-linked capsules and statistical analysis 
plotting capsule diameter versus capsule number, B) AFM height analysis of a dried 
capsule; the red arrows indicate where height measurements were made 
 
  
The ease with which these oil-filled capsules can be prepared suggests a 
practicality for many types of encapsulation, where the encapsulant is either dissolved in 
an oil phase or is itself a hydrophobic liquid.  In many cases, clinical use of attractive 
drug candidates has been impeded by their poor aqueous solubility.  For the 
chemotherapy drug doxorubicin (DOX) (shown in Figure 3.4), water solubility is 
achieved by protonation of the primary amine.  Drug modifications of this type can alter 
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pharmacokinetic profiles and in some cases increase renal clearance and thus shorten 
circulation lifetimes.  Using the oil-in-water assembly method described above, DOX in 
its neutral form can be encapsulated in the oil phase of the capsule.  The inherent 
fluorescence of DOX allows its visualization in the capsule by confocal microscopy.  
Figure 3.4 shows a three-dimensional projection image of these DOX-filled capsules 
(fluorescence at 580 nm).   
 
Figure 3.4  Confocal micrograph of DOX-filled, cross-linked capsules 
 
 
Relative to lipid emulsions or polymer micelles, drug encapsulation using cross-
linked, polymer capsules should allow for higher drug loadings and is limited only by the 
solubility of the drug in the oil medium.  In addition, the use of PEG-grafted polyolefins 
in the oil-water interfacial assembly method presents PEG grafts and oligopeptide-
functional PEG grafts (e.g. copolymer 30) at the capsule surface.  This unique feature 
should enhance capsule biocompatibility and may facilitate potential applications in 
targeted drug delivery. 
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3.2.2 Polymer Capsules Prepared from Reactive PCOE-g-PEG Copolymers at the 
Oil-water Interface 
Ring-opening cross-metathesis cross-linking of interfacially segregated 
PEGylated polyolefins represents a rapid route to produce polymer capsules without the 
need for additional processing steps often encountered with other capsule preparation 
techniques (e.g. LbL assembly, nanoparticles templating).  However, this method also 
presents a number of limitations when preparing capsules for application in drug 
delivery.  First, PCOE-g-PEG copolymers, such as copolymer 25, which are prepared by 
polymerization of ester-linked macromonomers 3 and 4 possess PEG grafts which are 
connected to the PCOE backbone through hydrolyzable ester linkages that may degrade 
upon storage in water and result in capsule instability.  Second, the metathesis cross-
linking technique utilizes a hydrophobic ruthenium benzylidene catalyst that remains 
encapsulated in the toluene droplet following cross-linking.  Removal of the catalyst from 
the toluene phase was challenging and concerns existed over its potential reactivity 
towards other encapsulated species.  Finally, attempts to control capsule size and 
dispersity using sizing techniques such as membrane extrusion were limited because 
metathesis cross-linking kinetics are difficult to control.  In most cases, metathesis cross-
linking using catalyst II was complete before membrane extrusion could be performed. 
An ideal capsule preparation method would involve loading a hydrophobic solute 
in the oil-filled core of the polymer assembly, reducing the capsule diameter to 1 μm or 
smaller (e.g. by membrane extrusion, sonication, or other sizing techniques), and rapidly 
cross-linking the assembly to encapsulate the drug.  We hypothesized that incorporating 
reactive, cross-linking functionality into the polymer backbone could address these issues 
by providing a means to control the kinetics and extent of cross-linking without the need 
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for additional hydrophobic additives.  In addition, we sought to utilize cross-linking 
chemistries that are reversible in response to environmental stimuli (e.g. pH changes).  
By doing so, we envisioned the design of polymer capsules with triggered degradation 
and drug release based on the pH of the capsule environment. 
In one example, we describe a new method of capsule cross-linking utilizing 
novel polyolefin-graft-PEG copolymers with pendent phenyl azides, prepared by ROMP 
of phenyl azide-functionalized cyclooctenes and PEGylated cyclooctene 
macromonomers.  Ether-linked, PEG macromonomers 9 and 10 were used to synthesize 
graft copolymers in these studies and impart much greater hydrolytically-stable to the 
PEG grafts and the resulting capsules.  The phenyl azide-functional amphiphilic 
copolymers segregate to the oil-water interface and undergo rapid cross-linking upon 
exposure to UV-light through highly reactive nitrenes generated upon photolysis of the 
phenyl azides.  This method of capsule cross-linking simplifies the prior cross-metathesis 
technique, as precise amounts of cross-linking functionality can be incorporated directly 
into the polymer backbone by ROMP.  Thus, variation of key properties such membrane 
thickness and cross-link density can be achieved without the need for additional additives 
(e.g. ruthenium catalysts and bis-cyclooctene cross-linkers) to the interfacial assembly.   
Another approach utilizes hydrazine-functional PCOE-g-PEG copolymers that are 
prepared by ROMP of a novel N-butyloxycarbonyl (Boc)-protected, acyl hydrazine-
functionalized cyclooctene.  Upon deprotection of the Boc protecting group with 
trifluoroacetic acid (TFA) and oil-water interfacial assembly, the assembled polymer is 
cross-linked with glutaraldehyde to yield robust polymer capsules with pH-reversible 
hydrazone cross-links.  
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3.2.2.1 Polymer Capsules Prepared by Photolysis of Phenyl Azide-functional PCOE-
g-PEG Copolymers at the Oil-water Interface 
The incorporation of phenyl azide functionality into the graft copolymer 
backbone, for photo-induced cross-linking, was accomplished by the synthesis and 
copolymerization of both amide-linked and ester-linked phenyl azide-functionalized 
cyclooctenes.  The choice of linker chemistry (between the cyclic olefin and azide) is an 
additional tunable parameter of the polymer capsule.  As the phenyl azide serves as the 
cross-linking moiety during capsule formation, variation in the hydrolytic stability of the 
cyclooctene-phenyl azide linkage should control the degradation rates of the cross-linked 
capsules. 
To prepare the hydrolytically-stable, amide-linked phenyl azide, amine-
functionalized cyclooctene 35 was first prepared in two steps from 5-bromo-1-
cyclooctene
26
 as shown in Scheme 3.3.  5-bromo-1-cyclooctene
 
(33) was converted to 5-
azido-1-cyclooctene (34) by nucleophilic substitution with sodium azide in 
dimethylsulfoxide (DMSO).  Next, the azide functionality was reduced with 
triphenylphosphine and water, and 5-amino-1-cyclooctene (35) was isolated by fractional 
distillation in 35% overall yield.  To synthesize the phenyl azide-functional cyclooctene, 
4-azidobenzonic acid
27,28
 (36) was converted to 4-azidobenzoyl chloride (37) with thionyl 
chloride and excess triethylamine, and 35 was added to this solution by syringe in a one-
pot reaction.  Following work-up and purification by column chromatography, amide-
linked, phenyl azide-functional cyclooctene 38 was isolated in 95% yield. 
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 Scheme 3.3  Synthesis of amide-linked, phenyl azide-functionalized cyclooctene 38 
 
 
The synthesis of hydrolytically-degradable, ester-linked cyclooctene phenyl azide 
was initially attempted by substituting 5-hydroxy-1-cyclooctene (1) for 35 in the reaction 
with 4-azidobenzoyl chloride as shown in Scheme 3.4A.   In this case, however, yields of 
monomer 39 were less than 10% in all reaction attempts.  We attributed low yields to the 
reduced reactivity and steric limitations of the secondary alcohol when compared to 
primary amine-functionalized 35.  In addition, monomer 39 is a liquid at room 
temperature, which reduces the storage stability of the highly reactive phenyl azide.  It 
was hypothesized that both ester and amide linkages would be required to impart 
hydrolytic degradability and promote crystallization, as we found that isolating phenyl 
azide-functionalized molecules as crystalline solids dramatically improves their long-
term storage stability.  To accomplish this, a multi-step synthetic approach was 
undertaken as illustrated in Scheme 3.4B.  In the first step, 5-hydroxy-1-cyclooctene (1) 
was reacted with N-Boc-protected glycine by carbodiimide coupling.  The Boc-protecting 
group was subsequently removed with anhydrous hydrochloric acid (4.0 M HCl solution 
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in dioxane) to yield glycine-functionalized cyclooctene 40 as the hydrochloride salt.  
Finally, 40 was reacted with 4-azidobenzoyl chloride (37) in the presence of excess 
triethylamine to give phenyl azide-functional cyclooctene 41, with both ester and amide 
linkages, in 85% yield.  As expected, the incorporation of the amide linkage promoted 
crystallization of 41, which dramatically improved its long-term stability.  Monomers 38 
and 41 remain chromatographically pure after over two years of storage at -80 
o
C in the 
dark. 
 
Scheme 3.4  Synthetic routes to hydrolytically-degradable, ester-linked phenyl 
azide-functionalized cyclooctenes 
 
 
Amide-linked and ester-linked phenyl azide-functionalized cyclooctenes 38 and 
41 were then copolymerized with ether-linked PEG macromonomers 9 and 10 and 
cyclooctene to prepare phenyl azide-functionalized graft copolymers.  The incorporation 
of azide functionality into polymer materials has recently gained considerable attention, 
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mainly due to interest in post-polymerization functionalization reactions with alkyne-
functional substrates using Sharpless type “click chemistry” (i.e. [3+2] 
cycloaddition).
29,30  
However, reports of azide incorporation into polyolefins have been 
limited, presumably due to the incompatibility of azides and transition metal catalysts.  
For example, Noels and coworkers were unsuccessful in their attempts to ROMP an 
azide-functional cyclooctene which they attributed to deactivation of the Ru(II)-arene 
catalyst.
31  
In more recent work, Binder and coworkers prepared poly(oxanorbornenes) 
with pendent azides, but these were synthesized by post-ROMP incorporation of azide 
functionality by reaction of sodium azide with bromide-functional polymers.
32  
Indeed, in 
our initial attempts to polymerize phenyl azide-functional cyclooctenes 38 and 41 using 
catalyst II, we found that polymerizations required relatively long times (1-2 hours) to 
achieve high conversions.  In addition, the polymers possessed very broad PDI values 
(>3.0) and multi-modal molecular weight distributions.   
In contrast, we found that phenyl azide-functionalized amphiphilic graft 
copolymers could be prepared by in very short time periods and with relatively good 
control of both molecular weight and molecular weight distribution using catalyst III.  
For example, copolymers 42 and 43 (shown in Scheme 3.5) were prepared using 20 mol 
% of amide-linked, phenyl azide-functional cyclooctene 38 or ester-linked, phenyl azide-
functional cyclooctene 41, 50 mol % unsubstituted cyclooctene, and 30 mol % PEG-
functionalized cyclooctene macromonomer 9 (PEG MW approx. 2200) in THF ([M] = 
1.0 mol/L).  Catalyst III was utilized at a monomer-to-catalyst ratio of 50:1.  
Polymerization was terminated with ethyl vinyl ether, and the polymer was isolated by 
precipitation into cold diethyl ether.  In contrast to polymerizations using catalyst II, 
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GPC analysis of polymer 42, prepared using catalyst III, showed a single Gaussian peak 
with number-average molecular weight of approximately 47,000 Da and a PDI of 2.6.  
1
H 
NMR analysis of polymers 42 and 43 in CDCl3 showed an absence of cyclic olefinic 
proton resonances at ? 5.70 ppm and new backbone olefin resonances at ? 5.35 ppm.  
Aromatic resonances from the phenyl azide at ? 7.04 and ? 8.00 ppm were also visible in 
the spectrum, and aromatic proton integration referenced against the olefinic backbone 
resonances suggested approximately 20 mol % of the azide-functional cyclooctene 
incorporated into the polymer.  ATR-FTIR analysis of polymers 42 and 43 confirmed the 
incorporation of azides 38 and 41, as indicated by the diagnostic azide stretch at 2190 cm
-
1
 and carbonyl stretching vibrations at 1662 cm
-1
 (amide carbonyl stretch of polymers 42 
and 43) and 1747 cm
-1
 (ester carbonyl stretch, polymer 43). 
 
Scheme 3.5  Synthesis of phenyl azide-functionalized graft copolymers by 
copolymerization of 38 or 41 with 17 and macromonomer 9 
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Before utilizing phenyl azide-functionalized copolymers to prepare polymer 
capsules, cross-linking studies using solvent-cast films of 42 and 43 were performed to 
confirm the effectiveness of nitrene cross-linking.  Solutions of these polymers were 
prepared in dichloromethane, cast onto glass slides, and dried in the dark.  Next, both 
thin-film samples were analyzed by ATR-FTIR spectroscopy before and after placement 
in a UV-cross-linking apparatus (302 nm light source).  As shown in Figure 3.5, after five 
minutes of exposure to 302 nm light, the diagnostic azide stretch at 2190 cm
-1
 disappears, 
suggesting a reaction of the incorporated phenyl azide.  In addition, the films were no 
longer soluble in water or organic solvents.  Attempts to re-dissolve the cast films in 
dichloromethane resulted in film swelling and delamination from the glass slide, but a 
homogeneous solution could not be obtained, suggesting effective cross-linking of the 
films.  Cross-linked films of copolymer 43, which contains a hydrolytically-degradable 
ester linkage between the phenyl azide functionality and the polymer backbone, could be 
hydrolyzed with an aqueous potassium hydroxide solution (0.1 M).  After stirring 
overnight, homogeneous solutions of 43 were obtained, suggesting that polymer cross-
linking occurs exclusively through reaction of the phenyl azide moiety.  Copolymer 42, 
which contains a hydrolytically-stable amide linkage, did not dissolve under similar 
conditions. 
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Figure 3.5  ATR-FTIR spectrum of a solvent-cast film of polymer 43 before and 
after UV cross-linking (5 min exposure) 
 
 
Upon photolysis, phenyl azides are converted to highly reactive nitrenes, which 
can undergo a number of chemical reactions as illustrated in Figure 3.6B.  For example, 
nitrenes are known to insert into C=C and C-H bonds to form aziridines and aryl amines, 
respectively,
33 
and we hypothesized that nitrene insertion into the polyolefin backbone 
seemed most plausible in light of these known chemistries.  However, based on the ATR-
FTIR spectrum in Figure 3.5, there is insufficient spectral data to determine the exact 
chemistries involved in nitrene cross-linking of the graft copolymer films (e.g. aziridine 
formation, C-H bond insertion).  
1
H NMR analysis of cross-linked copolymer 43 
following hydrolysis and lyophilization also yielded few clues to the exact nature of the 
nitrene cross-linking reaction due to the complexity of the hydrolyzed polymer structure 
and the number of nitrene reactions that are possible. 
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To prepare polymer capsules using the nitrene cross-linking technique, polymer 
42 or 43 was dissolved in toluene (0.2 wt % solution) and added to a glass vial containing 
deionized water (10 mL).  The heterogeneous mixture was shaken gently for several 
seconds to form the polymer assembly as illustrated in Figure 3.6A.  The vial was then 
placed in a UV cross-linking apparatus and exposed to 302 nm light for one minute.  The 
vial was gently shaken to redisperse the capsules and re-exposed to 302 nm light for one 
minute.  This process was repeated three more times for a total of 5 minutes of UV 
exposure.  
 
Figure 3.6  A) Illustrative representation of oil-water interfacial assembly and UV 
cross-linking of phenyl azide-functional copolymers, B) potential nitrene chemistries 
involved in interfacial cross-linking 
 
 
  81 
Capsules prepared by this method using copolymer 42 are shown in Figure 3.7A.  
The contrast in this confocal scanning laser micrograph is provided by the encapsulation 
of a hydrophobic fluorescent dye, Coumarin 153 (excitation 423 nm, emission 530 nm) in 
the toluene phase of the assembly.  Like the polymer assemblies created from copolymer 
25, the UV cross-linked capsules created with copolymer 42 are polydisperse in nature 
with diameters ranging from 10 – 40 microns.  The capsules maintain their spherical 
shape and retain the dye in the oil-filled interior following the cross-linking reaction. 
 
Figure 3.7  A) Confocal micrograph of Coumarin 153-filled, photo-cross-linked 
capsules prepared from copolymer 42, B) collapsed capsules in solution after 
interface removal with methanol, C) dried capsules drop-cast from solution  
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  To demonstrate the effectiveness of nitrene cross-linking, the oil-water interface 
was removed by washing with methanol.  Rather than dissolve away, the capsule 
membrane collapses and appears to retain some of the encapsulated dye as shown in 
Figure 3.7B.   Fluorescence from released dye can also be seen in the background 
suggesting that the small molecules can permeate through the polymer membrane.  UV 
cross-linked capsules were drop-cast onto glass slides and visualized in the dried state by 
confocal microscopy as shown in Figure 3.7C.  In this experiment, the mechanical 
robustness of the capsule membrane is exemplified, as dried capsule membranes are 
observable with folds and ridges resulting from evaporation of the toluene phase and 
membrane collapse upon drying.  In this micrograph, some released dye can be seen as a 
halo around the capsules further suggesting the permeability of small molecules across 
the membrane.  To investigate the properties of the capsule membrane, UV cross-linked 
capsules prepared from copolymer 42 were drop cast from solution, coated with gold, and 
analyzed by SEM.   Figure 3.8A shows an almost completely intact capsule membrane 
after drying while Figure 3.9B represents a dried capsule that has ruptured, presumably 
due to the reduced pressure (10
-7
 Torr) required for SEM analysis.  Like the AFM data 
presented in Figure 3.3B, this micrograph further illustrates the extremely thin nature 
(less than 50 nm) of the polymer membrane produced from the interfacial 
assembly/cross-linking method. 
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Figure 3.8  SEM micrographs of UV cross-linked capsules prepared from copolymer 
42 
3.2.2.2  Polymer Capsules Prepared from Acyl Hydrazine-containing PCOE-g-PEG 
Copolymers at the Oil-water Interface 
The ability to trigger drug release from polymeric delivery systems in response to 
physiological stimuli (e.g. changes in pH, ionic strength, temperature) is a promising 
method to target drug delivery to a specific diseased site (e.g. solid tumors).  Of these 
physiological stimuli, changes in environmental pH have been the most widely studied 
for triggered drug release.
34
  This is due to pronounced pH gradients that exist in 
microenvironments of both healthy and diseased tissues in the body.  For example, the 
pH in the stomach can be as low as 1.0 but rapidly increases to 6.0 – 6.5 in the small 
intestine.  Within the cellular microenvironment, pH values range from 7.4 in the 
extracellular matrix to values of 6.0 – 4.5 in endosomal and lysosomal compartments, 
respectively.  When targeting drugs to tumors, many groups have attempted to exploit the 
pH gradient between normal tissue and solid tumors, which possess values of 
approximately 7.4 and 6.0, respectively.
35,36 
 One approach has been to covalently attach 
drugs to polymeric delivery systems using pH-sensitive linkages that are reversible in 
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acidic pH environments.  Thus, drug release can be isolated specifically in low pH 
environments encountered in solid tumors or inside diseased cells.  Of these chemistries, 
the reaction between hydrazines and aldehyde or ketone-containing drugs to form 
hydrazone linkages (shown in Figure 3.9) has been widely used for pH-triggered drug 
delivery.
34  
In neutral and basic pH environments, hydrazone hydrolysis is slow, but in 
acidic environments, hydrolysis becomes favored and results in triggered release of the 
conjugated drug from the delivery system.  Thus, faster drug release rates are observed in 
environments with increasing acidity.  Fréchet and coworkers utilized this chemistry to 
conjugate DOX, which contains ketone functionality, to hydrazine-functionalized 
polyester dendrimers and demonstrated dramatically accelerated DOX release in 
environments with a pH value of 5.5 or less.
37,38
  Kataoka and coworkers used a similar 
approach to conjugate DOX to a hydrazine-functionalized, PEG-b-polyamino acid 
copolymer.
39
  They also observed selective DOX release in the lysosomal compartments 
(i.e. pH 6.0 or less) of SBC-3 lung cancer cells using confocal microscopy. 
 
Figure 3.9  pH-reversible hydrazone formation by condensation of hydrazine and an 
aldehyde or ketone 
 
 
We hypothesized that utilizing pH-sensitive reactions to cross-link amphiphilic 
polyolefins at the oil-water interface would produce stimuli-responsive polymer capsules, 
potentially capable of pH-triggered drug release.  Our initial efforts focused on the 
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synthesis of photo-cross-linkable, phenyl azide-functional cyclooctenes that were linked 
by pH-sensitive hydrazone or acetal moieties, such as compounds 44 and 45, in Figure 
3.10.  However, the synthesis and polymerization of these compounds proved 
challenging.  Attempts to ROMP compound 44 were unsuccessful, possibly due to 
catalyst reactivity towards the hydrazone functionality, and compound 45 could not be 
isolated in sufficient purity for polymerization.  Thus, a new pH-sensitive cross-linking 
strategy, which utilizes hydrazine-functionalized, amphiphilic graft copolymers in 
conjunction with bis-aldehyde cross-linking was devised to circumvent the use of phenyl 
azide-functional monomers 44 and 45.   
 
Figure 3.10  Examples of pH-reversible cyclooctene-phenyl azide derivatives 
 
While a number of methodologies exist to introduce hydrazine functionality into 
amphiphilic polyolefins, we chose to synthesize a Boc-protected, hydrazine-
functionalized cyclooctene since the introduction of this functional monomer provides 
much greater control over hydrazine content when compared to other post-polymerization 
functionalization strategies.   To accomplish this, 5-cyano-1-cyclooctene (46) was first 
synthesized in two steps by monobromination of cyclooctadiene (COD) followed by 
nucleophilic substitution with sodium cyanide as reported by Grubbs and coworkers.
26  
Nitrile-functionalized 46 was then oxidized to 5-carboxylic acid-1-cyclooctene (47) by 
alkaline hydrolysis with hydrogen peroxide in 62% yield.
40  
In the final step, tert-butyl 
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carbazate was coupled to 47 by DMAP-catalyzed, carbodiimide coupling.  Following 
purification by column chromatography and crystallization in hexanes, Boc-protected, 
acyl hydrazine-functionalized cyclooctene 48 was isolated as a solid in 63% yield. 
 
Scheme 3.6  Synthesis of Boc-protected, hydrazine-functionalized cyclooctene 48 
 
Hydrazine-functional copolymer 49 was then prepared using 50 mol % Boc-
protected, hydrazine-functionalized cyclooctene (48), 20 mol % unsubstituted 
cyclooctene, and 30 mol % PEG-functionalized cyclooctene macromonomer 9 (PEG MW 
approx. 2200) in DCM ([M] = 1.0 mol/L) using catalyst II as illustrated in Scheme 3.7.  
The molecular weight of the copolymer was controlled by the addition of the chain 
transfer agent, 1-hexene ([M]/[CTA] = 100).  Boc-protection of the hydrazine-
functionalized cyclooctene is needed for ROMP, as primary amines, and presumably 
hydrazines, coordinate to ruthenium benzylidene catalysts, such as catalysts I, II, and III, 
and render them unreactive for metathesis chemistry.  In this case, Boc-protected 48 was 
found to successfully undergo ROMP when copolymerized with 17 and 9 in the presence 
of catalyst II.  
1
H NMR analysis of copolymer 49 in d6-DMSO revealed an absence of 
cyclic olefin resonances at ? 5.70 ppm and new olefin resonances at ? 5.35 corresponding 
the polyolefin backbone.  Proton resonances at ? 1.39 ppm corresponding to the tert-butyl 
protons on the Boc protecting group and resonances at ? 9.47 ppm and ? 8.65 ppm, 
corresponding to the Boc-protected hydrazine, confirmed the incorporation of 48 into the 
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copolymer structure.  However, unique resonances corresponding to the methyne proton 
adjacent to the acyl hydrazine at ? 1.95 ppm and tert-butyl protons of the Boc protecting 
group (? 1.39 ppm) overlap with other polyolefin backbone resonances which precluded 
the quantification of 48 incorporated into copolymer 49.  
13
C NMR analysis provided 
further evidence of successful incorporation of hydrazine-functionalized 48 as carbonyl 
resonances of the Boc-protected hydrazine were observed at ? 155.0 ppm and ? 174.3 
ppm.  GPC analysis in THF approximated the molecular weight of copolymer 48 to be 
97,800 g/mol with a PDI of 2.06. 
 
Scheme 3.7  Synthesis of hydrazine(Boc)-functional PCOE-g-PEG copolymer 49 
 
 
Boc-protected copolymer 49 was deprotected with a 50% solution (v/v) of 
trifluoroacetic acid (TFA) in dichloromethane as illustrated in Scheme 3.8.  Following 
precipitation into diethyl ether, hydrazine-functionalized graft copolymer 50 was isolated 
in near quantitative yield.  
1
H NMR analysis of copolymer 50 revealed an absence of tert-
butyl proton resonances at ? 1.39 ppm, confirming the deprotection of the Boc protecting 
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group.  In this case, the copolymer is isolated as the trifluoracetate salt following 
deprotection as it was found that copolymer 50 can be utilized in the salt form for the 
preparation of polymer capsules by glutaraldehyde cross-linking.  For long-term storage 
of the copolymer, the neutralization of the TFA salt with an organic base such as 
triethylamine proved to be advantageous to prevent polymer degradation. 
 
Scheme 3.8  Synthesis of hydrazine-functional PCOE-g-PEG copolymer 50 
 
 
Polymer capsules were prepared by interfacial assembly of copolymer 50 and 
subsequent cross-linking by addition of glutaraldehyde as shown in Figure 3.11.  
Experimentally, copolymer 50 (15 mg) was dissolved in deionized water (10 mL) 
followed by addition of toluene (0.5 g).  The mixture was shaken gently to form the 
polymer assembly, and 400 mg of a 50 wt % aqueous glutaraldehyde solution was added 
to create a 2 wt % solution of glutaraldehyde.   The mixture was allowed to stand for at 
least 4 hours to produce the hydrazone cross-linked capsules.  The toluene-filled capsules 
float to the top of the aqueous solution and excess water and glutaraldehyde were 
removed by pipette.  Fresh DI water (adjusted to pH 8.0 by addition of NH4OH) was 
  89 
added to the capsule solution, and this washing process was repeated a total of four times.  
The use of water-soluble graft copolymers and cross-linkers, such as glutaraldehyde, is 
advantageous since repeated washing steps efficiently remove excess reagents.  Dialysis 
of the capsules against basic water (pH 8.0) using a 250,000 molecular weight cutoff 
membrane was also found to be an effective method of removing excess polymer and 
glutaraldehyde. 
 
Figure 3.11  Illustration of oil-water interfacial assembly and cross-linking of 
hydrazine-functional copolymer 50 with glutaraldehyde 
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To test the effectiveness of hydrazone cross-linking, polymer capsules prepared 
using copolymer 50 were drop-cast onto glass slides and evaluated by optical 
microscopy.  As seen in Figure 3.12, the capsules maintain the structural integrity due to 
cross-linking and the thin polymer membrane is observable at 20X magnification.   
 
Figure 3.12  Optical micrographs of hydrazone cross-linked polymer capsules 
prepared from copolymer 50 (20X magnification) 
 
 
To further investigate the cross-linked capsules by confocal scanning laser 
microscopy, a fluorescent-labeled, hydrazine-functionalized graft copolymer was 
prepared in an analogous fashion to copolymer 50 but with the addition of 0.5 mol % 
Rhodamine B-labeled cyclooctene 32.  Following polymerization and deprotection with 
TFA, fluorescent-labeled copolymer 50 was utilized to prepare hydrazone cross-linked 
capsules as described above.  As seen in Figure 3.13A, copolymer 50 shows a strong 
interfacial preference as the fluorescence signal is observed almost exclusively at the oil-
water interface.  Following introduction of methanol to the capsule suspension, the 
interface is removed, revealing collapsed capsules with cross-linked polymer membranes 
as illustrated in Figure 3.13B.  The capsule membrane can also be visualized by simply 
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drop-casting the capsule suspension followed by solvent evaporation as seen in Figures 
3.13C and 3.13D.  These images further illustrate the very thin, mechanically robust 
polymeric shell that is produced using the hydrazone cross-linking technique.  
 
 
Figure 3.13  Confocal micrographs of hydrazone cross-linked polymer capsules 
prepared using fluorescent-labeled, copolymer 50; A) toluene-filled capsules, B) 
collapsed capsule following interface removal with methanol, C) and D) dried 
capsules that were cast from solution 
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To evaluate the degradation properties of hydrazone cross-linked polymer 
capsules, two fluorescent-labeled capsule samples were prepared from copolymer 50, 
drop-cast from solution onto a glass slide, and then immersed in either acidic (HCl, pH 
2.5) or neutral (PBS, pH 7.4) water.  Sample degradation was monitored over time by 
confocal microscopy, as this allows for direct visualization of the degradation process.  
Figure 3.14 shows comparative images of capsules immersed in acidic water (Figure 
3.14A) or neutral water (Figure 3.14B) after 0, 1, 2, 3, and 8 hours.  Before immersion in 
water (0 hour), both capsules are flat with characteristic ridges created from the drying 
process.  As seen in Figure 3.14A, after 1 hour of immersion in acidic water, the capsule 
appears to become porous with visible holes in the polymer membrane.  This image 
suggests that capsule degradation occurs in acidic water, as expected from capsules cross-
linked by hydrazone linkages.  In comparison, Figure 3.14B shows time-lapse images of 
a capsule immersed in phosphate buffered saline (pH 7.4).  In this case, the capsule does 
not degrade but appears to swell over time, a result of its hydrophilicity and cross-linking.  
Taken together, this data suggests that capsule degradation is a pH-dependant process 
with minimal degradation observed at neutral pH and slow degradation occurring due to 
hydrazone hydrolysis at pH 2.5.   
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Figure 3.14  Time-lapse, confocal projection micrographs of hydrazone cross-linked 
polymer capsules prepared using fluorescent-labeled copolymer 50 after immersion 
in A) pH 2.5 water (HCl), B) pH 7.4 phosphate buffered saline  
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To compare the degradation and swelling of hydrazone-crosslinked capsules at 
pH 2.5 versus pH 7.4, cross-sectional image stacks of the two samples were used to 
produce three-dimensional height images using ImageJ software.  In both cases, the 
capsules are not visible in height images compiled at 0 minutes and are barely visible in 
the images compiled after 30 minutes of immersion (Z place scale 0 – 18 μm) due to the 
extremely thin nature of the collapsed polymer membrane.  Figure 3.15A compares the 
height image of a capsule following 30 minutes and 8 hours of immersion in pH 2.5 
water.  From these two images, it is clear that capsule swelling occurs at low pH as 
evidenced by the increase in height of the capsule, particularly at the capsule perimeter.  
However, when compared to similar images of the capsule immersed in PBS (Figure 
3.15B), swelling in this environment is much more pronounced after 8 hours of 
immersion.  Furthermore, comparison of the two images after 8 hours of immersion 
reveals some degradation in center of the capsule at pH 2.5, as evidenced by the 
decreased overall height of the polymer membrane when compared to the capsule 
immersed in PBS.  In contrast, significant swelling of the entire capsule is observed for 
the sample immersed in PBS with little evidence of degradation.  While this data suggests 
that hydrazone cross-linked capsule degradation is more pronounced at pH 2.5 versus 7.4, 
additional experiments will be needed to verify these observations.  These experiments 
include the investigation of capsule degradation at neutral and acidic pH over longer time 
periods (several days to weeks) and GPC analysis of capsule degradation products at a 
range of pH values (e.g. 1.0 – 7.4) over time.  This initial proof-of-concept along with 
additional experiments may prompt exploration of hydrazone cross-linked capsules for 
pH-triggered release of encapsulated solutes. 
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Figure 3.15  Three-dimensional height images constructed from confocal 
microscopy analysis of hydrazone cross-linked polymer capsules, A) pH 2.5 water 
(HCl), B) pH 7.4 phosphate buffered saline  
3.2.3 Water-filled Polymer Capsules Prepared by Water-in-oil Assembly and Cross-
linking of PCOE-g-PEG Copolymers 
We have demonstrated that amphiphilic PEGylated polyolefins are well-suited for 
assembly and stabilization of oil-water interfaces.  The majority of the experiments 
described in Chapter 3 of this thesis utilize oil-in-water dispersions for assembly and 
cross-linking, as this method is applicable for the encapsulation of hydrophobic drugs and 
other water-insoluble agents.  However, for some applications, it is advantageous to 
produce polymer capsules from water-in-oil dispersions, thereby permitting the 
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encapsulation of water-soluble compounds.  To demonstrate the versatility of PCOE-g-
PEG copolymers in producing water-filled polymer capsules, these copolymers were also 
utilized to produce stable, water-in-toluene dispersions, which were subsequently UV 
cross-linked using a bis-phenyl azide cross-linking additive.   
Initial attempts to prepare water-in-toluene dispersions were made using 
copolymer 42 which contains 20 mol % phenyl azide functionality and 30 mol % PEG 
2200 macromonomer 9.  This level of PEG incorporation renders the copolymer very 
soluble in water, and we found that amphiphilic graft copolymers with such high PEG 
contents did not successfully form water-in-oil dispersions.  Instead, PCOE-g-PEG 
copolymers such as copolymer 52 (shown in Figure 3.16), prepared in a similar fashion to 
copolymer 29 but with 5 mol % PEG 4400 grafts proved suitable for stabilizing water-in-
toluene droplets.  Copolymer 52 is not soluble in water but highly soluble in toluene, 
which proved to be a key feature for preparing water-in-oil capsules.   
Initial efforts to cross-link water-in-toluene assemblies focused on the 
incorporation of phenyl azide functionality into the copolymer through copolymerization 
of 38.  Although these copolymers produced cross-linked capsules, we found that the use 
of a toluene-soluble, bis-phenyl azide was also effective for UV cross-linking of water-
in-toluene dispersions.  bis-Azide cross-linker 51 was prepared in one-step from 
commercially available, 4-aminophenyl sulfone as shown in Scheme 3.9.  Utilizing this 
small molecule cross-linker obviates the need to synthesize and copolymerize 38, and 
thus, copolymer 52 can be prepared using the commercially available catalyst II.  These 
features are particularly attractive for making large batches of cross-linked capsules due 
to the reduced reagents costs and fewer synthetic steps needed. 
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Scheme 3.9  Synthesis of bis-phenyl azide cross-linker 51 
 
  
To prepare water-in-toluene capsules, copolymer 52 (12.5 mg) and bis-phenyl 
azide cross-linker 51 (5 mg) were dissolved in 10 mL of toluene followed by addition of 
0.25 g of deionized water.  The mixture was vigorously shaken to form the water-in-
toluene assemblies which were subsequently UV cross-linked using a 302 nm light 
source as illustrated in Figure 3.16.  The depiction of PEG grafts residing mainly in the 
aqueous phase of the dispersion is based on the known solubility preference of PEG 4400 
in water compared to toluene.  Although it is thought that PEG provides a stabilizing 
steric effect to oil-in-water dispersions prepared from PCOE-g-PEG copolymers, 
copolymer 52 clearly mediates the water/oil interface and produces dispersions which are 
stable for many hours, even without UV cross-linking.  Water-filled capsules settle to the 
bottom of the toluene solution over time and repeated pipetting and washing with fresh 
toluene proved to be an effective method of purifying and concentrating the capsules. 
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Figure 3.16  Illustrative depiction of polymer capsules prepared from the water-in-
toluene assembly of copolymer 52 and UV cross-linking with bis-phenyl azide 51 
 
To demonstrate the effectiveness of cross-linking using bis-phenyl azide 51, 
water-in-toluene capsules were analyzed by optical microscopy.  As illustrated in Figure 
3.17A, spherical capsules are prepared by this method with mechanically robust 
membranes that are visible upon drying and highlighted by black boxes.  This approach 
can also be utilized for encapsulating water-soluble reagents such as tetraethylene glycol 
and potassium hydroxide for accelerated sand core binder disintegration as shown in 
Figures 3.17B and 3.167, respectively.   These capsules are currently being evaluated as 
part of an on-going collaboration with General Motors. 
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Figure 3.17  Optical micrographs of water-in-toluene capsules, A) cross-linked, 
water-filled capsules after drying, B) encapsulated tetraethylene glycol (50 wt % 
aqueous solution,) C) encapsulated potassium hydroxide (10 wt % aqueous solution) 
3.3 Capsule Sizing by Membrane Extrusion and Ultrasonication 
The size and size distribution of drug carriers are critical parameters that impact 
both their biodistribution
41
 and drug release rate
42
 in drug delivery applications.  For 
example, an upper size limit of approximately 5 - 10 μm exists for injectable drug 
delivery systems due to the size of capillaries in which the carriers must traverse.  
Recently, there has been growing interest in producing delivery systems with particle 
sizes less than 200 nm because of their prolonged blood circulation lifetimes and reduced 
liver uptake compared to larger particles.
43
  The interfacial assembly techniques 
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described in this chapter thus far utilize simple hand shaking of oil-water assemblies to 
produce polymer capsules with diameters in the range of tens of microns and which 
possess a relatively broad size distribution.  In an effort to reduce the size and 
polydispersity of polymer capsules to a more applicable size range for drug delivery, we 
investigated two different methods of capsule sizing, membrane extrusion and 
ultrasonication.  
Membrane extrusion involves the passage of a liquid suspension of vesicles or 
polymer assemblies through track-etch membranes with well-defined pore sizes in the 
micron to nanometer size range.  The extrusion process causes the vesicles to rupture 
when their lysis tension is exceeded, forming smaller vesicles upon elution from the pore 
opening.
44,45
 The technique has been widely used to reduce the size of multi-lamellar 
liposomes
46,47
 and polymersomes
48
 from tens of microns to 1μm or less .  Recently, our 
group demonstrated that membrane extrusion could also be utilized to reduce the size of 
nanoparticles-covered droplets from 50 – 200 μm to 1 – 10 μm with a relatively narrow 
size distribution.
49
  These reports inspired attempts to reduce the size of polymer 
assemblies made from amphiphilic graft copolymers using membrane extrusion 
techniques.  Indeed, we found that membrane extrusion was suitable for sizing polymer 
capsules prepared by interfacial assembly.  For example, Figure 3.18 illustrates a 
confocal micrograph of Coumarin 153-filled assemblies prepared from copolymer 42 
before and after 10 passes through a membrane extruder equipped with a track-etch 
membrane having 1 μm pores.  After extrusion, the capsule diameter was effectively 
reduced from 10 – 40 μm to approximately 1 μm with a relatively narrow size 
distribution.  We observed that after several hours, the extruded, uncross-linked capsules 
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coalesce to form larger structures with a broadened size distribution.  Photo-cross-linking 
of the phenyl azide-functional graft copolymer at the oil-water interface is particularly 
useful in this case since the capsules can be rapidly cross-linked following membrane 
extrusion to effectively “lock in” the desired size and distribution.  In comparison, the 
size and distribution of UV cross-linked capsules were unchanged after several days of 
storage.  Utilizing this membrane extrusion and rapid UV cross-linking technique to 
finely tune size features of polymer capsules may prove useful in tailoring polyolefin 
capsules for potential delivery applications. 
 
Figure 3.18 Confocal micrographs of Coumarin 153-filled, oil-in-water assemblies 
prepared from copolymer 42, A) hand-shaken assemblies, B) capsules obtained after 
11 passes through a track-etch membrane (1 μm pore size) and subsequent UV 
cross-linking 
 
 
  Attempts to size capsules to the sub-micron size level were also conducted using 
the described membrane extrusion technique using track-etch membranes with 100 nm 
pores.  In this case, extrusion through the smaller pores resulted in capsule instability, 
presumably due to increased pressure during the extrusion process.  Thus, intact sub-
micron capsules were difficult to prepare using this method and other methods of sizing 
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were explored.  For example, ultrasonication has been used extensively to produce small, 
unilamellar liposomes from the larger, multilamellar vesicles that form from simple lipid 
hydration techniques.
50,51
  In this case, the induced pressure of sonication can reduce 
liposomes to the nanometer size range (e.g. 50 – 100 nm), and it was found that this 
technique could be also utilized to form nanometer-sized capsules from larger, hand-
shaken graft copolymer assemblies.  In initial experiments, toluene-in-water assemblies 
produced using copolymer 42 were sonicated for several minutes to reduce the droplet 
size, but toluene evaporation proved problematic and resulted in either polymer 
precipitation or micelle formation in the aqueous phase.  This issue was overcome by the 
use of a high-boiling hydrophobic liquid, glyceryl trioctanoate (i.e. trioctanoin), in place 
of toluene in the oil-in-water dispersion.  To produce trioctanoin-filled capsules, polymer 
42 (50 mg) was combined with trioctanoin (50 mg) and dissolved in 0.5 mL of 
dichloromethane.  This solution was added to a flask containing deionized water (50 mL) 
and placed in a sonicating bath for 15 min.  During the sonication process, 
dichloromethane evaporates from the dispersion, leaving a translucent solution of graft 
copolymer-stabilized trioctanoin droplets that were subsequently photo-cross-linked to 
yield sub-micron, polymer capsules as illustrated in Figure 3.19.  The capsules produced 
by this technique could not be visualized by optical microscopy, suggesting a sub-micron 
size distribution.  Dynamic light scattering (DLS) analysis of the cross-linked capsules at 
a 90
o
 angle (also shown in Figure 3.16) reveals an average capsule diameter of 
approximately 160 nm with a relatively narrow size distribution (standard deviation = 21 
nm).  The ability to produce oil-filled capsules in this size regime, combined with the 
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biocompatible PEG periphery, may permit their eventual use in a variety of systemic and 
targeted drug delivery applications. 
 
Figure 3.19  Illustrative depiction and DLS analysis (angle = 90
o
) of sub-micron 
polymer capsules produced by sonication and UV cross-linking of copolymer 42-
stabilized trioctanoin-in-water assemblies 
3.4 Summary and Outlook 
In summary, amphiphilic PCOE-g-PEG graft copolymers were utilized in oil-
water interfacial assembly and cross-linked to form polymer capsules with thin, 
mechanically robust cross-linked membranes.  In one method, a bis-cyclooctene PEG 
derivative was used in conjunction PCOE-g-PEG copolymer and cross-linked at the oil-
water interface by ring-opening cross-metathesis with a ruthenium benzylidene catalyst.  
In a second approach, reactive functionality capable of cross-linking was incorporated 
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into the polymer backbone by copolymerization of phenyl azide and acyl hydrazine-
functional cyclooctene derivatives.  The reactive polymers were cross-linked by photo-
generated nitrenes (in the phenyl azide case) or by addition of glutaraldehyde (in the acyl 
hydrazine case) to form capsules that possess tunable degradability (i.e. non-degradable 
or pH-dependent degradability).  This interfacial assembly and cross-linking approach 
also permits the preparation of both water-in-oil capsules, enabling the encapsulation of 
hydrophilic agents such as tetraethylene glycol and potassium hydroxide.  In addition, the 
assemblies can be sized from tens of microns to the 150 nm - 1 μm size range by either 
membrane extrusion or ultrasonication techniques.  These techniques are complementary 
to the UV cross-linking approach as the assemblies can be sized and then rapidly cross-
linked to “lock-in” the desired capsule size.  Furthermore, these sizing techniques 
produce capsules that are of an applicable size range for many drug delivery applications.  
This data combined with preliminary encapsulation studies using a hydrophobic dye, 
Coumarin 153 and neutral doxorubicin suggest that the these capsules might be useful in 
the encapsulation and delivery of a variety hydrophobic agents. 
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CHAPTER 4 
POLYOLEFIN-GRAFT-PEG COPOLYMERS AS COATINGS FOR WATER 
PURIFICATION MEMBRANES 
4.1 PEGylation Strategies to Reduce Fouling of Water Purification Membranes 
One example application deemed suitable for the polyolefin-graft-PEG 
copolymers described in Chapter 2 is in the area of water purification membranes.  
Fouling represents a critically important barrier against wider adoption of polymer 
membranes for many applications, including those intended for water purification.
1,2
 
 
Surface and inner-membrane fouling by solutes such as proteins, emulsified oil droplets, 
and various types of particles leads to considerable loss in flux and selectively over time.
3  
While a number of commodity polymers have been fabricated into useful and 
commercially viable membranes, new synthetic polymers designed to improve existing 
membranes are needed to prevent fouling and/or improve separation efficiency, and 
advance the performance of existing commercial membranes beyond their current state. 
The known anti-fouling and surface-active properties of polyethylene glycol 
(PEG), or polyethylene oxide (PEO), are appealing for integration into polymer 
membranes.
4,5 However, the water solubility and crystallinity of PEG make it unsuitable 
for fabrication into robust membranes for aqueous applications.  Thus, covalent 
attachment of PEG to hydrophobic polymers provides a means by which PEG-based 
polymers can be integrated into membranes with anti-fouling character, yet maintain 
membrane integrity in an aqueous environment.  PEG has been covalently attached to a 
variety of membrane materials, including cellulose,
6
 
poly(acrylonitrile),
7
 
poly(acrylonitrile-co-vinyl chloride),
8
 
polysulfone,
9,10
 
and polypropylene and cellulose 
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acetate.
11
 
 Such PEGylated membranes typically show considerably different properties 
from the non-PEGylated versions, especially with regards to reduced fouling, and 
permeability/selectivity characteristics.
9,12-14
 
 For polysulfone UF membranes, UV-
induced reactions of PEG derivatives have been used for membrane surface 
modification.
9,10  In these examples, the ester linkage chosen to connect PEG to the 
underlying membrane is convenient synthetically, but ultimately not suitable for water 
purification applications due to the hydrolytic instability of esters.  Composite 
membranes prepared from polymer blends, such as polyether 
sulfone/poly(vinylpyrrolidone),
15
 and poly(vinylidene fluoride) (PVDF)/PVDF-
PEGylated PMMA,
13,14
  
also provide examples of materials that exhibit reduced fouling 
relative to conventional commercial membranes. 
4.2 Polycyclooctene-graft-PEG (PCOE-g-PEG) Copolymers as Coatings  
Polyolefin-graft-PEG amphiphilic graft copolymers were prepared and used as 
anti-fouling coatings on commercial poly(vinylidene fluoride) ultrafiltration (PVDF-UF) 
membranes.  These graft copolymers were fabricated into dense film membranes, and 
characterized in this form to evaluate their water uptake and ability to resist protein 
adsorption.  Then, functionalized variants of the graft copolymers were prepared and 
applied as sub-micron thin-film coatings to PVDF-UF membrane supports.  These 
composite membranes were subjected to oil-in-water emulsion feed streams under 
crossflow conditions at ~150 psi.   
The presence of reactive functionality on the PEGylated polyolefin backbone 
proved critically important for the successful application of these coated composite UF 
membranes.  Simple physical adsorption of the amphiphilic graft copolymer on the 
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underlying membrane proved ineffective as a coating method for these applications, due 
to delamination observed in the early stages of the crossflow experiment.  However, 
cross-linking of the graft copolymers following the coating step proved effective for 
stabilization of the coating during crossflow, and provided a mechanism by which 
membrane fouling from oil-in-water emulsions was reduced markedly relative to the 
uncoated membranes.  The presence of phenyl azide functional groups on the graft 
copolymer, and the UV-induced reactivity of these groups, provided a stabilization of the 
graft copolymer coating on the underlying PVDF-UF membranes, and prevented 
membrane fouling over time. 
4.2.1 Synthesis of Amphiphilic PCOE-g-PEG Copolymers   
Amphiphilic graft copolymers containing polycyclooctene backbones, and various 
length and density of PEG grafts, were prepared by ruthenium benzylidene-catalyzed 
ring-opening metathesis polymerization (ROMP) of cyclooctene with PEG-functional 
cyclooctene macromonomers as described in Chapter 2.  Graft copolymers 53 – 57, with 
both 1100 g/mol and 2200 g/mol PEG side chains, were prepared by polymerization of 
different ratios of cyclooctene (17) and PEGylated macromonomers 8 and 9.  These 
macromonomers were prepared by the 5-hydroxycyclooctene-initiated anionic 
polymerization of ethylene oxide (Scheme 2.3).
 
 This macromonomer synthesis enables 
the integration of PEG into the copolymer structure by ROMP, obviating the need for 
post-polymerization grafting chemistry.  Moreover, this approach connects the PEG 
grafts to the polymer backbone by ether bonds, which carries the advantage of hydrolytic 
and chemical stability that is needed in long-term aqueous-based membrane applications. 
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As shown in Scheme 4.1, graft copolymers 53 - 57 were prepared by ROMP of the 
appropriate monomers/macromonomers in dichloromethane, using Grubbs’ Generation II 
catalyst (catalyst II),
16 
with a 250:1 monomer-to-catalyst ratio, and 1-hexene as the chain 
transfer agent (100:1 monomer-to-chain transfer agent ratio).  The polymerization was 
terminated by addition of ethyl vinyl ether, and the polymer was isolated as a powder 
following precipitation into cold hexane containing 1 wt % of 2,6-di-tert-butyl-p-cresol 
(BHT).  Gel permeation chromatography in CHCl3 (against linear polystyrene standards) 
was used to estimate the molecular weights and polydispersities of the graft copolymers, 
as presented in Table 4.1.  As expected for polymers prepared by ROMP using a 
monofunctional chain-transfer agent, the polydispersity of these samples was estimated 
by GPC to be in the range of ~ 2.0.  Importantly, the copolymers obtained by this 
process, as characterized by NMR spectroscopy, show comonomer incorporation into the 
graft copolymer structure in accord with the feed ratio employed. 
 
Scheme 4.1  Synthesis of PCOE-g-PEG with varying PEG length and graft density 
by ROMP of macromonomers 8 and 9 
 
 
Table 4.1  Characteristics of PCOE-g-PEG copolymers 53 - 57 
 
Copolymer
a
 Molar Ratio 17:8:9 PEG wt % Mn (Da, GPC) PDI Water Uptake (wt %) 
53 80:20:0 73 42,800 1.9 220 - 240 
54 90:10:0 55 34,400 2.0 60 - 70 
55 92:8:0 49 15,800 1.6 50 - 60 
56 92:6:2 53 22,700 1.8 45 - 50 
57 91:8:1 54 27,800 2.1 40 - 45 
a
 [M]=2.0 mol/L, [M]/[Cat] = 500, [M]/[1-Hexene] = 100, 40 
o
C in CH2Cl2.  
b
 GPC in CHCl3 versus polystyrene standards. 
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Phenyl azide-functionalized cyclooctene 38 was prepared as previously shown in 
Scheme 3.5, and used in ROMP copolymerizations with cyclooctene and PEG-functional 
macromonomer 10 (PEG MW 4,400 g/mol) in order to integrate this desirable reactive 
functionality into the graft copolymer structure.  Monomer 38 was integrated into PCOE-
g-PEG copolymers by metathesis copolymerization using Grubbs’ Generation III catalyst 
(catalyst III)
17 
to give graft copolymer 58 as shown in Scheme 4.2.  For the membranes 
prepared in this work, graft copolymer 58 was prepared using 20 mol % cyclooctene 
azide 38, 60 mol % cyclooctene (17), and 20 mol % PEG 4400 macromonomer 10.  This 
copolymer composition of amphiphilic graft copolymer 12 proved convenient for the 
PVDF-UF coating experiments for its solubility in ethanol, a suitable solvent for 
solution-based coating of PVDF-UF membranes (and in principle other commercial 
membranes), and also provided sufficient aryl azide functionality for effective cross-
linking of the polymer coating.  Typical preparations of graft copolymer 58 gave 
materials that by GPC in THF appeared as a single Gaussian peak; polymer with number-
average molecular weights of ~35,000 g/mol, and PDI values of ~1.7, were obtained.  
1
H 
NMR spectroscopy performed on CDCl3 solutions of 58 showed the expected backbone 
olefin resonances at ~ ? 5.4 ppm and no signals for residual cyclic olefin monomers (~ ? 
5.7 ppm).  Aromatic resonances from the phenyl azide group were observed at ? 7.04 and 
? 8.00 ppm, and integrated against protons of the polymer backbone to confirm the 
expected mole percent incorporation.  FTIR spectroscopy of 58 showed a diagnostic 
azide stretch at ~2100 cm
-1
.  This synthetic strategy connects the reactive azide 
functionality to the polymer backbone through an amide bond which, like the ether 
connectivity of the PEG chains, is stable hydrolytically and thus well-suited for aqueous-
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based membrane applications.  We also prepared several combinations of polymers of 
type 58, by fixing macromonomer 10 at 20 mol %, and varying 38 from 5-15 mol %, and 
17 from 65-75 mol %.  However, solubility proved problematic in these cases, as ethanol 
no longer dissolved the polymer, and good solvents such as chloroform and toluene swell 
or otherwise damage many underlying membrane supports.  Thus, the composite 
membrane experiments described herein were performed with polymer 58 prepared with 
20 mol % cyclooctene azide 38, 60 mol % cyclooctene (17), and 20 mol % PEG 4400 
macromonomer 10. 
 
Scheme 4.2  Preparation of photo-reactive PCOE-g-PEG copolymer 58 by ROMP of 
phenyl azide-functional cyclooctene 38 
4.2.2 Polycyclooctene-graft-PEG Copolymers: Membrane Preparation and 
Characterization 
Before applying polyolefin-graft-PEG copolymers as coatings to PVDF-UF 
membranes, dense films of the copolymers were prepared and characterized for their pure 
water uptake and pure water flux under dead-end flow conditions.  Such characterization 
is important for determining coating compositions that possess sufficient hydrophilicity 
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for water purification applications.  Dense film membranes of PCOE-g-PEG copolymers 
53 - 57 were prepared by Dr. Ravindra Revanur of the Emrick group by casting films 
from 20 wt % toluene solutions of the copolymers onto glass plates, then drawing the 
films to the desired thicknesses using a Gardco film applicator.  Residual solvent was 
removed from the films by allowing them to stand at room temperature, then by their 
placement in a vacuum oven at reduced pressure (20 ºC, 12 hrs).  For the preparation of 
cross-linked polymer films, ring-opening cross-metathesis using a bis-cyclooctene cross-
linker was employed.
18
  For these studies, bis-cyclooctene 60 with a tetraethylene glycol 
linker connected via hydrolytically-stable ether linkages was prepared by base-catalyzed, 
SN2 chemistry with 5-hydroxycyclooctene (1) and tetraethylene glycol dimesylate (59) in 
DMF, as shown in Scheme 4.3.  Films were then prepared from a toluene solution 
containing ~20 wt % of the graft copolymer and ~7 wt % of bis-cyclooctene 60, to which 
was added a toluene solution of catalyst II (~3 mg) under constant agitation.  As cross-
linking occurs quickly using this method, the polymer/cross-linker/catalyst mixture was 
cast immediately on a glass slide to for the membrane as a cross-linked dense film of ~50 
mm thickness.  This cross-linking imparted the dense films with far more robust 
properties than obtained when attempting to prepare films without cross-linking.  
Moreover, the degree of cross-linking provides a means by which water uptake can be 
controlled.  As shown in Table 4.1, PCOE-g-PEG membranes could be prepared with 
variable hydrophilicity, as indicated by the water uptake values.  In copolymers 
containing lower PEG-grafting density (i.e., from 1-8 mol % PEG 1,100 g/mol and/or 
PEG 2,200 g/mol), water uptake values in the 40-70% range were observed.  Steady state 
water uptake values were obtained by dividing the difference in weight of the wet 
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(soaked in water) and dry membranes by that of the dry membrane.  These membranes 
with lower PEG weight percentages qualitatively exhibited appreciable mechanical 
properties, such that they could be removed from the glass plate onto which they were 
cast, and handled without tearing. 
 
Scheme 4.3  Preparation of hydrolytically-stable, bis-cyclooctene cross-linker 60 
 
 
PCOE-g-PEG copolymer membranes with higher PEG densities, for example 20 
mol % of PEG 1,100 g/mol, possessed very high water uptake values (200% or greater).  
However, copolymer films with such high PEG content were not mechanically robust, 
requiring cross-linking and/or an underlying substrate for effective application to water 
purification membranes.  Increasing PEG density in the PCOE-g-PEG copolymer dense 
films was seen, as expected, to result in enhanced pure water flux, using an Amicon 
stirred cell in a dead-end flow setup.   As shown in Table 4.1, films of polymers 54 and 
57, having similar weight percent PEG, were seen to have appreciable differences in 
water sorption and flux values.  This may, however, not be an intrinsic property of the 
polymer composition, but rather due to variation in cross-linking efficiency from sample-
to-sample.  Nonetheless, it does appear that the integration of PEG 2,200 g/mol into the 
copolymer structures has a positive effect on both water sorption and flux.   
Table 4.2 shows the effect of cross-linker concentration on both water sorption 
and permeance values.  Membranes prepared from polymer 57 in the absence of cross-
linking exhibit high water sorption and flux values.  As seen in the table, water sorption 
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and flux drops to about 50% of the initial value with about 2 wt % cross-linker.  This 
control over sorption and flux continues to about 7 wt % cross-linker, at which point a 
lower limit appears at about one-third the initial level.  Additional experiments with these 
dense films were conducted to analyze the effect of cross-linker weight percent on water 
flux values obtained at various feed pressures in a dead-end flow setup.  This is seen in 
Figure 4.1.  From the dense membrane without any cross-linker, a measurable permeate 
was collected at a feed pressure of only 10 psi.  The effect of percent cross-linker on feed 
pressure needed to obtain constant water flux shows that an appreciable level of control 
over flux can be obtained in these films, and that even upon cross-linking, sufficient 
water flux is observed such that application of these materials as coatings on commercial 
membranes is feasible. 
Table 4.2  Effect of bis-cyclooctene cross-linker 60 concentration on percent of water 
sorption and water permeance through the membranes prepared from polymer 57;  
membrane thickness ~ 50 ?m 
 
 
 
Figure 4.1  Effect of bis-cyclooctene cross-linker 60 concentration on water flux 
through the membranes prepared from copolymer 57 
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Protein adsorption on PCOE-g-PEG copolymer films were tested by immersion in 
bovine serum albumin (BSA) solutions and quantified using the Bradford titration 
method.
19
 In these experiments, very low levels (~ 1 ?g/cm2) of protein adsorption were 
observed. In fact, the appreciable anti-fouling properties of these graft copolymer films 
made protein adsorption difficult to quantify by this method.  This contrasts the situation 
for many commercial membranes, such as polysulfone and polyamide membranes, in 
which protein adsorption is appreciable and readily quantified.  Fluorescence confocal 
laser scanning microscopy provides an alternative visual method to evaluate fouling
20
 on 
both commercial and novel synthetic membranes.  Figure 4.2 shows fluorescence 
confocal microscope images of several membranes following exposure to aqueous 
solutions of fluorescent BSA.  These membranes were cut as ~2 cm
2
 sections from 
polyamide reverse osmosis (RO) thin film composite membranes, cellulose acetate 
asymmetric RO membranes, polysulfone UF membranes, and PCOE-g-PEG dense films. 
The membranes were immersed in a phosphate buffered saline (PBS, pH 7.4) solution of 
fluorescein-conjugated BSA (0.02 mg/mL) for 24 hours, followed by rinsing with PBS.  
As shown in Figure 4.2, confocal fluorescence images of these membranes (excitation at 
488 nm) reveal striking differences in protein adsorption on the commercial membranes 
relative to the PEGylated graft copolymer film.  The PCOE-g-PEG membrane sample 
used these experiments contained 54 wt % PEG (polymer 57), a modest level of 
PEGylation, yet clearly sufficient for resisting fouling.  This data shows that the 
PEGylated graft copolymers are well-suited to prevent protein fouling, which is expected 
to translate to resisting fouling by oil particles in oil-in-water emulsions.  
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Figure 4.2 Fluorescence confocal microscopy images of protein adsorption 
(fluorescein-BSA in aqueous buffer solution at pH 7.4) on a dense film of PCOE-g-
PEG (far right, copolymer 57) and on commercial samples of treated polyamide, 
cellulose acetate, and polysulfone; the black bar in each image is 50 microns 
4.2.3 Phenyl Azide-functionalized Graft Copolymer Coatings on PVDF-UF 
Membranes 
Initial studies targeted the preparation of PCOE-g-PEG coated PVDF-UF 
membranes, followed by evaluation of the coated membranes in a crossflow unit at 150 
psi.  However, in the early stages of the crossflow experiments, delamination of the graft 
copolymer coating from the membrane support was observed, due to the substantial 
hydrophilicity and swelling of the coating that overcomes its adhesion to the underlying 
PVDF support.  Moreover, we found that cross-linking strategies using bis-cyclooctene 
60 described above were not easily applied to cases involving underlying support 
membranes, due to the presence of defects within the coating that could not be avoided.  
Thus, a different method was sought to generate the desired composite membranes, in 
which the coating and cross-linking steps were conducted separately, by embedding UV-
reactive phenyl azide groups into the copolymer structure.  For this, graft copolymer 58 
containing phenyl azide pendent groups was used, anticipating a nitrene-induced cross-
linking upon exposure of the polymer-coated membrane to UV-irradiation. 
The PVDF-UF membranes used in this study were purchased from Sterlitech, Inc.  
For the coating procedure, an ethanol solution of graft copolymer 58 (~ 50 mg/mL, Mn ~ 
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35,000 Da, PDI 1.7) was applied by Dr. Ravindra Revanur by spin coating onto the 
membrane support to give a sub-micron graft copolymer coating.  The coated membrane 
was then placed in a UV-light source (UVP, Inc.) and irradiated at 302 nm for 6 minutes.  
UV-irradiation converts the phenyl azide (Ph-N3) groups into nitrenes (Ph-N:) by loss of 
nitrogen gas.  The nitrenes generated in this process are highly reactive
21,22
 and can insert 
into olefins in the polymer backbone to give aziridines, as well as C-H bonds in the 
polymer backbone and grafts, and possibly in the underlying PVDF-UF support, to give 
amines.  This UV-induced cross-linking proved successful for stabilizing the graft 
copolymer coating on the PVDF-UF membrane surface, and eliminated problems 
associated with rapid delamination of the coating during crossflow.  ATR-FTIR 
performed on the composite membrane following irradiation was used to confirm the 
complete disappearance of diagnostic azide stretch at ~ 2100 cm
-1 
in the graft copolymer 
structure.  Whether any of the nitrenes generated during irradiation insert into the 
underlying substrate is a characterization challenge under investigation at this time. 
4.3 Crossflow Experiments on Graft Copolymer-coated PVDF-UF Composite 
Membranes 
Crossflow experiments were performed in Professor Benny Freeman’s laboratory 
(University of Texas-Austin) on both uncoated and graft copolymer-coated PVDF-UF 
membranes were conducted at a feed pressure of 150 psi, and a crossflow velocity of 0.5 
GPM.  The feed solution consisted of a 1500 ppm oil-in-water emulsion (9:1 ratio of 
soybean oil: DC 193 surfactant obtained from The Dow Chemical Company), prepared 
by mixing the oil, water, and surfactant in a blender at 3000 rpm for ~3 minutes to give a 
homogeneous emulsion.  Periodic evaluation of the oil concentration was carried out 
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using a total organic compounds (TOC) analyzer (Shimadzu TOC-5050A).  It was 
immediately seen that the delamination problem observed for graft copolymers 53 - 57 
during the crossflow operation did not occur in the irradiated coated membranes prepared 
from phenyl azide-functionalized graft copolymer 58.  The polymer coating remained 
intact despite the very high (>80 wt %) weight percent of PEG in the polymer coating.  
Control experiments confirmed the importance of phenyl azide incorporation.  For 
example, a PVDF-UF membrane was coated with a graft copolymer containing an 4:1 
molar ratio of cyclooctene and PEG-4400 cyclooctene macromonomer 10, followed by 
an irradiation step identical to that used for the azide-containing coating.  Crossflow 
experiments with oil-water emulsion feed solutions carried out with these uncross-linked 
copolymer coated membranes led to rapid membrane fouling, and thus minimal positive 
influence of the coating.  This is shown in Figure 4.3, in which the uncoated (dashed line) 
and coated (solid line) PVDF supports follow the same membrane fouling trend reflected 
in decreased flux as a function of time.  Water contact angle measurements taken on the 
membrane surface after crossflow (~ 60 - 65
o
) were quite close to those of the uncoated 
membrane (64 - 67
o
), confirming the loss of graft copolymer from the surface, and much 
higher than membranes with stable cross-linked graft copolymer coatings (shown in 
Figure 4.3).  Thus, subsequent experiments exclusively used the azide-functionalized 
amphiphilic graft polymer as the coating material. 

  121 
membrane shows a considerable decline in flux during the same period, from ~ 14 
LMH/atm to ~ 6 - 7 LMH/atm.  
 
Figure 4.4  Crossflow experimental results with coated and uncoated PVDF-UF 
membranes; A) flux values obtained using membranes coated with a cross-linked 
coating of graft copolymer 58, B) continuation of crossflow experiment to eight days, 
C) oil rejection values 
 
 
When this coated vs. uncoated membrane experiment is extended to longer time 
periods, as shown in Figure 4.4B, a cross-over is seen, such that water flux through the 
coated membrane equals and then exceeds that of the uncoated membrane.  Ultimately, 
the uncoated membrane is expected to approach zero flux at some time period, due to 
complete fouling.  This result carries considerable significance given the long usage 
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lifetime desired for membranes of this type, and the stability against oil droplet fouling 
provided by the graft copolymer coating.  Interestingly, in some cases the observed flux 
of the graft copolymer coated membrane increases slightly over the measured period.  
This may be due to some loss of the graft copolymer in areas of the coated membrane 
where cross-linking was inefficient, either on the membrane surface, or perhaps more 
likely in areas where the polymer had penetrated the membrane pores.  No matter the 
cause of this increased flux, it does not lead to rapid fouling.   
Finally, as shown in Figure 4.4C, the graft copolymer coating was seen to 
improve the rejection of oil droplets, as determined by permeate analysis.  The uncoated 
PVDF-UF membranes provide increasing oil droplet rejection as a consequence of 
fouling, while the graft copolymer coated membranes maintained 99-98.5% rejection 
during the course of the experiment. 
Figure 4.5 shows SEM images of the top surface (Figure 4.5A) of both the 
uncoated and coated (Figure 4.5B) PVDF-UF membranes used in this study.  SEM shows 
convincingly that the graft copolymer coating completely covers the membrane pore 
structure.  Cross-sectional SEM images of the coated membrane confirm that pore 
penetration of the graft copolymer into the membrane does occur (Figures 4.5D and 
4.5E).  While the presence of the graft copolymer on the membrane surface, and in the 
inner-pore structure, is expected to lower the initial water flux, the substantial 
hydrophilicity of the graft copolymer used in the coating process leads to only a moderate 
initial flux decline that can eventually be overcome by the reduction in fouling over time 
relative to the uncoated membranes.  An ideal coating process would minimize such pore 
penetration; efforts along these lines are in progress.  Importantly, the graft copolymer 
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coating remains intact on the support throughout the crossflow experiments.  This is 
confirmed in the SEM image of Figure 4.5C, taken on the composite membrane 
following removal from the crossflow unit.  In addition, it seems that a smoother 
membrane surface in the coated composite is present following crossflow experiments.  
This may be associated with some loss of graft copolymer coating during crossflow 
operation, but is more likely a result of reorganization of the graft polymer during and 
after the crossflow experiment.  Nevertheless, after crossflow operation, the water contact 
angle of the coated composite membrane (44 - 46
o
) remains identical to that before the 
crossflow, and is considerably lower than that of the uncoated membrane (64 - 67
o
). 
Finally, while fouling prevention can be attributed to the PEGylation, it should also be 
noted that the smoother surface of the coated membranes might augment the effect. 
 
 
Figure 4.5  SEM images of PVDF-UF membranes, A) top view before coating, B) top 
view after coating and UV-irradiation with graft copolymer 58, C) top view after 
crossflow experiments, D) cross-section before coating with 58; E) cross-section 
after coating 
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4.4 Summary and Outlook   
We have synthesized and applied polycyclooctene-graft-PEG copolymers as anti-
fouling coatings for commercial PVDF-UF membranes.  Problems associated with 
delamination of the graft copolymer from the underlying membrane were overcome using 
phenyl azide functionalized polymers for UV-irradiation and cross-linking on the PVDF-
UF support.  Crossflow experiments conducted with oil-in-water emulsions feed sources 
confirmed that the graft copolymer coating prevents fouling, and leads to an eventual 
crossover in flux with the uncoated commercial membranes.  Future studies will include 
an optimization of both the graft copolymer as well as the coating process, taking 
advantage of the tunable nature of the graft copolymer itself, as well as the coating 
process.  Moreover, the ability of these copolymer coatings to prevent fouling in other 
membranes, including those used in reverse osmosis for desalination will be studied. 
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CHAPTER 5 
SYNTHESIS AND APPLICATION OF AN AMPHIPHILIC RUTHENIUM 
BENZYLIDENE CATALYST WITH PEG-SUBSTITUTED LIGANDS 
5.1 Impact of Ligand Environment on the Properties of Ruthenium Benzylidene 
Metathesis Catalysts 
The advent of well-defined ruthenium benzylidene catalysts has dramatically 
expanded the scope of metathesis reactions and polymerizations that can be performed in 
the presence of polar organic functionality and protic solvents.  In general, catalyst 
properties are largely governed by the ligand environment surrounding the ruthenium 
center, which allows for tailoring of catalyst activity and solubility.  For example, 
Grubbs’ second generation ruthenium benzylidene catalyst II (Figure 5.1) utilizes an N-
heterocyclic carbene ligand (4,5-dihydroimidazolylidene) that provides much greater 
metathesis activity than the first generation bis-tricyclohexylphosphine substituted 
ruthenium benzylidene catalyst I.
1
  More recently, ruthenium catalysts have been 
prepared with pyridine, and derivatives of pyridine, as ligands in place of 
tricyclohexylphosphine.
2,3
  For example, the 3-bromopyridine substituted ruthenium 
catalyst III has been shown to polymerize cyclic olefins by ring-opening metathesis 
polymerization (ROMP) at unprecedented rates, with very fast initiation that leads to 
characteristics of “living” polymerization when used in conjunction with certain 
norbornene and oxanorbornene monomers.
4  
Efforts to improve the activity of ruthenium 
metathesis catalysts have been undertaken by a number of research groups over the past 
few decades.
5  
However, improvement in the solubility and metathesis activity of 
ruthenium catalysts in polar solvents, particularly in water, is limited to only a few 
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reports.  In light of this fact, nearly all metathesis reactions and polymerizations reported 
to date have been performed in organic solvents.   
 
Figure 5.1  Chemical structures of Grubbs’ Generation I, II, and III catalysts 
5.2 Ring-Opening Metathesis Polymerization in Protic Solvents 
ROMP in protic solvents and aqueous environments has been accomplished 
previously with non-benzylidene catalysts, such as ruthenium salts,
6 
and more recently 
with ruthenium benzylidene catalysts containing tailored ligands, such as phosphines 
with ionic substituents in place of the more common tricyclohexylphosphine (Figure 
5.2).
7-10  
For example, catalysts IV and V, which bear cationically-functionalized 
phosphine ligands, are soluble and initiate ROMP in both methanol and water.  However, 
the ruthenium alkylidene analogues of IV and V (i.e. propagating species) rapidly 
decompose in methanol and neutral water resulting in poor monomer conversion.  In 
contrast, ROMP of norbornene and oxanorbornene derivatives, initiated by catalysts IV 
and V, was shown to be rapid and possess characteristics of a “living” polymerization in 
acidic water (HCl or DCl, from 0.3 to 1.0 equiv. relative to IV and V).  It was 
hypothesized that the addition of BrØnstead acids to the aqueous polymerization media 
neutralized hydroxide ions, which were shown to rapidly decompose catalysts IV and V.   
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Figure 5.2  Examples of water-soluble ruthenium catalysts bearing ionic, phosphine 
ligands 
 
 
This initial demonstration of metathesis activity using charged ruthenium 
benzylidene catalysts was an important step toward the synthesis of water-soluble 
polymers and substrates in purely aqueous media.  However, several limitations of these 
catalysts have prompted new research.  For example, catalysts IV - VI are soluble only in 
protic media and are therefore limited to polymerizations in water or methanol.  A highly 
versatile metathesis catalyst would be soluble in aqueous and organic media and 
efficiently perform metathesis reactions in a variety of solvents.  In addition, these 
catalysts lack the N-heterocyclic carbene (NHC) ligand which has been shown to 
dramatically improve the metathesis activity of ruthenium benzylidene catalysts.  
The ruthenium benzylidene catalyst described in this chapter is made amphiphilic 
by incorporation of polyethylene glycol (PEG)-substituted pyridine ligands and 
effectively polymerizes cyclic olefins in both aqueous and organic media.  In prior work 
by our group, PEGylated pyridine compounds were prepared for use as ligands to 
solubilize CdSe quantum dots in water.
11  
Following reports on pyridine and 3-
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bromopyridine substituted ruthenium benzylidene catalysts by Grubbs and coworkers,
2,3 
and motivated by our interest in water-soluble polyolefins and interfacial chemistries,
12-14
 
these PEG-substituted pyridines were tested for their ability to solubilize Grubbs’ second 
generation catalyst (catalyst II) by simple ligand exchange of the tricyclohexylphosphine 
ligands.  This ligand exchange was found to provide access to a new metathesis catalyst 
that performs ROMP in both water and organic solvents.  This work represents one the 
first reports of ROMP in a completely aqueous environment using the highly active NHC 
type ruthenium benzylidene catalyst.  During the course of this project, PEGylated 
ruthenium catalysts VII and VIII (shown in Figure 5.3), which also possess the NHC 
ligand, were reported by Grubbs and coworkers.
15,16  
PEGylation of these catalysts was 
accomplished through the synthesis of PEG-functionalized NHC ligands, and VII and 
VIII were observed to effectively perform ring-closing metathesis (RCM) and ROMP in 
both water and methanol.  Attempts to perform similar metathesis reactions in organic 
media using VII and VIII were not reported.  In contrast to catalysts IV – VI, catalyst 
VIII, a PEGylated analogue of Hoveyda-Grubbs catalyst, efficiently performs cross-
metathesis, RCM, and ROMP in neutral water.  Addition of HCl to aqueous metathesis 
reactions initiated by VIII did not improve catalytic activity.  NMR spectroscopy of VIII 
in D2O showed a lack of benzylidene resonances (? 16.4 ppm in CD2Cl2) which was 
attributed the formation of micelles with the catalyst comprising the core and PEG (MW 
2000 g/mol) forming the corona.  No discussion was presented on how catalyst 
aggregation in water impacts metathesis activity. 
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Figure 5.3  Chemical structures of PEGylated ruthenium catalysts prepared by 
Grubbs and coworkers 
5.3 Synthesis of PEG-functional Pyridine Ligands and PEGylated Ruthenium 
Benzylidene Catalyst 63 
The synthesis of PEG-substituted pyridines, such as para-substituted tetraethylene 
glycol 62, was accomplished by Mitsunobu coupling of 4-hydroxypyridine (61) in the 
presence of excess tetraethylene glycol (TEG) (Scheme 5.1).  The presence of the chain-
end hydroxyl group of 62 is key, as this provides water solubility that is not observed in 
the methyl ether terminated TEG analogs.  However, purification of 62 is difficult and the 
clean separation of 62 from excess TEG could not be achieved by column 
chromatography on silica or alumina.  Similar polarities of the TEG and 62 give near 
identical behaviors on these separation media.  Thus, purification of 62 was accomplished 
by removal of excess tetraethylene glycol by vacuum distillation followed by column 
chromatography on silica gel.  This strategy proved effective for PEG-pyridines with up 
to four ethylene glycol repeat units.  When PEGylated pyridine was made with hexa- or 
heptaethylene glycol, even distillation was unsuccessful in attempted purification of the 
ligand. 
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Scheme 5.1  Synthesis of PEG-substituted pyridine ligand 62 by Mitsunobu coupling 
of tetraethylene glycol and 4-hydroxypyridine (61)  
 
 
Exchanging the tricyclohexylphosphine ligands of catalyst II for PEG-pyridine 
ligands was accomplished with a 10-fold excess of 62 (or related compounds with 
different ethylene glycol chain lengths) in minimal dichloromethane as shown in Scheme 
5.2.  Removal of dichloromethane in vacuo affords a mixture of 63 and 62 as a dark 
green oil.  Dilution of this green oil in water causes precipitation of 
tricyclohexylphosphine, which is removed cleanly following centrifugation.  Dark green 
homogeneous solutions of 63 and 62 can then be formed in many solvents, including 
water, methanol, toluene, and dichloromethane, all of which can be used for metathesis 
chemistry.  Catalysts prepared in a similar fashion with 4-hydroxypyridine or PEG-
pyridine ligands possessing one or more ethylene glycol repeats formed homogeneous 
solutions in methanol.  PEG-pyridine ligands possessing 4 or more ethylene glycol repeat 
units formed homogeneous solutions in water.  meta-Substituted PEG pyridine ligands 
have also been prepared and utilized in ligand exchange chemistry.  These were found to 
require longer reaction time for successful ligand exchange with II but give comparable 
metathesis activity as 63.   
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Scheme 5.2  Synthesis of amphiphilic ruthenium benzylidene catalyst 63 by ligand 
exchange of catalyst II with PEG-substituted pyridine 62 
 
 
Nuclear magnetic resonance spectroscopy (
1
H, 
13
C, and 
31
P) performed on the 
mixture of 63 and 62 in D2O and CDCl3 confirms the success of the ligand exchange.  
The
 1
H NMR spectrum of the catalyst mixture taken in CDCl3 shows resonances from ? 
3.5-3.7 ppm, characteristic of the methylene protons of PEG.  A singlet at ? 19.2 ppm 
corresponds to the benzylidene proton. As shown in Figure 5.4, this benzylidene proton is 
0.11 ppm downfield from the benzylidene proton in the 3-bromopyridine substituted 
catalyst III, and 0.07 ppm downfield from the benzylidene proton of catalyst II.  Unlike 
catalyst III, the PEG-pyridine substituted catalyst 63 described here is used in the 
presence of excess PEG-pyridine.  Attempts to remove excess ligand using conventional 
flash chromatography resulted in catalyst decomposition of catalyst 63, presumably due 
to the affinity of the PEG-pyridine ligands for silica gel.  Thus, the graphical 
representation of catalyst 63, with its two PEG-pyridine ligands coordinated to the 
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ruthenium center, is based on the known structure of catalyst III.
2  
The lack of 
crystallinity of 63 prevents characterization by X-ray diffraction, and attempted mass 
spectrometric characterization was unsuccessful. 
 
Figure 5.4  Comparison of benzylidene proton resonances for catalysts II, III, and 
63 in CDCl3 
5.4 ROMP of Cyclic Olefins Initiated by 63 
5.4.1 ROMP Initiated by Catalyst 63 in Organic Solvents 
Catalyst 63 was tested for its ability to polymerize cyclic olefins in 
dichloromethane, and found to successfully polymerize cyclooctene and norbornene to 
full conversion at room temperature in seconds.  The average molecular weights of the 
polymers produced could be controlled easily by adjustment of the monomer-to-catalyst 
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ratios.  Figure 5.5 and Table 5.1 show GPC data for polymers 65 - 68 obtained from the 
polymerization of exo,exo-5,6-bis(methoxycarbonyl)-7-oxabicyclo[2.2.1] hept-2-ene (64) 
using catalyst 63 in dichloromethane at various monomer-to-catalyst ratios.  In all ratios, 
polyolefins 65 - 68 were produced with low PDI values (<1.1) and good control over 
average molecular weight.  Figure 5.5 shows a plot of molecular weight versus monomer-
to-catalyst ratio, and a gel permeation chromatogram of polymer 67 prepared using a 
monomer-to-catalyst ratio of 200:1.   The linear correlation of molecular weight and 
monomer-to-catalyst ratio, combined with the low PDI values of the resulting polymers, 
provide evidence for the “living” nature of this polymerization using this PEG-substituted 
ruthenium benzylidene catalyst.  These results are in accord with those of Grubbs and 
coworkers on 3-bromopyridine substituted ruthenium catalysts, and contrast the 
polymerization of 63 with catalyst II, which produces polymers with PDI values greater 
than 1.5. 
 
Figure 5.5  GPC analysis of polymers obtained by ROMP of 64 using catalyst 63 in 
DCM, A) plot of molecular weight versus monomer/catalyst ratio, B) GPC 
chromatogram of polymer 67 
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Table 5.1  Characteristics of polymers 65 – 68 prepared by ROMP of 64 using 
catalyst 63 in DCM 
 
5.4.2 ROMP Initiated by Catalyst 63 in Water 
The metathesis activity of catalyst 63 was tested in a completely aqueous 
environment on the water-soluble oxanorbornene 70, synthesized by Mitsunobu coupling 
of exo-oxanorbornene imide (69) with tetraethylene glycol (Scheme 5.3).  In neutral 
water, catalyst 63 failed to polymerize 70.  However, polymerization occurred in aqueous 
solution at low pH (2 or lower) as evidenced by a rapid increase in solution viscosity 
immediately after injection of 63 to a solution of 70 in acidified water.  The pH-
dependent metathesis activity is in accord with previously reported results for ionic, 
phosphine substituted ruthenium catalysts.
7-9  
In this case, the presence of a Brønsted acid 
likely activates the catalyst by protonation of PEG-pyridine ligands, which diminishes 
their ligation capability and increases the reactivity of catalyst 63 towards cyclic olefins. 
 
Scheme 5.3  Synthesis of tetraethylene glycol-substituted oxanorbornene 70 by 
Mitsunobu coupling of 69 and tetraethylene glycol 
  
 
Polymera [M]/[Cat 63b] Mp
c (g/mol) Mn
c (g/mol) Mw
c (g/mol) PDI 
65 50 15,100 13,900 14,600 1.05 
66 100 26,000 24,400 25,300 1.04 
67 200 46,800 42,300 44,300 1.05 
68 400 82,500 65,900 71,400 1.08 
a
[M] = 0.2 M in CH2Cl2, 
b
Used as a 0.03 M solution in DCM, 
c
Determined by GPC in THF relative to PS standards 
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Figure 5.6 provides GPC-derived molecular weight data for polymers 71 - 73, 
prepared by polymerizations that employed various ratios of monomer 70 to catalyst 63 
in water at pH 1.5.  The average molecular weight of polymers 71 - 73 could be adjusted 
to higher or lower values by variation of the monomer-to-catalyst ratio.  However, the 
estimated molecular weights of the polymers obtained, using GPC in DMF, were not 
consistent with theoretical estimations.  For example, in the polymerization of 
oxanorbornene 70 using monomer-to-catalyst ratios of 25:1 (polymer 71) and 50:1 
(polymer 72), the polymers obtained had GPC-estimated Mn values of 67,000 and 
116,000 g/mol, respectively.  Full monomer conversion was confirmed by 
1
H NMR 
spectroscopy recorded in CDCl3, where resonances at ? 6.5 ppm for the cyclic olefin 
were not observed.  Under ideal conditions of quantitative initiation and absence of 
termination reactions, Mn values of approximately 10,000 and 20,000 g/mol would have 
been obtained for polymers 71 and 72, respectively.  This rather significant discrepancy 
in theoretical vs. experimental molecular weight, along with the relatively broad PDI 
values (1.3 to 2.4), suggest that initiation by catalyst 63 under these conditions is 
incomplete or slow.  In contrast, good agreement of theoretical versus experimentally 
estimated molecular weight (by GPC) was found for the polymerization of 64 in 
dichloromethane.   
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Figure 5.6  GPC analysis of polymer 71 obtained by ROMP of 70 using 63 in water 
 
 
Table 5.2  Characteristics of polymers 71 – 73 prepared by ROMP of 70 using 
catalyst 63 in water 
 
Polymera [M]/[Cat 63b] Mp
c (g/mol) Mn
c (g/mol) Mw
c (g/mol) PDI 
71 25 79,000 67,000 90,700 1.35 
72 50 177,400 116,200 204,400 1.76 
73 100 263,700 137,800 327,200 2.37 
 
5.5 Summary and Future Studies 
In summary, a new amphiphilic ruthenium benzylidene metathesis catalyst 
containing PEG-substituted pyridine ligands is reported.  PEG-substituted catalyst 63 
possesses the beneficial attributes of both the enhanced reactivity given by the N-
heterocyclic carbene ligand and amphiphilicity imparted by PEGylation.  Catalyst 63 is 
soluble in both organic and aqueous solvents and was shown to effectively polymerize 
cyclic olefins in both dichloromethane and water.  In dichloromethane, polymers with 
a
[M] = 0.15 M in acidified water (pH=1.5), 23 
o
C for 30 min, 
b
Used as a 0.015 M solution in acidified water (HCl, 
pH=1.5), 
c
Determined by GPC in DMF relative to PMMA standards 
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low polydispersity indices are obtained, suggesting a controlled or “living” 
polymerization similar to the 3-bromopyridine substituted catalyst III.  The 
polymerization of cyclic olefins in water proceeds rapidly but without the molecular 
weight control observed in the case of dichloromethane.  
Unlike PEGylated catalysts VII and VIII, which utilize polydisperse samples of 
relatively high molecular weight PEGs (MW >2000 g/mol), the use of PEG-pyridines 
with discrete ethylene glycol chain lengths can be utilized to produce a well-defined, 
amphiphilic catalyst with solubility in water and organic solvents.  To accomplish this, 
future studies could focus on isolation of catalyst 63 in the absence of excess ligand.  In 
this thesis work, the isolation of a pure catalyst has been limited because of difficulties in 
separating 63 from excess PEG-pyridine ligand.  This problem may be overcome by 
utilizing PEG-pyridines in ligand exchange chemistry with catalyst IX as shown in 
Scheme 5.4.  Catalyst IX possesses volatile pyridine ligands that can be removed under 
reduced pressure.  If an exact stoichiometric amount of PEG-pyridine is exchanged for 
pyridine ligands, pure catalyst 63 might be made in this fashion.  If successful, key 
questions regarding the chemical structure and aqueous solubility of pure 63 in the 
absence of excess ligand can be addressed.  In addition, the polymerization kinetics 
associated with 63, including the effect of solution pH and other parameters, can be 
further probed. 
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Scheme 5.4 Proposed synthesis of pure ruthenium benzylidene catalyst 63 by ligand 
exchange of catalyst IX with PEG-substituted pyridine 62 
 
 
The synthetic route illustrated in Scheme 5.4 requires precise control over 
stoichiometry and very pure samples of PEG-pyridine ligand 62.  To date, the synthesis 
of appreciable quantities of pure 62 has been hindered due to previously described 
purification problems.  Protection strategies may be utilized in the future to improve the 
yield and purity of PEG-pyridine 62.  For example, as shown in Scheme 5.5, 
tetraethylene glycol can be reacted with an appropriate silyl chloride (e.g. tert-
butyldimethylsilyl chloride) to give monoprotected tetraethylene glycol 74.  Due to the 
large difference in polarity between the alcohol and TBDMS functionality, it is 
anticipated that the separation of 74 and excess tetraethylene glycol by column 
chromatography should become significantly less challenging.  Mono-protected 74 will 
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then be reacted with a stoichiometric quantity of 4-hydroxypyridine under Mitsunobu 
coupling to give protected PEG-pyridine 75.  Acidic deprotection and subsequent 
neutralization should yield pure PEG-pyridine 62 with chain end hydroxyl functionality, 
which can be utilized in ligand exchange chemistry with catalyst II.   
 
Scheme 5.5 Proposed synthesis of PEG-pyridine ligand 62 using silyl-protected 
tetraethylene glycol 73  
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CHAPTER 6 
PROJECT OUTLOOK 
6.1 Drug Release Studies using Polyolefin Capsules 
During the course of this thesis work, significant efforts were made to tailor the 
properties of polymer capsules prepared from PCOE-g-PEG copolymers for 
encapsulation and release applications.  Future efforts will continue in this direction as 
further exploration of capsule properties such as membrane degradability, permeability, 
and solute release are critical in this area.  In initial encapsulation and release 
experiments using the anti-inflammatory drug Naproxen, significant drug release (>90%) 
was observed after only a few hours from polymer capsules prepared from assembly and 
UV cross-linking of phenyl azide-functional graft copolymers, such as copolymer 42.  
This data is consistent with other drug release studies using polymer capsules prepared 
from polymersomes or by LbL techniques.
1-3
  Thus, the encapsulation and sustained 
release of small molecules will be a major goal moving forward.   
In an effort to create polymer capsules capable of either sustained or triggered 
release, several approaches have been contemplated.  In one approach, a hydrophobic 
drug or other solute might be encapsulated in a non-volatile, hydrophobic oil such as 
soybean oil or trioctanoin.  In this case, release would be slowed due to the preferential 
solubility of the solute in the hydrophobic oil, and parameters such as membrane 
thickness, cross-link density, and cross-linker chemistry could be varied to fine tune 
release properties.  Figure 6.1 shows one proposed example where a hydrophobic drug, 
such as tetraethylene glycol-substituted camptothecin 76, is solubilized in trioctanoin and 
encapsulated using PCOE-g-PEG copolymers.  In this case, 76 has little therapeutic 
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activity due to the substitution at the 20-OH position of camptothecin, but upon ester 
hydrolysis in aqueous environments, the therapeutically-active drug is regenerated.  
Studies that focus on degradation and drug release from polymer capsules prepared with 
hydrolytically-stable cross-links (e.g. amide-linked phenyl azide cross-linked capsules) 
versus pH-sensitive cross-links (e.g. hydrazone cross-linked capsules) will be critical in 
achieving either sustained or triggered release from the capsule. 
 
Figure 6.1  Illustration of solute encapsulation utilizing trioctanoin-filled polymer 
capsules prepared from PCOE-g-PEG copolymers 
 
 
Based on release experiments performed with polymer capsules prepared by LbL 
techniques, it has been shown that large macromolecules can be encapsulated and 
retained in the core of these capsules.  For example, Caruso and coworkers demonstrated 
the sustained encapsulation of the protein Transferrin in disulfide cross-linked capsules 
prepared by LbL assembly,
4
 and Möhwald and coworkers showed that glutaraldehyde 
  144 
cross-linked LbL capsules with a membrane thickness of ~ 20 nm were not permeable to 
high molecular weight dextran (460 - 2000 kDa).
5
  Thus, a second strategy for controlled 
release of small molecules might involve the encapsulation of a polymer-drug conjugate 
of sufficient molecular weight as to limit the diffusion of the polymer but allow release of 
the small molecule once liberated from the backbone.  For example, Figure 7.2 illustrates 
the encapsulation of a camptothecin-functionalized polyester previously reported by the 
Emrick group.
6
  This novel polymer-drug conjugate was synthesized by copper-catalyzed 
“click coupling” of a propargyl-functionalized polyester and an azide-containing 
camptothecin derivative.  In this case, the polyester-camptothecin conjugate should be 
retained in the capsule core based on its large size.  However, upon significant hydrolysis 
of the polyester backbone or the ester linkage at the 20-OH position of the pendent 
camptothecin, drug diffusion across the membrane should be observed with release 
kinetics governed by the rate of ester hydrolysis.  Studies to probe the molecular weight 
cut-off of the capsule membrane might also be performed using a range of polyester 
molecular weights (e.g. 5,000 – 50,000 g/mol).  Variations in membrane properties such 
as cross-link density and chemistry may also be explored to fine-tune release properties.  
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Figure 6.2  Illustration of polyester-camptothecin conjugate encapsulation and 
hydrolysis-controlled drug release from polymer capsules 
  
 
Methods to vary the permeability of the capsule membrane might also be pursued 
using a novel copolymer illustrated in Scheme 6.1.  In preliminary studies, ester-linked, 
?,?-diene 77, has been integrated into PCOE copolymers through a combination ROMP-
ADMET polymerization mechanism using catalyst II.  In this reaction, it is hypothesized 
that ROMP of cyclic olefins proceeds rapidly with 77 acting as a di-functional chain-
transfer agent, producing oligomers containing terminal olefins.  Over time, the 
molecular weight of copolymer 78 is increased through ADMET condensation of the 
terminal olefin end-groups.  Utilizing this strategy, high molecular weight polyolefins 
could be prepared with a controllable number of hydrolytically-degradable ester linkages 
in the polymer backbone through variation of 77 in the polymerization feed.  If 
copolymer 78 is utilized in interfacial assembly and UV cross-linking, polymer capsules 
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with hydrolytically-stable amide cross-links and a hydrolytically-degradable polymer 
backbone would be produced.  Over time, the capsules should not dissolve away due to 
the stable cross-links, but the permeability of the capsule membrane should change based 
on ester hydrolysis of the polymer backbone.   Variation of 77 in the copolymerization 
feed might produce capsules with selective permeability to macromolecules of various 
molecular weights which could prove useful for release applications, chemical 
transport/catalysis systems, and bioreactors. 
 
Scheme 6.1  Synthesis of hydrolytically-degradable PCOE-g-PEG copolymer 79 for 
the preparation of variable permeability polymer capsules  
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CHAPTER 7 
EXPERIMENTAL SECTION 
7.1 Materials 
cis-Cyclooctene, succinic anhydride (99%), lithium aluminum hydride (95%), and 
bis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride (catalyst I) were 
purchased from Sigma-Aldrich or Alfa Aesar.  Potassium hydroxide (technical grade), 
sodium hydroxide (97%), and hydrogen peroxide (34 - 37% aqueous solution) were 
purchased from Fisher Scientific and used as received.  1,5-Cyclooctadiene (99%) 
(COD), m-chloroperoxybenzoic acid (MCPBA) (77%), 4-dimethylaminopyridine 
(DMAP) (99%), 1,3-dicyclohexylcarbodiimide (DCC) (99%), N,N’-
diisopropylcarbodiimide (DIC) (99%), 1-hexene (97%), ethyl vinyl ether (99%), ethylene 
oxide (EO) (99.5%), 3-bromopyridine (99%), sodium azide (99.5%), triphenylphosphine 
(99%), piperidine (99%), 2,2,2-trifluoroethanol (TFE) (99.5%), diisopropylethylamine 
(99.5%), polyethylene glycol (MW 2000 g/mol), Rhodamine B (90%), 3-bromopyridine 
(99%), sodium azide (99.5%), triphenylphosphine (99%), HCl (4.0 M in dioxane), 
diisopropyl azodicarboxylate (95%), maleic anhydride (99%), maleimide (99%), 
diethylene glycol vinyl ether (98%), dimethylsulfoxide (DMSO) (99.5%), thionyl 
chloride (99%), potassium chunks (98%), sodium cyanide (97%), tert-butyl carbazate 
(98%), sodium nitrite (97%), 4-aminobenzoic acid (99%), 4-aminophenyl sulfone (97%), 
triisopropylsilane (99%), tert-butyl bromoacetate (98%), potassium tert-butoxide (95%) 
and Grubbs’ Generation II catalyst (catalyst II) were purchased from Sigma-Aldrich and 
used without further purification.  Hydrobromic acid (HBr) (33% in acetic acid) was 
purchased from Fluka.  Camptothecin (98%) was purchased from Acros and used as 
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received.  Naphthalene (99%, Aldrich) was recrystallized from methanol and sublimed 
before use.  4-Hydroxypyridine (95%, Aldrich) was passed through a plug of neutral 
alumina (80/20 CHCl3/MeOH eluent), precipitated into diethyl ether, filtered, and dried 
in vacuo.  Furan (99%, Aldrich) was purified by vacuum distillation over calcium 
hydride.  Triethylene glycol monomethyl ether (95%, Aldrich) was purified by fractional 
distillation over calcium hydride.  Tetraethylene glycol (99%, Alfa-Aesar) was purified 
by fractional distillation over calcium hydride.  Grubbs’ Generation III catalyst (catalyst 
III) was prepared according to literature procedures.
1 
 Tetrahydrofuran (THF) was 
distilled from sodium benzophenone ketyl.  Dichloromethane and triethylamine were 
distilled from calcium hydride before use.  Polyethylene glycol monomethyl ether 
(mPEG) 750 was purchased from Polysciences, Inc and purified by column 
chromatography (in CHCl3/Acetone/MeOH mixtures) before use.  mPEG 1000 was 
purchased from Shearwater Polymer, Inc. and used without further purification.  Fmoc-
Gly-OH, Fmoc-Ser(But)-OH, Fmoc-Asp(OBut)-OH, Fmoc-Arg(Pbf)-OH, Boc-Gly-OH, 
trifluoroacetic acid, 1-hydroxybenzotriazole (HOBt) hydrate, O-(Benzotriazol-1-yl)-
N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), and 2-chlorotrityl chloride 
resin (1.4 mmol/g, 100-200 mesh) were purchased from Advanced ChemTech.  PVDF-
UF membrane with 30,000 molecular weight cutoff was purchased from Sterlitech 
Corporation, USA.  
7.2 Methods and Instrumentation 
Molecular weights and PDIs of macromonomers 3 and 4 were measured using gel 
permeation chromatography in THF (elution rate = 1.0 mL/min) and referenced against 
linear PEG standards.  The system utilized three-columns (Polymer Laboratories Mixed-
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D columns, 5 mm, 300 x 7.5 mm) and a refractive index detector (Waters R4010 or 
Knauer K-2301). Macromonomers 8, 9, 10, 15 and 16 and copolymers 42, 43, 49 and 58 
were analyzed in THF (1.0 mL/min) and referenced against linear polystyrene standards.  
The system utilizes three-columns (PL Mixed-D columns, 5 ?m, 300 x 7.5 mm), a dual 
wavelength UV detector (Knauer K-2600, analysis at 260 nm), and a refractive index 
detector (Knauer K-2301).  GPC analyses of copolymer 18 – 26 and bis-cyclooctene 31 
were performed in dimethylformamide (DMF) (with 0.01 M LiCl, elution rate = 0.5 
mL/min) and referenced against linear polystyrene standards.  The system utilized three-
columns (Polymer Laboratories Mixed-D columns, 5 mm, 300 x 7.5 mm) and a refractive 
index detector (Waters R4010).  GPC analyses of polymers 71 – 73 were performed in 
DMF (1.0 mL/min) with LiBr (0.05 M) using a PL GPC 50 system at 50 °C equipped 
with two PL Resipore
®
 columns (3 ?m, 300 x 7.5 mm) and referenced against linear 
poly(methyl methacrylate) standards.  GPC analyses of polymers 27 – 29 and copolymers 
53 – 57 were performed in chloroform (elution rate = 1.0 mL/min) using a PL GPC 50 
system at 25 °C equipped with two Polymer Laboratories (PL) Mixed D columns (5 ?m, 
300 x 7.5 mm) and referenced against linear polystyrene standards.  High temperature 
GPC of hydrogenated polymers 18a – 26a was performed on a Polymer Laboratories PL-
GPC 200 equipped with a Wyatt Minidawn multiple angle laser light scattering 
(MALLS) detector using trichlorobenzene (135 
o
C) at a flow rate of 1.0 mL/min.  
NMR spectra were collected on either a Brüker DPX 300 spectrometer: 
1
H at 300 
MHz and 
13
C at 75 MHz or on a Brüker Avance 400 spectrometer: 
1
H at 400 MHz and 
13
C at 100 MHz.  Attenuated Total Reflectance Infrared Spectroscopy (ATR-FTIR) was 
performed on a Perkin-Elmer Spectrum One spectrometer equipped with a Universal 
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Diamond ATR sampling accessory.  DSC experiments were performed on a TA 
instruments Q1000 at a heating rate of 10 
o
C/min.  UV data was obtained using a Hitachi 
U-3010 spectrophotometer at a scan rate of 60 nm/mi.  Confocal images were obtained 
using an inverted microscope with TCS SP2 confocal system (Leica).  Atomic force 
microscopy (AFM) images were obtained using a Digital Instruments Dimension 3100 
atomic force microscope.  Electrospray Ionization (ESI) mass spectroscopy was 
performed on a Brüker Esquire liquid chromatography instrument.  Matrix assisted laser 
desorption/ionization mass spectroscopy was performed on a Brüker Reflex III.  A CL-
1000 UV light source (UVP, Inc.) was utilized for UV cross-linking at 302 nm (intensity 
3800 microwatts/cm
2
).  Scanning electron microscopy (SEM) images were obtained on a 
Jeol 6320FXV Field Emission SEM.  Dynamic light scattering analysis was performed 
on a Particle Sizing Systems Nicomp 380 at a 90
o
 angle.  A Rame-hart model 1000 
goniometer system was used for contact angle measurements.  Pure water flux through 
dense membrane made from polymers 53 – 57 was measured with Amicon 8200 stirred 
ultrafiltration cell.  HPLC analysis was performed using a Waters Alliance 2695 multi-
solvent delivery system equipped with a Waters 2996 photodiode array detector and a 
Waters XTerra
®
 column (C8, 5 ?m, 4.6 x 150 mm).  
7.3 Synthetic Procedures 
Synthesis of 5-hydroxy-1-cyclooctene (1) 
 
 
OH
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5-hydroxy-1-cyclooctene was prepared in two steps from commercially available 
1,5-cyclooctadiene as described by Grubbs and coworkers.
2
 
Succinic acid mono-cyclooct-4-enyl ester (2) 
 
3.00 g (2.38 mmol) of 5-hydroxy-1-cyclooctene (1) 2.38 g (2.38 mmol) of 
succinic anhydride, and 50 mg (0.41 mmol) of N,N-dimethylaminopyridine (DMAP) 
were combined and stirred in refluxing toluene (20 mL) for 16 hours.  The solution was 
cooled to room temperature, washed with 1 M HCl (aq), and concentrated to yield a 
white solid.  The product was purified by crystallization in hexanes to afford 4.58 g (85 
%) of 2: m.p. 55-57 
o
C; 
1
H NMR (CDCl3) ? 10.75 (br s, 1H), 5.65 (m, 2H), 4.85 (m, 1H), 
2.55-2.67 (m, 4H), 1.57-2.4 (m, 10H) ppm; 
13
C NMR (CDCl3) ? 178.9 (acid), 171.9 
(ester), 130.2, 123.0, 76.7, 34.0, 33.9, 29.6, 29.4, 25.9, 22.2, 22.7 ppm; IR (KBr) 3018, 
2938, 2866, 1728 (ester), 1704 (acid), 1447, 1408, 1355, 1255, 1236, 1213, 1171 cm
-1
. 
Representative synthesis of ester-linked PEG macromonomer (4) 
 
           m ~ 22 
2.0 g (8.8 mmol) of 2, 8.8 g (8.8 mmol) of poly(ethylene glycol) monomethyl 
ether (MW 1000 g/mol), and 106 mg (0.88 mmol) DMAP were stirred in dry CH2Cl2 (15 
mL) under N2.  Separately, 2.2 g (10.6 mmol) of DCC was dissolved in 1.4 g (17.6 
mmol) of pyridine and DCM (15 mL); this solution was then added by syringe to the 
reaction mixture containing 2 and stirred for 12 hours at room temperature under N2. 
O
OH
O
O
O
O
O
O
O
O
m
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Upon completion, the mixture was washed with 1 M  HCl (aq) and concentrated.  The 
product was dissolved in a mixture of hexane and ethyl acetate and twice extracted with 
water.  The aqueous phase was extracted with CH2Cl2, concentrated, and dissolved in 
toluene.  This solution was washed twice with a sat. NaCl (aq) and dried using MgSO4.  
Toluene was removed by evaporation, and the product was dissolved in a minimal 
amount of diethyl ether and precipitated into cold hexane.  The product was collected and 
dried under vacuum overnight to yield 8.1 g (76 %) of 4 as a white solid: m.p. 42-43 
o
C; 
1
H NMR (CDCl3) ? 5.65 (m, 2H), 4.83 (m, 1H), 4.22 (t, 2H), 3.5-3.7 (complex, br m, 
~90H), 3.38 (s, 3H), 2.55-2.67 (m, 4H), 1.57-2.4 (m, 10H) ppm; 
13
C NMR (CDCl3) ? 
172.4 (ester), 171.6 (ester), 129.8, 129.6, 76.8, 72.0, 70.6, 69.1, 63.9, 59.1, 33.7, 33.6, 
29.5, 29.2, 25.6, 24.9, 22.3 ppm.  
Representative synthesis of ether-linked PEG macromonomer (9) 
 
         m ~ 50 
In a flame dried air-free flask, 5-hydroxy-1-cyclooctene (1) (6.8 mL of 1.0 M 
solution in THF, 6.8 mmol) was added to dry THF (150 mL) while stirring under N2.  
The solution was titrated with potassium napthalenide (0.2 M in THF) until a slight green 
end-point was observed (~ 35.0 mL).  The cyclooctene alkoxide solution was stirred for 
an additional 30 minutes at room temperature before being cooled to 0 
o
C in an ice/water 
bath.  Ethylene oxide (15.0 mL, 340.6 mmol) was condensed at -78 
o
C using a stainless 
steel gas transfer manifold, then slowly warmed to room temperature while transferring 
to the cooled cyclooctene alkoxide solution under static vacuum.  The reaction mixture 
O
O
OH
m-1
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was pressurized with argon, sealed, and stirred at room temperature for 16 hr.  The 
solution was concentrated and the residue was purified by column chromatography on 
silica gel (93/7 ? 90/10 CHCl3/MeOH).  The product recovered from the column was 
dissolved in a minimal amount of chloroform and precipitated into diethyl ether.  A white 
powder was isolated by filtration and dried under vacuum to yield 11.3 g (75% yield) of 
macromonomer 9. 
1
H NMR (CDCl3) ? 5.62 (m, 2H), 3.28-3.84 (complex, br m, 228 H), 
2.54 (br s, 1H), 1.28-2.36 (complex br m, 11H); 
13
C NMR (CDCl3) ? 130.2, 129.6, 81.1, 
72.7, 71.0, 70.7, 70.4, 67.8, 61.8, 34.2, 33.5, 25.9, 25.8, 22.8; ATR-FTIR 3491, 2882, 
1467, 1359, 1341, 1280, 1242, 1100, 1060, 959, 841, 725 cm
-1
; GPC (THF, relative to 
PEG standards) Mn 2300 Da, Mw 2350 Da, PDI 1.09. 
Synthesis of cyclooctene-PEG azide (13) 
 
               m ~ 49 
Macromonomer 9 (13.0 g, 5.7 mmol) was added to a dry round-bottom flask and 
dissolved in anhydrous THF (100 mL).  The solution was cooled to 0 
o
C and 
methanesulfonyl chloride (0.6 mL, 7.1 mmol) was added by syringe.  Triethylamine (1.2 
mL, 8.5 mmol) was subsequently added by syringe over approximately 5 minutes.  The 
reaction mixture was stirred for an additional 30 minutes at 0 
o
C, warmed to room 
temperature, and stirred for 16 hours.  The mixture was concentrated, diluted with 95% 
ethanol (100 mL), and sodium azide (1.9 g, 28.5 mmol) was added.  The mixture was 
heated to reflux and stirred for 16 hours.  The reaction contents were allowed to cool to 
room temperature and concentrated by rotary evaporation.  The residue was purified by 
O
O
N3
m
  154 
column chromatography on silica gel (93/7 ? 90/10 CHCl3/MeOH).  The desired 
fractions were combined and concentrated, and the residue was dissolved in a minimal 
amount of chloroform and precipitated into diethyl ether.  The white powder was isolated 
by filtration and dried under vacuum to yield the desired macromonomer (12.8 g, 98% 
yield). 
1
H NMR (d6-DMSO) ? 5.62 (m, 2H), 3.25-3.75 (complex, br m, 228 H), 2.54 (br 
s, 1H), 1.28-2.35 (complex br m, 11H); 
13
C NMR (d6-DMSO) ? 130.0, 129.1, 79.8, 70.3, 
69.8, 69.4, 67.4, 50.3, 34.0, 33.5, 25.4, 25.3, 22.3; ATR-FTIR 2882, 2741, 2098, 1466, 
1360, 1341, 1279, 1241, 1146, 1100, 1060, 959, 841 cm
-1
; GPC (THF, relative to PEG 
standards) Mn 2360 Da, Mw 2550 Da, PDI 1.08. 
Synthesis of cyclooctene-PEG amine (14) 
 
          m ~ 49 
COE-PEG azide 13 (12.8 g, 5.6 mmol) and triphenylphosphine (2.9 g, 11.1 mmol) 
were dissolved in THF (90 mL).  The contents were stirred for 30 minutes with visible 
bubbling due to N2 evolution. Water (10 mL) was subsequently added resulting in a 
heterogeneous solution.  The reaction mixture was stirred an additional 16 hours at room 
temperature and eventually becoming a homogenous solution.  Water was removed from 
the reaction by azeotropic distillation with benzene.  The reaction mixture was then 
concentrated, dissolved in a minimal amount of chloroform, and precipitated into diethyl 
ether.  The product was isolated by filtration, washed several times with diethyl ether, 
and dried in vacuo to afford 10.8 g (89% yield) of the desired macromonomer as a white 
powder.  
1
H NMR (d6-DMSO) ? 5.60 (m, 2H), 3.35-3.75 (complex, br m, 228 H), 2.64 (t, 
O
O
NH2
m
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2H), 1.28-2.35 (complex br m, 11H); 
13
C NMR (d6-DMSO) ? 129.1, 128.9, 79.9, 73.1, 
70.3, 69.8, 69.6, 67.2, 34.0, 29.8, 25.3, 25.2, 22.3;  GPC analysis of macromonomer 14 
was not possible due to interactions with the GPC column media which artificially 
inflated molecular weight and PDI values. 
Synthesis of cyclooctene-PEG-carboxylic acid (15) 
 
m ~ 49 
COE-PEG amine 14 (13.7 g, 6.0 mmol) and succinic anhydride (1.5 g, 15.0 
mmol) were dissolved in chloroform (60 mL).  Methanol (10 mL) was added to improve 
solubility, and the reaction mixture was stirred for 16 hours at room temperature. The 
mixture was concentrated and purified by column chromatography on silica gel (93/7 ? 
90/10 CHCl3/MeOH).  The desired fractions were combined and concentrated, and the 
residue was dissolved in a minimal amount of chloroform and precipitated into diethyl 
ether.  The white powder obtained was isolated by filtration and dried under vacuum to 
yield macromonomer 15 (13.1 g, 95% yield). 
1
H NMR (d6-DMSO) ? 12.07 (s, 1H), 7.88 
(s, 1H), 5.60 (m, 2H), 3.25-3.75 (complex, br m, 228 H), 3.15 (m, 2H), 1.25-2.42 
(complex br m, 11H); 
13
C NMR (d6-DMSO) ? 173.8, 171.0, 130.0, 129.1, 79.9, 70.2, 
69.9, 69.2, 67.1, 33.9, 32.7, 29.9, 29.1, 25.2, 25.1, 22.2; ATR-FTIR 2881, 1733, 1467, 
1359, 1342, 1279, 1241, 1147, 1099, 1060, 960, 841 cm
-1
. GPC (THF, relative to PEG 
standards) Mn 2470 Da, Mw 2770 Da, PDI 1.12. 
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Synthesis of cyclooctene-PEG-GRGDS (16) 
 
m ~ 49 
RGD-functionalized PEG macromonomer 16 was synthesized via Fmoc-based 
solid phase peptide synthesis with the coupling agent HBTU using a 2-chlorotrityl 
chloride resin.  2-chlorotrityl chloride resin (2.89 g of resin with 1.40 mmol of functional 
groups per gram of resin, 4.05 mmol, 100-200 mesh) was weighed into an oven-dried, 
glass-fritted reaction tube and swollen with dry DCM (40 ml) for 5-10 minutes.  The 
resin was filtered, and a solution of Fmoc-Ser(But)-OH (2.02 g, 5.26 mmol) in dry 
DIPEA (3.50 ml, 20.2 mmol),and dry DCM (30-40 ml) was added to the reaction tube.  
The tube was capped, vented, and agitated with nitrogen.  After 30 minutes, the resin was 
filtered and rinsed with dry DMF three times.  The remaining reactive groups on the resin 
were capped with a 80/15/5 dry DCM/methanol/DIPEA solution (40 ml, 2 x 10 min.) and 
then rinsed with reagent grade DMF.  The Fmoc group was removed with a 25/75 
piperidine/DMF cleavage solution (2 x 40 ml).  The solution was added to the resin, and 
the resin was agitated for three minutes.  Following filtration, fresh cleavage solution was 
added and agitated for 20 minutes.  The resin was filtered and rinsed with DMF six times, 
DCM three times, isopropanol three times, and hexanes six times.  The resin was dried by 
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filtration for 15 minutes, transferred to a vial, and dried under vacuum for 24-36 hours.  
The loading density was estimated by the mass differential between the unloaded and 
loaded resin.  
After loading Fmoc-Ser(But)-OH, a portion of the dried resin (1.05 g, 0.447 
mmol) was transferred to a dry, glass-fritted reaction tube and swollen with 20 ml of 
DCM for 5 minutes.  Fmoc-Asp(But)-OH (0.920 g, 2.49 mmol), HOBt (0.382 g, 2.49 
mmol), HBTU (0.831 g, 2.19 mmol), and DMF (15 mL, reagent grade) were combined in 
an oven-dried round bottom flask, and DIPEA (reagent grade, 0.80 mL, 4.47 mmol) was 
added to form a clear, yellow solution.  The activated amino acid solution was then added 
to the resin, and the resin was agitated for one hour, filtered, and washed with DMF three 
times. The Fmoc protecting group was cleaved with 25/75 piperidine/DMF, after which 
the resin was washed with DMF six times. The amino acid addition procedure was 
repeated for Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, and a second unit of Fmoc-Gly-OH. 
Following the addition of the second glycine residue, the Fmoc protecting group 
was cleaved, and the resin was thoroughly washed with DMF.  A solution of cyclooctene-
PEG-carboxylic acid (15) (8.26 g, 3.42 mmol), HOBt (0.38 g, 2.49 mmol), HBTU (0.83 
g, 2.19 mmol), DIPEA (1.00 mL, 5.60 mmol), and 25 ml of DMF was added to the resin 
and agitated from four hours.  The resin was filtered and washed with DMF and DCM 
three times.  A fresh solution of cyclooctene-PEG-carboxylic acid (15) (4.32 g, 1.79 
mmol), HOBt (0.27 g, 1.76 mmol), HBTU (0.67 g, 1.77 mmol), DIPEA (1.00 mL, 5.60 
mmol), and DMF (20 mL) prepared, added to the resin, and agitated for four hours.  The 
resin was washed with DMF and DCM five times.   
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The macromonomer was then cleaved from the resin under mildly acidic 
conditions (4:1 DCM:TFE).  After 90 minutes, the resin was filtered into a clean flask, 
and fresh solution was added.  The resin was agitated for another 30 minutes, filtered, and 
washed with 4:1 DCM:TFE and then DCM three times.  This resulting filtrate was 
concentrated on a rotary evaporator and then precipitated into diethyl ether.  After sitting 
at 4°C for several hours, the product was isolated by filtration and then dried under 
vacuum.  To remove uncoupled GRGDS oligopeptide, the crude product was dissolved in 
deionized water and filtered to remove the insoluble material.  The filtrate was 
subsequently lyophilized and 610 mg (41% yield) of macromonomer 16 was isolated as a 
white product. 
1
H NMR (d6-DMSO) ? 8.82 (s), 7.80 - 8.18 (m), 5.58 (m), 4.69 (m), 4.30 
(t), 4.22 (m), 3.25-3.75 (br m), 3.15 (m), 3.04 (br s), 2.96 (s), 2.65 (m), 2.47 (s), 2.35 (s), 
2.24 (m), 1.93 – 2.14 (m), 1.80 – 1.90 (m), 1.50 – 1.76 (m), 1.38 (d), 1.10 (s); 
13
C NMR 
(d6-DMSO) ? 171.9, 171.6, 170.5, 169.5, 168.8, 159.0, 158.7, 158.3, 157.9, 130.2, 129.3, 
119.5, 116.6, 113.7, 110.9, 80.5, 80.1, 73.1, 70.4, 70.0, 69.8, 69.3, 67.3, 61.6, 53.0, 49.2, 
34.1, 32.9, 30.8, 30.7, 28.4, 27.8, 27.3, 25.4, 25.2, 22.4, 19.1, 17.7, 12.4; GPC (THF, 
relative to PEG standards) Mn 1880 Da, Mw 2130 Da, PDI 1.13. MALDI Peak MW m/z = 
3261 g/mol. 
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Example Copolymerization using Macromonomer 4 (Copolymer 17) 
 
Macromonomer 4 (0.50 g, 0.52 mmol) was weighed into a reaction tube and 
degassed under vacuum while stirring at 45 
o
C.  Cyclooctene (58 mg, 0.52 mmol) was 
injected into the vessel under N2.  Catalyst II (3.5 mg, 4.1 μmol) was weighed into a 
small vial, degassed, and dissolved in dry dichloromethane (1.0 mL) under N2.  The 
catalyst solution was introduced by syringe, and the mixture was stirred at 45 
o
C.  Once 
stirring had ceased due to the increased solution viscosity, ethyl vinyl ether (1 mL) was 
added and a small amount of DCM (~1 mL) was added to improve stirring.  The contents 
were precipitated into cold hexane, filtered, and dried under vacuum to yield copolymer 
17 (0.42 g, 84%).  
1
H NMR (CDCl3) ? 5.34 (br, olefin 2H), 4.86 (br s, 1H), 4.22 (t, 2H), 
3.5-3.7 (complex, br m), 3.36 (s, 3H), 2.61 (br m, 4H), 2.32 (br s), 1.94 (br s), 1.50 (br s), 
1.26 ppm (br s); 
13
C NMR (CDCl3) ? 172.7 (ester), 172.3 (ester), 130.0, 130.8, 129.3, 
74.7, 72.3, 70.9, 69.4, 64.2, 59.4, 34.4, 33.0, 30.0, 29.7, 29.5, 28.8, 25.6 ppm. IR (NaCl 
plate) 2922, 2867, 1733 (ester), 1456, 1349, 1300, 1250, 1111, 1040, 968, 860 cm
-1
.  
GPC (DMF w/ 0.01% LiCl vs. linear polystyrene standards) Mn = 330,000 g/mol, Mw = 
515,000 g/mol, PDI = 1.56. 
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Representative synthesis of PCOE-g-PEG copolymer (Copolymer 27)  
 
      m ~ 24 
PEG 1200 (m ~ 24) macromonomer (8) (0.16 g, 0.13 mmol) and cyclooctene 
(0.17 g, 1.54 mmol) were combined in a dry reaction tube.  0.2 mL of a 0.05 M 1-hexene 
solution in dichloromethane was added to the reaction under N2 followed by 0.7 mL of 
dry dichloromethane.  In a separate vial, catalyst III (5.9 mg, 6.7 μmol) was dissolved in 
0.2 mL dry dichloromethane.  Both the monomer mixture and catalyst solution were 
subjected to two freeze/pump/thaw cycles and subsequently warmed to 40 
o
C.  The 
catalyst solution was then rapidly added to the monomer solution and stirred until 
vitrified (approx. 5 min).  Ethyl vinyl ether (1 mL) was added to terminate the 
polymerization and dichloromethane was added to dilute the polymer solution.   The 
product was precipitated into cold hexane containing 1 wt % BHT, isolated by filtration, 
and dried under vacuum to yield 0.30 g (90% yield) of copolymer 27 as an off-white 
solid. 
1
H NMR (CDCl3) ? 5.36 (m), 3.37-3.97 (br m), 3.24 (br s), 2.43 (br s), 1.94, (br m), 
1.27-1.53 (br m); 
13
C NMR (CDCl3) ? 130.2, 72.6, 70.6, 70.3, 61.7, 32.6, 29.6, 29.1; 
ATR-FTIR 2921, 2852, 1468, 1344, 1281, 1242, 1104, 963, 842 cm
-1
. GPC (CHCl3, 
relative to PS standards) Mn 24,000 Da, Mw 48,500 Da, PDI 2.02. 
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Hydrogenation of PCOE-g-PEG graft copolymers (Copolymer 26a) 
 
m ~ 16 
Hydrogenated copolymers 18a – 26a were synthesized according to published 
procedures.
1
  Precipitation of copolymers 18a - 25a were performed in cold hexane.  
Precipitation of 26a was performed in cold methanol. Hydrogenated copolymer 26a: 
1
H 
NMR (CDCl3) ? 4.86 (broad s, 1H), 4.24 (t, 2H), 3.5-3.7 (complex, br m), 3.38 (s, 3H), 
2.61 (br m, 4H), 1.65 (br s), 1.50 (br s), 1.26 ppm (br s); 
13
C NMR (CDCl3) ? 172.7 
(ester), 172.3 (ester), 75.2, 72.2, 70.8, 69.4, 64.0, 59.4, 30.0, 25.6 ppm. IR (NaCl plate) 
2919, 2852, 1733 (ester), 1464, 1349, 1299, 1250, 1139, 1110, 1040, 957, 858 cm
-1
.   
Synthesis of bis-cyclooctene PEG 2000 (31)   
 
m ~ 45 
Succinic acid mono-cyclooct-4-enyl ester (2) (2.55 g, 11.2 mmol), polyethylene 
glycol (MW 2000 g/mol) (9.00 g, 4.50 mmol), and N,N-dimethylaminopyridine (110 mg, 
0.90 mmol) were stirred in dry CH2Cl2 (30 mL) under N2.  In a separate flask, 
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dicyclohexylcarbodiimide (1.96 g, 9.50 mmol) was dissolved with pyridine (1.18 g, 14.9 
mmol) and CH2Cl2 (10 mL); this solution was added by syringe to the reaction mixture 
and stirred for 24 hours at room temperature under N2. The mixture was washed with 1 M 
HCl (aq) and concentrated.  The product was dissolved in water and extracted with 
hexane/ethyl acetate.  The aqueous phase was extracted with CH2Cl2, dried over MgSO4, 
concentrated, and dried under vacuum overnight to yield the bis-cyclooctene PEG 
product (10.3 g, 95 %) as a white, waxy solid; 
1
H NMR (CDCl3) ? 5.65 (m, 4H), 4.83 (m, 
2H), 4.22 (t, 4H), 3.5-3.7 (complex, br m, ~180H), 2.55-2.67 (m, 8H), 1.57-2.4 (m, 20H) 
ppm; 
13
C NMR (CDCl3) ? 172.4 (ester), 171.6 (ester), 129.8, 129.6, 76.8, 72.0, 70.6, 
69.1, 63.9, 59.1, 33.7, 33.6, 29.5, 29.2, 25.6, 24.9, 22.3 ppm; MALDI Peak MW m/z = 
2393.7 g/mol. 
Synthesis of Rhodamine B-functionalized cyclooctene (32) 
 
260 mg (2.09 mmol) of 5-hydroxy-1-cyclooctene (1), 500 mg (1.04 mmol) of 
Rhodamine B, and 1.5 mg (0.13 mmol) DMAP were stirred in dry CH2Cl2 (5 mL) under 
N2.  In a separate flask, 0.26 g (1.25 mmol) dicyclohexylcarbodiimide was dissolved with 
0.20 g (2.5 mmol) pyridine and CH2Cl2 (5 mL); this solution was then added by syringe 
to the reaction mixture and stirred for 24 hours at reflux under N2.  The mixture was 
washed with 1 M HCl (aq) and concentrated.  The product was purified by column 
chromatography to yield 460 mg (75 %) of 32. 
1
H NMR (CDCl3) ? 8.22 (m, 1H), 7.70-
ON NCl
O
O
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7.77 (m, 2H), 6.74-7.26 (m, 3H), 5.54 (m, 2H), 4.71 (m, 1H), 4.46 (m, 1H), 4.10 (m, 1H), 
3.58-3.67 (m, 8H), 0.85-2.20 (br m, 22H) ppm; 
13
C NMR (CDCl3) ? 164.6 (ester), 
159.03, 157.9, 155.65, 133.3, 133.0, 131.5, 131.4, 131.0, 130.5, 130.4, 130.3, 129.8, 
129.5, 129.4, 114.4, 113.7, 96.5, 96.2, 78.9, 46.2, 35.3, 34.2, 33.3, 33.0, 30.8, 29.8, 26.1, 
25.8, 25.5, 25.1, 25.0, 24.7, 23.1, 22.4, 12.8 ppm; ESI mass spec. m/z 551.0; UV-Vis ?max 
= 556 nm. 
Example Copolymerization using Rhodamine B-labeled cyclooctene (32) 
PEGylated cyclooctene macromonomer 4 (0.50 g, 0.53 mmol) (MW ca. 950), 
cyclooctene (58 mg, 0.52 mmol), and Rhodamine B labeled 32 (3.1 mg, 5.3 μmol) were 
weighed into a small tube and dissolved in 0.2 mL dry CH2Cl2.  The contents were 
subjected to two freeze/pump/thaw cycles and then stirred at 40 
o
C under N2.  Catalyst II 
(3.52 mg, 4.14 μmol) was weighed into a small vial, degassed, and dissolved in dry 
CH2Cl2 (0.35 mL) under N2.  The catalyst solution was introduced by syringe, and the 
mixture was stirred at 40 
o
C until stirring ceased due to increased viscosity (approx. 15 
minutes).  The reaction was terminated using dodecyl vinyl ether, and CH2Cl2 (~1 mL) 
was added to improve stirring.  The contents were precipitated into cold hexane, filtered, 
and dried under vacuum to yield the fluorescent copolymer (0.46 g, 82%).  
1
H NMR 
(CDCl3) ? 5.34 (br, olefin 2H), 4.86 (br s, 1H), 4.22 (t, 2H), 3.5-3.7 (complex, br m), 3.36 
(s, 3H), 2.61 (br m, 4H), 2.32 (br s), 1.94 (br s), 1.50 (br s), 1.26 ppm (br s); 
13
C NMR 
(CDCl3) ? 172.7 (ester), 172.3 (ester), 130.0, 130.8, 129.3, 74.7, 72.3, 70.9, 69.4, 64.2, 
59.4, 34.4, 33.0, 30.0, 29.7, 29.5, 28.8, 25.6 ppm. IR (NaCl plate) 2922, 2867, 1733 
(ester), 1456, 1349, 1300, 1250, 1111, 1040, 968, 860 cm
-1
.  GPC (DMF w/ 0.01% LiCl 
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vs. linear polystyrene standards) Mn = 235,000 g/mol, Mw = 313,000 g/mol, PDI = 1.33.  
UV-Vis ?max = 556 nm. 
Synthesis of 5-bromo-1-cyclooctene (33) 
 
5-Bromo-1-cyclooctene was prepared in 80% yield from 1,5-cyclooctadiene as 
reported by Ashby and coworkers.
3
  
Synthesis of 5-azido-1-cyclooctene (34) 
 
5-bromo-1-cyclooctene (34) (18.0 g, 95.2 mmol) and sodium azide (18.6 g, 285.5 
mmol) were dissolved in dimethylsulfoxide (150 mL) and heated to 115 ºC for 4 hours.  
The mixture was cooled to room temperature, poured into water (400 mL), and extracted 
twice with diethyl ether.  The organic fractions were combined, dried over MgSO4, and 
concentrated to a dark brown oil.  The product was purified, first, by column 
chromatography on silica gel eluting with hexanes, followed by distillation (b.p. 37 ºC, 
85 mTorr) to yield 6.5 g (45% yield) of a colorless oil. 
1
H NMR (CDCl3) ? 5.64 (m, 2H), 
3.47 (m, 1H), 2.37 (m, 1H), 2.17 (m, 3H), 1.39 - 1.96 (complex m, 6H) ppm; 
13
C NMR 
(CDCl3) ? 133.3, 130.0, 129.5, 125.8, 62.3, 33.9, 32.9, 31.2, 30.5, 28.6, 26.0, 23.2, 22.4 
ppm; ATR-IR 3018, 2929, 2858, 2087, 1467, 1446, 1368, 1318, 1251, 1123, 1033, 991, 
971, 926, 882, 726 cm
-1
. 
Synthesis of 5-amino-1-cyclooctene (35) 
 
Br
N3
NH2
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5-azido-1-cyclooctene (34) (5.9 g, 39.0 mmol) was diluted with THF (50 mL) and 
triphenylphosphine (14.3 g, 54.6 mmol) was added while stirring.  The mixture was 
stirred for 30 minutes with visible gas evolution resulting from the loss of N2.  Deionized 
water (5 mL) was subsequently added, and the contents were stirred for 12 hours.  The 
mixture was concentrated, dissolved in diethyl ether, and extracted three times with 1 M 
HCl (aq).  The combined aqueous fractions were neutralized to pH 12 with a 30 wt % 
NaOH solution (aq) and extracted 3 times with diethyl ether.  The combined organic 
fractions were dried over MgSO4 and concentrated.  The product was purified by 
distillation (b.p. 40 ºC, 40 mTorr) to yield 3.8 g (78% yield) of a colorless oil. 
1
H NMR 
(CDCl3) ? 5.62 (m, 2H), 2.85 (m, 1H), 2.02 – 2.27 (m, 3H), 1.22 – 1.72 (m, 6H) ppm; 13C 
NMR (CDCl3) ? 130.2, 129.6, 51.7, 39.0, 37.0, 26.2, 25.9, 24.0 ppm; ATR-IR 3354, 
3281, 3014, 2917, 2852, 1661, 1595, 1466, 1448, 1370, 1241, 1068, 882, 756, 723 cm
-1
. 
Synthesis of 4-azidobenzoic acid (36) 
 
4-azidobenzoic acid was prepared in 70% yield from 4-aminobenzoic acid as 
described by Ulbricht and coworkers.
4,5 
Synthesis of amide-linked, phenyl azide-functional cyclooctene (38) 
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4-azidobenzoic acid (36) (2.0 g, 12.2 mmol) was added to a dry round-bottom 
flask and dissolved in anhydrous THF (100 mL) under N2.  The solution was cooled to 
0
o
C and thionyl chloride (0.9 mL, 12.8 mmol) was added by syringe over approx. 5 
minutes.  The reaction mixture was allowed to stir for 1 hr while warming to room 
temperature.  The reaction was again cooled to 0 
o
C and triethylamine (4.2 mL, 24.4 
mmol) was added by syringe.  A white precipitate was immediately formed and the 
mixture was allowed to stir for an additional 15 minutes at 0 
o
C.  A solution of 5-amino-
1-cyclooctene (35)
 
(1.7 g, 13.4 mmol) in anhydrous THF (10 mL) was then added by 
syringe and the reaction was warmed to room temperature and stirred for 16 hours.  The 
reaction mixture was filtered over Celite to remove the salt by-products and the solution 
was concentrated to a light yellow solid.  The crude product was dissolved in diethyl 
ether and washed once with DI water and once with 1 M HCl (aq).  The organic layer 
was dried over MgSO4 and concentrated.  The resulting solid was purified by column 
chromatography on silica gel (90/10 ? 70/30 hexanes/ethyl acetate) followed by 
crystallization from hexanes to afford 3.0 g (91% yield) of 38 as light yellow crystals. 
1
H 
NMR (CDCl3) ? 7.74 (m, 2H), 7.02 (m, 2H), 6.23 (br s, 1H), 5.72 (m, 2H), 4.16 (m, 1H), 
2.14-2.40 (complex br m, 4H), 1.80-2.01 (complex br m, 2H), 1.50-1.76 (complex br m, 
4H); 
13
C NMR (CDCl3) ? 165.1, 143.1, 131.5, 130.5, 129.8, 128.7, 128.6, 118.9, 49.9, 
35.3, 34.4, 26.0, 25.9, 23.4; ATR-FTIR 3306, 3058, 3023, 2933, 2855, 2410, 2120, 1625, 
1601, 1571, 1542, 1498, 1337, 1279, 1187, 1149, 1123, 847, 768, 725 cm
-1
. 
Synthesis of glycine(Boc)-functionalized cyclooctene  
 
O
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5-hydroxy-1-cyclooctene (1) (5.0 g, 39.6 mmol) and Boc-protected glycine (6.6 g, 
37.6 mmol) were combined in a round-bottom flask and dissolved in anhydrous 
dichloromethane (80 mL) and anhydrous dimethylformamide (20 mL).  In a separate 
flask, dicyclohexylcarbodiimide (DCC) (7.8 g, 38.0 mmol) and N,N-
dimethylaminopyridine (DMAP) (0.50 g, 4.1 mmol) were combined and dissolved in 
dichloromethane (20 mL).  The solution of DCC and DMAP were subsequently added to 
the solution of 1 and Boc-protected glycine while stirring with N,N’-dicyclohexylurea 
(DCU) precipitate observed almost immediately after addition.  The mixture was stirred 
for 16 hours at room temperature under N2.  DCU was removed by filtration, and the 
contents were concentrated to yield a viscous oil.  The crude product was then dissolved 
in diethyl ether and washed twice with water.  The organic layer was dried over MgSO4, 
concentrated, and purified by column chromatography on silica gel (90/10 ? 80/20 
hexanes/ethyl acetate) to yield 9.4 g (85% yield) of a colorless, viscous oil.
  1
H NMR 
(CDCl3) ? 5.60 (m, 2H), 5.05 (br s, 1H), 4.86 (m, 1H), 3.81 (d, 2H), 2.30 (m, 1H), 2.03-
2.15 (m, 3H), 1.78-1.95 (m, 2H), 1.63-1.74 (m, 1H), 1.48-1.62 (m, 3H), 1.40 (s, 9H); 
13
C 
NMR (CDCl3) ? 170.0, 156.0, 130.1, 129.8, 80.1, 77.7, 43.0, 33.9, 33.8, 28.6, 25.8, 25.0, 
22.5; ATR-FTIR 3370, 3015, 2976, 2933, 2861, 1700, 1511, 1467, 1452, 1390, 1365, 
1282, 1249, 1198, 1161, 1054, 1030, 964, 918, 865, 778, 726 cm
-1
. 
Synthesis of glycine-functionalized cyclooctene (HCl salt) (40) 
 
Glycine(Boc)-functionalized cyclooctene (3.0 g, 10.6 mmol) was weighed into a 
dry, round-bottom flask and dissolved in anhydrous THF (20 mL).  HCl (20 mL, 4.0 M in 
O
NH3
O
Cl
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dioxane) was added to the stirring solution by syringe, and the contents were stirred for 
12 hrs at room temperature under N2.  After stirring for some time, a white precipitate 
was observed.  The mixture was concentrated, and the solid contents were suspended in 
hexane, filtered, and dried under reduced pressure to yield 2.2 g (94% yield) of a white 
powder.  
1
H NMR (d6-DMSO) ? 8.55 (br s, 3H), 5.66 (m, 2H), 4.81 (m, 1H), 3.69 (s, 
2H), 2.35 (m, 1H), 2.03-2.19 (br m, 3H), 1.85 (m, 2H), 1.73 (m, 1H), 1.63 (m, 2H), 1.47 
(m, 1H); 
13
C NMR (d6-DMSO) ? 166.8, 129.7, 129.5, 77.0, 49.9, 33.1, 33.0, 25.1, 24.5, 
21.7; ATR-FTIR 3206, 3010, 2937, 2860, 1737, 1553, 1513, 1463, 1430, 1403, 1223, 
1126, 1058, 1038, 971, 912, 885, 730 cm
-1
. 
Synthesis of ester-linked, phenyl azide-functional cyclooctene (41) 
 
4-azidobenzoic acid (36) (1.00 g, 12.2 mmol) was added to a dry round-bottom 
flask and dissolved in anhydrous THF (50 mL) under N2.  The solution was cooled to 0 
o
C and thionyl chloride (0.47 mL, 6.4 mmol) was added by syringe.  The mixture was 
stirred for 1 hr while warming to room temperature.  The reaction was again cooled to 0 
o
C and triethylamine (6.30 mL, 36.6 mmol) was added over five minutes by syringe.  A 
white precipitate was immediately formed and the contents were stirred for 15 minutes at 
0 
o
C.  In a separate flask, glycine-functionalized cyclooctene 40 (1.5 g, 6.7 mmol) was 
dissolved in anhydrous THF (10 mL) and added to the reaction by syringe.  The reaction 
contents were then warmed to room temperature and stirred for 16 hours.  The mixture 
was filtered over Celite to remove the salt by-products and concentrated to a light yellow 
solid.  The solid was dissolved in diethyl ether and washed once with DI water and once 
O
N
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with 1 M HCl (aq).  The organic layer was dried over MgSO4 and concentrated.  The 
product was purified by column chromatography on silica gel (80/20 ? 70/30 
hexanes/ethyl acetate) followed by crystallization in hexanes to afford 1.7 g (85% yield) 
of 41 as light yellow crystals. 
1
H NMR (CDCl3) ? 7.80 (m, 2H), 7.04 (m, 2H), 6.78 (br m, 
1H), 5.67 (m, 2H), 4.94 (m, 1H), 4.15 (d, 2H), 2.35 (br m, 1H), 2.06-2.20 (br m, 3H), 
1.91 (br m, 2H), 1.51-1.80 (complex br m, 4H); 
13
C NMR (CDCl3) ? 169.7, 166.5, 143.8, 
130.4, 130.1, 129.6, 129.0, 119.2, 77.7, 42.3, 33.8, 25.7, 25.0, 22.3; ATR-FTIR 3366, 
3020, 2933, 2858, 2114, 2089, 1734, 1640, 1603, 1548, 1498, 1364, 1302, 1285, 1203, 
995, 847, 761 cm
-1
.   
Synthesis of phenyl azide (amide)-functionalized PCOE-g-PEG 2200 (Copolymer 
42)  
 
m ~ 49 
PEG 2200 (m ~ 49) macromonomer (9) (0.62 g, 0.27 mmol), cyclooctene (0.05 g, 
0.45 mmol), and phenyl azide-functional cyclooctene 38 (0.05 g, 0.19 mmol) were 
combined in a dry reaction tube.  0.7 mL of anhydrous THF was added to the reaction 
under N2.  In a separate vial, catalyst III (16.0 mg, 18.1 μmol) was dissolved in 0.2 mL 
dry THF.  Both the monomer mixture and catalyst solution were subjected to two 
freeze/pump/thaw cycles and subsequently warmed to room temperature.  The catalyst 
solution was rapidly added to the monomer mixture and stirred for 30 min.  Ethyl vinyl 
m
NH OO
N3
O
OH
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ether (1 mL) was added to terminate the polymerization and dichloromethane was added 
to dilute the polymer solution.  The product was precipitated into diethyl ether, isolated 
by filtration, and dried under vacuum to yield 0.67 g (93% yield) of a light purple solid. 
1
H NMR (CDCl3) ? 7.74 (d), 7.02 (d), 5.35 (m), 4.30 (m), 4.12 (m),  3.37-3.80 (br m), 
3.23 (br m), 2.30 (br s), 1.94, (br m), 1.27-1.53 (br m); ATR-FTIR 3477, 2882, 2121, 
1634, 1467, 1360, 1342, 1279, 1241, 1147, 1102, 1061, 962, 842 cm
-1
. GPC (THF, 
relative to PS standards) Mn 46,700 Da, Mw 123,300 Da, PDI 2.64. 
Synthesis of phenyl azide (ester)-functionalized PCOE-g-PEG 2200 (Copolymer 43) 
 
m ~ 49 
PEG 2200 (m ~ 49) macromonomer (9) (0.63 g, 0.27 mmol), cyclooctene (0.05 g, 
0.45 mmol), and phenyl azide-functional cyclooctene 41 (0.06 g, 0.18 mmol) were 
combined in a dry reaction tube.  0.7 mL of anhydrous THF was added under N2.  In a 
separate vial, catalyst III (16.1 mg, 10.4 μmol) was dissolved in 0.2 mL dry THF.  Both 
the monomer mixture and catalyst solution were subjected to two freeze/pump/thaw 
cycles and subsequently warmed to room temperature.  The catalyst solution was rapidly 
added to the monomer mixture and stirred for 30 min.  Ethyl vinyl ether (1 mL) was 
added to terminate the polymerization and dichloromethane was added to dilute the 
polymer solution.  The product was precipitated into diethyl ether, isolated by filtration, 
m
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and dried under vacuum to yield 0.63 g (85% yield) of a light purple solid. 
1
H NMR 
(CDCl3) ? 7.80 (br s), 7.03 (br s), 5.35 (m), 4.95 (s), 4.16 (s), 3.40-3.80 (br m), 3.22 (s), 
2.49 (br s), 1.93, (br m), 1.27-1.53 (br m); 
13
C NMR (CDCl3) ? 170.0, 166.4, 143.7, 
130.8, 130.4, 130.0, 129.5, 129.1, 128. 8, 119.1, 87.3, 79.5, 72.63, 71.1, 71.0, 70.7, 68.1, 
61.9, 54.1, 42.1, 34.1, 33.7, 32.7, 33.5, 29.8, 29.2, 28.6, 27.3, 25.4, 23.3;  
Synthesis of 5-cyano-1-cyclooctene (46) 
 
 
5-cyano-1-cyclooctene was prepared in 68% yield from 5-bromo-1-cyclooctene 
(33) as described by Grubbs and coworkers.
2
 
Synthesis of 5-carboxylic acid-1-cyclooctene (47) 
 
 
5-carboxylic acid-1-cyclooctene was prepared in 62% yield from 5-cyano-1-
cyclooctene (46) as described by Hartley and coworkers.
6 
Synthesis of hydrazine (Boc)-functionalized cyclooctene (48) 
 
5-carboxylic acid-1-cyclooctene (47) (5.0 g, 32.4 mmol), tert-butyl carbazate (4.7 
g, 35.7 mmol), and DMAP (0.5 g, 3.8 mmol) were weighed into an oven-dried round 
bottom flask and dissolved in 100 mL anhydrous dichloromethane under N2.  DCC (7.4 
g, 35.7 mmol) was added to the solution as a solid with stirring, and a white precipitate 
was immediately observed.  The reaction was stirred for 16 hrs at room temperature 
C N
OH
O
N
H
O
H
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under N2.  The reaction solution was filtered, and the product was concentrated to a 
viscous liquid.  The contents were dissolved in diethyl ether and cooled to -20 
o
C for 6 
hours to precipitate dissolved DCU.  Following filtration, the filtrate was washed with 0.1 
M HCl (aq) and then 0.1 M NaHCO3 (aq).  The organic phase was dried with MgSO4 and 
concentrated to a viscous oil.  The product was purified by column chromatography on 
silica gel (80/20 ? 70/30 hexanes/ethyl acetate) followed by crystallization in hexanes to 
afford 5.5 g (63% yield) of white crystals.  
1
H NMR (CDCl3) ? 7.70 (br s, 1H), 6.73 ( br 
s, 1H), 5.65 (m, 2H), 1.28 - 2.40 (complex br m, 20H); 
13
C NMR (CDCl3) ? 177.4, 155.9, 
130.8, 129.8, 81.8, 43.1, 32.2, 30.1, 28.3, 28.1, 26.1, 24.2; ATR-FTIR 3236, 3016, 2928, 
2855, 1734, 1710, 1662, 1631, 1540, 1450, 1367, 1255, 1161, 1009, 863, 719 cm
-1
. 
Synthesis of hydrazine (Boc)-functionalized PCOE-g-PEG 2200 (Copolymer 49) 
 
m ~ 49 
 
PEG 2200 (m ~ 49) macromonomer (9) (1.25 g, 0.54 mmol), cyclooctene (0.04 g, 
0.36 mmol), and hydrazine (Boc)-functional cyclooctene 48 (0.24 g, 0.89 mmol) were 
combined in a dry round-bottom flask.  0.35 mL of a 0.05 M 1-hexene solution in DCM 
was added to the reaction under N2 followed by 1.2 mL dry DCM.  In a separate vial, 
catalyst II (6.1 mg, 7.2 μmol) was dissolved in 0.2 mL dry DCM.  The catalyst solution 
was rapidly added to the monomer mixture and stirred until the polymerization had 
vitrified (approx. 10 minutes).  Ethyl vinyl ether (1 mL) was added to terminate the 
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polymerization and dichloromethane was added to dilute the polymer solution.  The 
product was precipitated into diethyl ether, isolated by filtration, and dried under vacuum 
to yield 1.45 g (95% yield) of an off-white solid. 
1
H NMR (d6-DMSO) ? 9.47 (d), 8.65 
(d), 5.35 (m), 3.30-3.75 (br m), 3.22 (br m), 1.75-2.20, (br m), 1.15-1.60 (br m); 
13
C 
NMR (d6-DMSO) ? 174.5, 154.9, 130.1, 129.8, 129.4, 129.1, 78.1, 77.5, 72.6, 71.1, 71.0, 
70.7, 67.6, 60.0, 43.2, 33.2, 32.8, 32.2, 30.1, 29.1, 28.3, 28.1, 26.1, 24.8; ATR-FTIR 
3291, 2882, 1726, 1466, 1359, 1342, 1279, 1241, 1103, 1060, 961, 841, 750 cm
-1
, GPC 
(THF, relative to PS standards) Mn 97,800 Da, Mw 201,700 Da, PDI 2.06 
Deprotection of hydrazine (Boc)-functionalized PCOE-g-PEG 2200 (Copolymer 50) 
 
m ~ 49 
 
Hydrazine (Boc)-functionalized PCOE-g-PEG 2200 (49) (550 mg) was dissolved 
in DCM (5 mL).  Trifluoroacetic acid (5 mL) was added and gas evolution was 
immediately observed.  The reaction contents were stirred for 1 hour, open to the 
atmosphere.   The deprotected polymer was precipitated into cold diethyl ether and 
filtered.  The polymer was dissolved in a dichloromethane/methanol mixture and 
precipitated again into cold diethyl ether.  Copolymer 50 was isolated by filtration and 
dried in vacuo to yield 420 mg  (95% yield) of a light yellow powder. 
1
H NMR (d6-
DMSO) ? 10.47 (s), 5.34 (m), 4.50 (s), 3.30-3.75 (br m), 3.22 (s), 1.75-2.20, (br m), 1.15-
1.60 (br m); 
13
C NMR (d6-DMSO) ? 174.1, 158.1, 130.0, 129.6, 129.2, 118.6, 115.7, 
m
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86.4, 78.1, 72.4, 71.1, 70.6, 70.2, 69.8, 67.6, 60.2, 53.3, 43.1, 40.1, 38.9, 33.4, 32.9, 32.0, 
29.9, 29.1, 28.5, 27.9, 26.7, 24.7, 22.6; ATR-FTIR 2882, 1675, 1466, 1342, 1280, 1241, 
1099, 961, 841, 721 cm
-1
.    
Synthesis of 4-azidophenyl sulfone (51) 
 
4-aminophenyl sulfone (6.2 g, 25.0 mmol) was dissolved in 50 mL of deionized 
water and cooled to 0
o
C.  15 mL of concentrated HCl was added and the solution was 
stirred for 5 minutes.  In a separate flask, NaNO2 (6.9 g, 100 mmol) was dissolved in 40 
mL of DI water and cooled to 0
o
C.  The NaNO2 solution was added to the 4-aminophenyl 
sulfone solution over 15 minutes being careful to control of temperature at 0
o
C.  The 
diazophenyl sulfone solution was then added to a solution of NaN3 (9.8 g, 150 mmol) in 1 
L of DI water which had been cooled to 0 
o
C.  4-azidophenyl sulfone precipitated 
immediately upon addition with N2 evolution forming a foaming suspension.  DI water 
(400 mL) was added over the course of the reaction to improve stirring.  The reaction was 
stirred for 30 minutes and ethyl acetate was added to dissolve the product.  The solution 
was transferred to a separatory funnel and extracted 3X with ethyl acetate.  The organic 
fractions were combined, dried of MgSO4, and concentrated to a yellow solid. The 
product was purified by column chromatography on silica gel (70/30 ? 50/50 
hexanes/ethyl acetate) followed by crystallization in hexanes to afford 2.3 g (31% yield) 
of yellow crystals. 
1
H NMR (d6-DMSO) ? 7.95 (d, 4H), 7.32 (d, 4H); ATR-FTIR 3085, 
3054, 2095, 1582, 1489, 1412, 1281, 1158, 1098, 820, 729 cm
-1
. 
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Representative synthesis of PCOE-g-PEG (Copolymer 56) 
 
PEG 1200 (m ~ 24) macromonomer (8) (0.2 g, 0.2 mmol), PEG 2200 (m ~ 49) 
macromonomer (9) (0.1 g, 0.06 mmol), and cyclooctene (0.3 g, 2.7 mmol) were 
combined in a dry reaction tube.  0.6 mL of a 0.05 M 1-hexene solution in 
dichloromethane was added to the reaction under N2 followed by 0.5 mL of dry 
dichloromethane.  In a separate vial, catalyst II (4.9 mg, 5.7 μmol) was dissolved in 0.4 
mL dry dichloromethane.  Both the monomer mixture and catalyst solution were 
subjected to two freeze/pump/thaw cycles and subsequently warmed to 40 
o
C.  The 
catalyst solution was then rapidly added to the monomer solution and stirred until 
vitrified (approx. 5 min).  Ethyl vinyl ether (1 mL) was added to terminate the 
polymerization and dichloromethane was added to dilute the polymer solution.   The 
product was precipitated into cold hexane containing 1 wt % BHT, isolated by filtration, 
and dried under vacuum to yield 0.58 g (93.5% yield) of an off-white solid. 
1
H NMR 
(CDCl3) ? 5.36 (m), 3.37-3.97 (br m), 3.24 (br s), 2.43 (br s), 1.94, (br m), 1.27-1.53 (br 
m); 
13
C NMR (CDCl3) ? 130.2, 72.6, 70.6, 70.3, 61.7, 32.6, 29.6, 29.1; ATR-FTIR 2921, 
2852, 1468, 1344, 1281, 1242, 1104, 963, 842 cm
-1
. GPC (CHCl3, relative to PS 
standards) Mn 22,700 Da, Mw 39,800 Da, PDI 1.76. 
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Synthesis of PCOE-g-PEG 4400-g-Phenyl Azide copolymer (Copolymer 58)  
 
PEG 4400 (m ~ 99) macromonomer (10) (1.7 g, 0.4 mmol), cyclooctene (0.1 g, 
1.1 mmol), and phenyl azide-functional cyclooctene 38 (0.1 g, 0.4 mmol) were combined 
in a dry reaction tube.  0.9 mL of a 0.05 M 1-hexene solution in dichloromethane was 
added to the reaction under N2 followed by 0.7 mL dry THF.  In a separate vial, catalyst 
III (9.2 mg, 10.4 μmol) was dissolved in 0.2 mL dry THF.  Both the monomer mixture 
and catalyst solution were subjected to two freeze/pump/thaw cycles and subsequently 
warmed to room temperature.  The catalyst solution was rapidly added to the monomer 
mixture and stirred for 30 min.  Ethyl vinyl ether (1 mL) was added to terminate the 
polymerization and dichloromethane was added to dilute the polymer solution.  The 
product was precipitated into diethyl ether, isolated by filtration, and dried under vacuum 
to yield 1.75 g (92% yield) of a light purple solid. 
1
H NMR (CDCl3) ? 7.74 (d), 7.02 (d), 
5.35 (m), 4.30 (m), 4.12 (m), 3.37-3.80 (br m), 3.23 (br m), 2.30 (br s), 1.94, (br m), 1.27-
1.53 (br m); ATR-FTIR 3477, 2882, 2121, 1634, 1467, 1360, 1342, 1279, 1241, 1147, 
1102, 1061, 962, 842 cm
-1
. GPC (THF, relative to PS standards) Mn 27,600 Da, Mw 
54,000 Da, PDI 1.96. 
Synthesis of tetraethylene glycol dimesylate (59) 
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10.0 g (51.0 mmol) of tetraethylene glycol was diluted with 200 mL of anhydrous 
THF under N2 and cooled to 0 
o
C.   Methanesulfonyl chloride (8.8 mL, 114.7 mmol) was 
added by syringe, and triethylamine (17.8 mL, 127.5 mmol) was then added as a solution 
in 50 mL anhydrous THF via addition funnel over approximately 30 minutes.  The 
reaction was allowed to warm to room temperature and stirred for an additional 2 hours.  
The reaction mixture was diluted with NaHCO3 (aq), and the product was extracted 2X 
with chloroform.  The product was concentrated, stirred over NaHCO3 (aq) for approx. 
30 minutes, and extracted 2X with chloroform.  The organic fractions were combined, 
washed with1 M HCl (aq), and stirred over carbon black and magnesium sulfate.  The 
solution was filtered and concentrated to yield 17.4 g (88 % yield) of a colorless oil. 
1
H 
NMR (CDCl3) ? 4.32 (m, 4H), 3.72 (m, 4 H), 3.62 (s, 8H), 3.03 (s, 6H); 13C NMR 
(CDCl3) ? 70.6, 69.3, 69.0, 37.7.   
Synthesis of bis-cyclooctene tetraethylene glycol (60)  
 
Sodium hydride (3.5 g, 145.2 mmol) was weighed into an oven dried RB flask 
and suspended in 300 mL of anhydrous DMF.  A solution of 5-hydroxy-1-cyclootene (1) 
(16.7 g, 132.0 mmol) in 50 mL of anhydrous THF was added to the sodium hydride 
suspension and stirred for 1.5 hr.  Tetraethylene glycol dimesylate (59) (18.5 g, 52.8 
mmol) was then added as a solution in 50 mL anhydrous DMF and stirred overnight at 
room temperature.  A small quantity of water was added slowly to the reaction mixture to 
quench the unreacted sodium hydride and subsequently diluted with a larger volume of 
water.  The product was extracted 3X with diethyl ether, dried over magnesium sulfate, 
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and concentrated.  The crude product was purified by column chromatography (silica, 
85/15 hexane/ethyl acetate ? 70/30 hexane/ethyl acetate) to afford 9.5 g (44 % yield) of 
product as a colorless oil. 
1
H NMR (CDCl3) ? 5.58 (m, 4H), 3.45-3.64 (complex m, 16H), 
3.32 (m, 2H), 2.27 (m, 2H), 1.28-2.18 (complex br m, 20H); 
13
C NMR (CDCl3) ? 130.2, 
129.7, 81.1, 71.1, 70.9, 70.8, 67.9, 34.3, 33.5, 25.9, 25.8, 22.8; ATR-FTIR 3014, 2925, 
2858, 1729, 1467, 1450, 1345, 1298, 1243, 1092, 1044, 988, 949, 880, 754, 725 cm
-1
. 
Synthesis of tetraethylene glycol substituted pyridine (62) 
 
 
To a dry, round-bottom flask was added 4-hydroxypyridine (3.00 g, 31.6 mmol), 
triphenylphosphine (9.10 g, 34.7 mmol), tetraethylene glycol (36.8 g, 189 mmol), and dry 
THF (125 mL).  The mixture was stirred under N2(g) at 0 °C (ice-water bath), and 
diisopropyl azodicarboxylate (6.80 mL, 34.7 mmol) was added by syringe over a 10 
minute period.  The mixture was stirred for 30 minutes, the ice bath was removed, and 
the reaction was allowed to stir under nitrogen for 12 hours at room temperature.  The 
reaction mixture was then concentrated, dissolved in chloroform, and extracted three 
times with 1 M HCl (aq).  The combined aqueous fractions were treated with a 30 weight 
percent NaOH solution until a pH of 12 was reached.  The product was extracted three 
times with chloroform, and the combined organic fractions were dried over MgSO4 and 
concentrated.  Excess tetraethylene glycol was removed by vacuum distillation, and the 
residue was purified by column chromatography over silica gel to yield 3.4 g of a 
colorless oil (40% yield): 
1
H NMR (CDCl3) ? 8.38 (d, 2H), 6.80 (d, 2H), 4.14 (t, 2H), 
3.83 (t, 2H), 3.55-3.70 (br m, 12H), 3.08 (br s, 1H); 
13
C NMR (CDCl3) ? 164.8, 150.6, 
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110.3, 72.6, 70.7, 70.2, 69.2, 69.1, 67.1, 61.2; ATR-FTIR 3246, 3036, 2870, 1639, 1591, 
1568, 1502, 1454, 1422, 1352, 1284, 1211, 1119, 1051, 1000, 991, 929, 887, 817, 730, 
699 cm
-1
; HPLC (7:3 H2O:acetonitrile (0.1% trifluoroacetic acid)) retention time, 1.62 
min. 
Synthesis of tetraethylene glycol substituted ruthenium benzylidene catalyst (63) 
 
A solution of Grubbs’ Generation II catalyst (catalyst II) (50.0 mg, 58.9 mmol) 
and PEG-pyridine ligand 62 (0.16 g, 0.59 mmol) in dry dichloromethane (0.3 mL) was 
stirred under nitrogen for 1 hour.  Dichloromethane was removed in vacuo, and the 
remaining green oil was diluted with water to precipitate tricyclohexylphosphine.  This 
aqueous solution was subjected to centrifugation for five minutes, to give a clear, dark 
green, aqueous solution that was removed by pipette.  The green aqueous catalyst 
solutions was concentrated under vacuum (Kügelrohr) to afford a viscous green oil 
composed of a mixture of 62 and 63.  This oil could be diluted in either organic solvents 
or water for use in ring-opening metathesis polymerization.  
1
H NMR (CDCl3) ? 19.20 (s, 
catalyst, benzylidene), 8.38 (d, PEG-pyridine ligand), 7.83 (d, catalyst), 7.71 (br s, 
catalyst), 7.65 (d, catalyst), 7.45 (m, catalyst), 7.33 (m, catalyst), 7.20 (m, catalyst), 7.05 
(m, catalyst), 6.94 (t, catalyst), 6.93 (s, catalyst), 6.80 (d, PEG-pyridine ligand), 6.76 (m, 
catalyst), 6.21 (br s, catalyst), 4.14 (t, PEG-pyridine ligand), 3.83 (t, PEG-pyridine 
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ligand), 3.55-3.70 (br m, PEG-pyridine ligand), 3.18 (m, catalyst), 2.93 (m, catalyst), 
2.57, (s, catalyst), 2.15-2.4 (br m, catalyst); 
31
P – no signals, indicative of absence of 
tricyclohexylphosphine. 
Synthesis of exo,exo-5,6-bis(methoxycarbonyl)-7-oxabicyclo[2.2.1] hept-2-ene (64) 
 
 
exo,exo-5,6-bis(methoxycarbonyl)-7-oxabicyclo[2.2.1] hept-2-ene was prepared 
as described by France and coworkers.
7
  
Representative polymerization of 64 in dichloromethane (Polymer 68) 
 
 
Exo,exo-5,6-bis(methoxycarbonyl)-7-oxabicyclo[2.2.1] hept-2-ene (64) (0.2 g, 0.9 
mmol) was stirred in dry dichloromethane (1.9 mL) at room temperature under N2(g).  
0.64 mL of a 0.03 M solution of 63 in dichloromethane was added rapidly by syringe.  
The mixture was stirred for 30 minutes, and ethyl vinyl ether (0.5 mL) was added.  
Precipitation into cold methanol gave a white solid that was filtered and dried in vacuo to 
afford 0.17 g (85% yield) of polymer 68.  
1
H NMR (CDCl3) ? 5.89 (m, 1H), 5.62 (m, 
2H), 5.05 (br m, 2H), 4.71 (br m, 1H), 3.68 (br m, 6H), 3.08 (m, 2H);  GPC (in THF vs. 
linear polystyrene standards) Mn = 65,900 g/mol, Mw = 71,400 g/mol, PDI = 1.08. 
Synthesis of 10-oxa-4-aza-tricyclo[5.2.1.0
2,6
]dec-8-ene-3,5-dione (69) 
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10-oxa-4-aza-tricyclo[5.2.1.0
2,6
]dec-8-ene-3,5-dione was prepared as described by 
Kwart and coworkers.
8
  
Synthesis of tetraethylene glycol substituted oxanorbornene (70) 
 
To a dry round-bottom flask was added the oxanorbornene imide, 10-oxa-4-aza-
tricyclo[5.2.1.0
2,6
]dec-8-ene-3,5-dione (69)
 
(3.00 g, 18.2 mmol), triphenylphosphine 
(5.50 g, 20.9 mmol), tetraethylene glycol (17.6 g, 90.8 mmol), and dry THF (150 mL).  
The mixture was stirred under N2 at 0 °C (ice-water bath), and diisopropyl 
azodicarboxylate (4.10 mL, 20.9 mmol) was added by syringe over a 10 minute period.  
The mixture was stirred for 30 minutes.  The ice bath was then removed, and the mixture 
stirred for 12 hours at room temperature.  The mixture was then concentrated, dissolved 
in ether, and extracted three times with water.  The aqueous fractions were combined, and 
the product was then extracted from the aqueous phase with chloroform.  The chloroform 
solution was dried over MgSO4 and concentrated, and the product was purified by 
column chromatography on silica gel using hexane/ethyl acetate mixtures to yield 3.8 g 
(61% yield) of a viscous, colorless oil. 
1
H NMR (CDCl3) ? 6.48 (s, 2H), 5.23 (s, 2H), 
3.55-3.70 (br m, 18H), 2.84 (s, 2H); 
13
C NMR (CDCl3) ? 176.4, 136.7, 81.0, 72.6, 70.7, 
70.6, 70.5, 70.2, 67.3, 61.8, 47.6, 38.3; ATR-FTIR 3458, 2896, 1772, 1694, 1429, 1398, 
1336, 1287, 1193, 1096, 1067, 1020, 916, 877, 853, 825, 813, 721, 710 cm
-1
; HPLC (7:3 
H2O:acetonitrile, 0.1% trifluoroacetic acid) retention time, 1.99 min. 
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Representative polymerization of 70 in water (Polymer 71) 
 
 
 
1.6 mL of a 0.015 M solution of 63 in acidified water (HCl, pH 1.5) was added to 
1.3 mL acidified water (HCl, pH 1.5) in a reaction tube, and the mixture was stirred at 
room temperature under nitrogen.  1.0 mL of a 0.60 M stock solution of tetraethylene 
glycol substituted oxanorbornene 70 in acidified water (HCl, pH=1.0) was injected 
rapidly into the catalyst solution, and the mixture was allowed to stir for 30 minutes.  
Diethylene glycol vinyl ether was added, and the mixture was then concentrated, 
dissolved in a minimal amount of CHCl3, and precipitated into cold hexane.  The hexane 
was decanted and the polymer residue dried under vacuum to afford 0.16 g (80% yield) 
of polymer 71 as a tacky solid: 
1
H NMR (CDCl3) ? 6.08 (br s, 1H), 5.78 (br m, 1H), 5.05 
(br m, 1H), 4.49 (br m, 1H), 3.55-3.70 (br m, 18H), 2.84 (br s, 2H); GPC (DMF with 
LiBr (0.05 M) vs. linear poly(methyl methacrylate) standards) Mn = 67,000 g/mol, Mw = 
90,700 g/mol, PDI = 1.35. 
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 (1) Love, J. A.; Morgan, J. P.; Trnka, T. M.; Grubbs, R. H. Angew. Chem. Int. 
Edit. 2002, 41, 4035-4037. 
 (2) Hillmyer, M. A.; Laredo, W. R.; Grubbs, R. H. Macromolecules 1995, 28, 
6311-6316. 
 (3) Ashby, E. C.; Coleman, D. J. Org. Chem. 1987, 52, 4554-4565. 
 (4) Ulbricht, M.; Hicke, H. G. Angew. Makromol. Chem. 1993, 210, 69-95. 
 (5) Ulbricht, M.; Hicke, H. G. Angewandte Makromol. Chem. 1993, 210, 97-
117. 
O
n
N
O
OH
3
O O
  183 
 (6)  Hartley, D. J. Chem. Soc. 1962, 4722. 
 (7)  France, M. B.; Alty, L. T.; Earl, T. M. J. Chem. Educ. 1999, 76, 659-660. 
 (8)  Kwart, H.; Burchuk, I. J. Am. Chem. Soc. 1952, 74, 3094-3097. 
 
  184 
BIBLIOGRAPHY 
      
Abuchowski, A. and F. F. Davis (1979). "Preparation and Properties of Polyethylene 
Glycol Trypsin Adducts." Biochimica Et Biophysica Acta 578(1): 41-46. 
Abuchowski, A., G. M. Kazo, et al. (1984). "Cancer-Therapy with Chemically Modified 
Enzymes .1. Antitumor Properties of Polyethylene Glycol-Asparaginase 
Conjugates." Cancer Biochemistry Biophysics 7(2): 175-186. 
Abuchowski, A., J. R. Mccoy, et al. (1977). "Effect of Covalent Attachment of 
Polyethylene-Glycol on Immunogenicity and Circulating Life of Bovine Liver 
Catalase." Journal of Biological Chemistry 252(11): 3582-3586. 
Abuchowski, A., T. Vanes, et al. (1977). "Alteration of Immunological Properties of 
Bovine Serum-Albumin by Covalent Attachment of Polyethylene-Glycol." 
Journal of Biological Chemistry 252(11): 3578-3581. 
Adams, M. L., A. Lavasanifar, et al. (2003). "Amphiphilic block copolymers for drug 
delivery." Journal of Pharmaceutical Sciences 92(7): 1343-1355. 
Ahmed, F. and D. E. Discher (2004). "Self-porating polymersomes of PEG-PLA and 
PEG-PCL: hydrolysis-triggered controlled release vesicles." Journal of 
Controlled Release 96(1): 37-53. 
Ahmed, F., R. I. Pakunlu, et al. (2006). "Shrinkage of a rapidly growing tumor by drug-
loaded polymersomes: pH-triggered release through copolymer degradation." 
Molecular Pharmaceutics 3(3): 340-350. 
Akizawa, T. K., K.; Koshikawa, S.; Ikada, Y.; Kishida, A.; Yamashita, M.; Imamura, K. 
(1989). Transactions American Society for Artificial Internal Organs 35: 333. 
Ali, M. M. and H. D. H. Stover (2006). "Interfacial living radical copolymerization of oil-
and water-soluble comonomers to form composite polymer capsules." Journal of 
Polymer Science Part A-Polymer Chemistry 44(1): 156-171. 
Allen, C., D. Maysinger, et al. (1999). "Nano-engineering block copolymer aggregates 
for drug delivery." Colloids and Surfaces B-Biointerfaces 16(1-4): 3-27. 
Allinger, N. L. and J. T. Sprague (1972). "Conformational-Analysis .84. Study of 
Structures and Energies of Some Alkenes and Cycloalkenes by Force Field 
Method." Journal of the American Chemical Society 94(16): 5734-&. 
Antipov, A. A., G. B. Sukhorukov, et al. (2001). "Sustained release properties of 
polyelectrolyte multilayer capsules." Journal of Physical Chemistry B 105(12): 
2281-2284. 
Arshady, R. (1989). "Preparation of Microspheres and Microcapsules by Interfacial 
Polycondensation Techniques." Journal of Microencapsulation 6(1): 13-28. 
Ashby, E. C. and D. Coleman (1987). "Evidence for Single Electron-Transfer in the 
Reactions of Lithium Dimethylcuprate with Alkyl-Halides." Journal of Organic 
Chemistry 52(20): 4554-4565. 
Badaru, A., D. M. Wilson, et al. (2006). "Sequential comparisons of one-month and 
three-month depot leuprolide regimens in central precocious puberty." Journal of 
Clinical Endocrinology and Metabolism 91(5): 1862-1867. 
Bae, Y., S. Fukushima, et al. (2003). "Design of environment-sensitive supramolecular 
assemblies for intracellular drug delivery: Polymeric micelles that are responsive 
  185 
to intracellular pH change." Angewandte Chemie-International Edition 42(38): 
4640-4643. 
Bala, I., S. Hariharan, et al. (2004). "PLGA nanoparticles in drug delivery: The state of 
the art." Critical Reviews in Therapeutic Drug Carrier Systems 21(5): 387-422. 
Bazan, G. C., E. Khosravi, et al. (1990). "Living Ring-Opening Metathesis 
Polymerization of 2,3-Difunctionalized Norbornadienes by Mo(Ch-Tert-Bu)(N-
2,6-C6h3-Iso-Pr2)(O-Tert-Bu)2." Journal of the American Chemical Society 
112(23): 8378-8387. 
Belfort, G., R. H. Davis, et al. (1994). "The Behavior of Suspensions and 
Macromolecular Solutions in Cross-Flow Microfiltration." Journal of Membrane 
Science 96(1-2): 1-58. 
Bell, C. L. and N. A. Peppas (1996). "Modulation of drug permeation through 
interpolymer complexed hydrogels for drug delivery applications." Journal of 
Controlled Release 39(2-3): 201-207. 
Bell, C. L. and N. A. Peppas (1996). "Water, solute and protein diffusion in 
physiologically responsive hydrogels of poly(methacrylic acid-g-ethylene 
glycol)." Biomaterials 17(12): 1203-1218. 
Berda, E. B., R. E. Lande, et al. (2007). "Precisely defined amphiphilic graft 
copolymers." Macromolecules 40(24): 8547-8552. 
Bielawski, C. W., D. Benitez, et al. (2002). "An "endless" route to cyclic polymers." 
Science 297(5589): 2041-2044. 
Bilyk, J. R., P. A. Rubin, et al. (1992). "Correction of enophthalmos with porous 
polyethylene implants." International Ophthalmology Clinics 32(3): 151-6. 
Binder, W. H. and C. Kluger (2004). "Combining ring-opening metathesis 
polymerization (ROMP) with sharpless-type "click" reactions: An easy method 
for the preparation of side chain functionalized poly(oxynorbornenes)." 
Macromolecules 37(25): 9321-9330. 
Binder, W. H. and R. Sachsenhofer (2007). "'Click' chemistry in polymer and materials 
science." Macromolecular Rapid Communications 28(1): 15-54. 
Blackwell, H. E., D. J. O'Leary, et al. (2000). "New approaches to olefin cross-
metathesis." Journal of the American Chemical Society 122(1): 58-71. 
Boom, R. M., I. M. Wienk, et al. (1992). "Microstructures in Phase Inversion Membranes 
.2. The Role of a Polymeric Additive." Journal of Membrane Science 73(2-3): 
277-292. 
Boudouris, B. W., C. D. Frisbie, et al. (2008). "Nanoporous poly(3-alkylthiophene) thin 
films generated from block copolymer templates." Macromolecules 41(1): 67-75. 
Bradford, M. M. (1976). "Rapid and Sensitive Method for Quantitation of Microgram 
Quantities of Protein Utilizing Principle of Protein-Dye Binding." Analytical 
Biochemistry 72(1-2): 248-254. 
Breitenkamp, K. and T. Emrick (2003). "Novel polymer capsules from amphiphilic graft 
copolymers and cross-metathesis." Journal of the American Chemical Society 
125(40): 12070-12071. 
Breitenkamp, K., J. Simeone, et al. (2002). "Novel amphiphilic graft copolymers 
prepared by ring-opening metathesis polymerization of poly(ethylene glycol)-
substituted cyclooctene macromonomers." Macromolecules 35(25): 9249-9252. 
  186 
Breitenkamp, R. B., Z. Ou, et al. (2007). "Synthesis and characterization of polyolefin-
graft-oligopeptide polyelectrolytes." Macromolecules 40(21): 7617-7624. 
Brezlow, D. S. (1984). Azides and Nitrenes - Reactivity and Utility. E. V. S. Scriven. 
Orlando, FL, Academic Press: 491-517. 
Brocchini, S. D., R (1999). Encyclopedia of Controlled Drug Delivery. E. Mathiowitz. 
New York, Wiley: 786-816. 
Brunner, J. (1993). "New Photolabeling and Cross-Linking Methods." Annual Review of 
Biochemistry 62: 483-514. 
Burdick, J. A. and K. S. Anseth (2002). "Photoencapsulation of osteoblasts in injectable 
RGD-modified PEG hydrogels for bone tissue engineering." Biomaterials 23(22): 
4315-4323. 
Cardoen, G., K. Breitenkamp, et al. (2006). "Manifold assembly for the convenient 
polymerization of ethylene oxide and butadiene." Macromolecules 39(20): 7170-
7173. 
Chai, J., D. Wang, et al. (2007). "Assembly of aligned linear metallic patterns on silicon." 
Nature Nanotechnology 2(8): 500-506. 
Chatterjee, A. K., J. P. Morgan, et al. (2000). "Synthesis of functionalized olefins by 
cross and ring-closing metatheses." Journal of the American Chemical Society 
122(15): 3783-3784. 
Choi, T. L. and R. H. Grubbs (2003). "Controlled living ring-opening-metathesis 
polymerization by a fast-initiating ruthenium catalyst." Angewandte Chemie-
International Edition 42(15): 1743-1746. 
Claverie, J. P., S. Viala, et al. (2001). "Ring-opening metathesis polymerization in 
emulsion." Macromolecules 34(3): 382-388. 
Connon, S. J. and S. Blechert (2003). "Recent developments in olefin cross-metathesis." 
Angewandte Chemie-International Edition 42(17): 1900-1923. 
Conti, B., F. Pavanetto, et al. (1992). "Use of Polylactic Acid for the Preparation of 
Microparticulate Drug Delivery Systems." Journal of Microencapsulation 9(2): 
153-166. 
Couvreur, P., M. J. BlancoPrieto, et al. (1997). "Multiple emulsion technology for the 
design of microspheres containing peptides and oligopeptides." Advanced Drug 
Delivery Reviews 28(1): 85-96. 
Czelusniak, I., E. Khosravi, et al. (2007). "Synthesis, characterization, and hydrolytic 
degradation of polylactide-functionalized polyoxanorbornenes." Macromolecules 
40(5): 1444-1452. 
Dai, Z. F., A. Voigt, et al. (2001). "Layer-by-layer self-assembly of polyelectrolyte and 
low molecular weight species into capsules." Advanced Materials 13(17): 1339-
1342. 
De Jesus, O. L. P., H. R. Ihre, et al. (2002). "Polyester dendritic systems for drug delivery 
applications: In vitro and in vivo evaluation." Bioconjugate Chemistry 13(3): 453-
461. 
Delaude, L., D. Jan, et al. (2000). "Ruthenium-based catalysts for the ring-opening 
metathesis polymerization (ROMP) of functionalized cyclic olefins." 
Macromolecular Symposia 153: 133-144. 
Dinsmore, A. D., M. F. Hsu, et al. (2002). "Colloidosomes: Selectively permeable 
capsules composed of colloidal particles." Science 298(5595): 1006-1009. 
  187 
Discher, B. M., H. Bermudez, et al. (2002). "Cross-linked polymersome membranes: 
Vesicles with broadly adjustable properties." Journal of Physical Chemistry B 
106(11): 2848-2854. 
Discher, B. M., D. A. Hammer, et al. (2000). "Polymer vesicles in various media." 
Current Opinion in Colloid & Interface Science 5(1-2): 125-131. 
Discher, B. M., Y. Y. Won, et al. (1999). "Polymersomes: Tough vesicles made from 
diblock copolymers." Science 284(5417): 1143-1146. 
Discher, D. E., V. Ortiz, et al. (2007). "Emerging applications of polymersomes in 
delivery: From molecular dynamics to shrinkage of tumors." Progress in Polymer 
Science 32(8-9): 838-857. 
Duan, H. W., M. Kuang, et al. (2005). "pH-Responsive capsules derived from 
nanocrystal templating." Langmuir 21(24): 11495-11499. 
Duncan, R. (2003). "The dawning era of polymer therapeutics." Nature Reviews Drug 
Discovery 2(5): 347-360. 
Engin, K., D. B. Leeper, et al. (1995). "Extracellular pH distribution in human tumours." 
International Journal of Hyperthermia 11(2): 211-6. 
Ferrando, M., A. Rozek, et al. (2005). "An approach to membrane fouling 
characterization by confocal scanning laser microscopy." Journal of Membrane 
Science 250(1-2): 283-293. 
Flory, P. J. (1953). Principles of polymer chemistry. Ithaca,, Cornell University Press. 
France, M. B., L. T. Alty, et al. (1999). "Synthesis of a 7-oxanorbornene derivative: A 
two-step sequence preparation for the organic laboratory." Journal of Chemical 
Education 76(5): 659-660. 
Fréchet, J. M. J., C. J. Hawker, et al. (1996). "Dendrimers and hyperbranched polymers: 
Two families of three-dimensional macromolecules with similar but clearly 
distinct properties." Journal of Macromolecular Science-Pure and Applied 
Chemistry A33(10): 1399-1425. 
Frisken, B. J., C. Asman, et al. (2000). "Studies of vesicle extrusion." Langmuir 16(3): 
928-933. 
Gacal, B., H. Durmaz, et al. (2006). "Anthracene-maleimide-based Diels-Alder "click 
chemistry" as a novel route to graft copolymers." Macromolecules 39(16): 5330-
5336. 
Gallivan, J. P., J. P. Jordan, et al. (2005). "A neutral, water-soluble olefin metathesis 
catalyst based on an N-heterocyclic carbene ligand." Tetrahedron Letters 46(15): 
2577-2580. 
Gaponik, N., I. L. Radtchenko, et al. (2003). "Labeling of biocompatible polymer 
microcapsules with near-infrared emitting nanocrystals." Nano Letters 3(3): 369-
372. 
George, M. H., M. A. Majid, et al. (1987). "The Anionic Synthesis and Characterization 
of Poly(Styrene-G-Ethylene Oxide) Copolymers." Polymer 28(7): 1217-1220. 
Ghosh, S. K. (2006). Functional coatings: by polymer microencapsulation. Weinheim 
Chichester, Wiley-VCH; John Wiley [distributor]. 
Gillies, E. R. and J. M. J. Fréchet (2005). "Dendrimers and dendritic polymers in drug 
delivery." Drug Discovery Today 10(1): 35-43. 
Gillies, E. R. and J. M. J. Fréchet (2005). "pH-responsive copolymer assemblies for 
controlled release of doxorubicin." Bioconjugate Chemistry 16(2): 361-368. 
  188 
Gordon, V. D., C. Xi, et al. (2004). "Self-assembled polymer membrane capsules inflated 
by osmotic pressure." Journal of the American Chemical Society 126(43): 14117-
14122. 
Greenwald, R. B., Y. H. Choe, et al. (2003). "Effective drug delivery by PEGylated drug 
conjugates." Advanced Drug Delivery Reviews 55(2): 217-250. 
Grigoriev, D. O., T. Bukreeva, et al. (2008). "New method for fabrication of loaded 
micro- and nanocontainers: Emulsion encapsulation by polyelectrolyte layer-by-
layer deposition on the liquid core." Langmuir 24(3): 999-1004. 
Gros, L., H. Ringsdorf, et al. (1981). "Polymeric Anti-Tumor Agents on a Molecular and 
on a Cellular-Level." Angewandte Chemie-International Edition 20(4): 305-325. 
Gu, F., L. Zhang, et al. (2008). "Precise engineering of targeted nanoparticles by using 
self-assembled biointegrated block copolymers." Proceedings of the National 
Academy of Sciences of the United States of America 105(7): 2586-2591. 
Harmer, M. A. (1991). "Photomodification of Surfaces Using Heterocyclic Azides." 
Langmuir 7(10): 2010-2012. 
Hartley, D. (1962). "Preparation of Delta-Oxoazelaic Acid." Journal of the Chemical 
Society (Nov): 4722. 
Hawker, C. J. and J. M. J. Fréchet (1996). "Comparison of linear, hyperbranched, and 
dendritic macromolecules." Step-Growth Polymers for High-Performance 
Materials 624: 132-144. 
Heller, J., J. Barr, et al. (2002). "Poly(ortho esters): synthesis, characterization, properties 
and uses." Advanced Drug Delivery Reviews 54(7): 1015-1039. 
Herisson, J. L. and Y. Chauvin (1971). "Transformation Catalysis of Olefins by Tungsten 
Complexes .2. Telomerization of Cyclic Olefins in Presence of Acyclic Olefins." 
Makromolekulare Chemie 141: 16. 
Heroguez, V., S. Breunig, et al. (1996). "Synthesis of alpha-norbornenylpoly(ethylene 
oxide) macromonomers and their ring-opening metathesis polymerization." 
Macromolecules 29(13): 4459-4464. 
Heroguez, V., M. Fontanille, et al. (2000). "Synthesis of latex particles by ring-opening 
metathesis polymerization in dispersed medium." Macromolecular Symposia 150: 
269-274. 
Heroguez, V., Y. Gnanou, et al. (1996). "Synthesis of alpha-norbornenyl polystyrene 
macromonomers and their ring-opening metathesis polymerization." 
Macromolecular Rapid Communications 17(2): 137-142. 
Heroguez, V., Y. Gnanou, et al. (1997). "Novel amphiphilic architectures by ring-
opening metathesis polymerization of macromonomers." Macromolecules 30(17): 
4791-4798. 
Hester, J. F., P. Banerjee, et al. (2002). "ATRP of amphiphilic graft copolymers based on 
PVDF and their use as membrane additives." Macromolecules 35(20): 7652-7661. 
Hester, J. F. and A. M. Mayes (2002). "Design and performance of foul-resistant 
poly(vinylidene fluoride) membranes prepared in a single-step by surface 
segregation." Journal of Membrane Science 202(1-2): 119-135. 
Hillmyer, M. A., W. R. Laredo, et al. (1995). "Ring-Opening Metathesis Polymerization 
of Functionalized Cyclooctenes by a Ruthenium-Based Metathesis Catalyst." 
Macromolecules 28(18): 6311-6316. 
Hoffman, A. (1998). Journal of Controlled Release 132: 153-163. 
  189 
Hoffman, A. S., P. S. Stayton, et al. (2007). "Design of "Smart" nano-scale delivery 
systems for Biomolecular therapeutics." Journal of Biomedical Nanotechnology 
3(3): 213-217. 
Hoffman, A. S., P. S. Stayton, et al. (2002). "Design of "smart" polymers that can direct 
intracellular drug delivery." Polymers for Advanced Technologies 13(10-12): 992-
999. 
Hong, S. H. and R. H. Grubbs (2006). "Highly active water-soluble olefin metathesis 
catalyst." Journal of the American Chemical Society 128(11): 3508-3509. 
Hopkins, T. E. and K. B. Wagener (2004). "ADMET synthesis of polyolefins targeted for 
biological applications." Macromolecules 37(4): 1180-1189. 
Ihre, H., O. L. P. De Jesus, et al. (2001). "Fast and convenient divergent synthesis of 
aliphatic ester dendrimers by anhydride coupling." Journal of the American 
Chemical Society 123(25): 5908-5917. 
Ihre, H. R., O. L. P. De Jesus, et al. (2002). "Polyester dendritic systems for drug delivery 
applications: Design, synthesis, and characterization." Bioconjugate Chemistry 
13(3): 443-452. 
Ikkala, O. and G. ten Brinke (2002). "Functional materials based on self-assembly of 
polymeric supramolecules." Science 295(5564): 2407-2409. 
Ilker, M. F., H. Schule, et al. (2004). "Modular norbornene derivatives for the preparation 
of well-defined amphiphilic polymers: Study of the lipid membrane disruption 
activities." Macromolecules 37(3): 694-700. 
Irvine, D. J., A. M. Mayes, et al. (2001). "Nanoscale clustering of RGD peptides at 
surfaces using comb polymers. 1. Synthesis and characterization of comb thin 
films." Biomacromolecules 2(1): 85-94. 
Iwata, H., M. I. Ivanchenko, et al. (1994). "Preparation of Anti-Oil Stained Membrane by 
Grafting Polyethylene-Glycol Macromer onto Polysulfone Membrane." Journal 
of Applied Polymer Science 54(1): 125-128. 
Kabanov, A. V., E. V. Batrakova, et al. (2002). "Pluronic (R) block copolymers as novel 
polymer therapeutics for drug and gene delivery." Journal of Controlled Release 
82(2-3): 189-212. 
Kabanov, A. V., E. V. Batrakova, et al. (2002). "Pluronic((R)) block copolymers for 
overcoming drug resistance in cancer." Advanced Drug Delivery Reviews 54(5): 
759-779. 
Kabanov, A. V., E. V. Batrakova, et al. (2005). "Polymer genomics: shifting the gene and 
drug delivery paradigms." Journal of Controlled Release 101(1-3): 259-271. 
Kataoka, K., A. Harada, et al. (2001). "Block copolymer micelles for drug delivery: 
design, characterization and biological significance." Advanced Drug Delivery 
Reviews 47(1): 113-131. 
Kim, B. and N. A. Peppas (2003). "In vitro release behavior and stability of insulin in 
complexation hydrogels as oral drug delivery carriers." International Journal of 
Pharmaceutics 266(1-2): 29-37. 
Kim, B. and N. A. Peppas (2003). "Poly(ethylene glycol)-containing hydrogels for oral 
protein delivery applications." Biomedical Microdevices 5(4): 333-341. 
Kim, S. Y., Y. M. Lee, et al. (2001). "Indomethacin-loaded methoxy poly(ethylene 
glycol)/poly(epsilon-caprolactone) diblock copolymeric nanosphere: 
  190 
pharmacokinetic characteristics of indomethacin in the normal Sprague-Dawley 
rats." Biomaterials 22(14): 2049-2056. 
Kim, T. G. and T. G. Park (2006). "Biomimicking extracellular matrix: cell adhesive 
RGD peptide modified electrospun poly(D,L-lactic-co-glycolic acid) nanofiber 
mesh." Tissue Engineering 12(2): 221-33. 
Kolb, H. C., M. G. Finn, et al. (2001). "Click chemistry: Diverse chemical function from 
a few good reactions." Angewandte Chemie-International Edition 40(11): 2004-
2021. 
Koo, L. Y., D. J. Irvine, et al. (2002). "Co-regulation of cell adhesion by nanoscale RGD 
organization and mechanical stimulus." Journal of Cell Science 115(7): 1423-33. 
Kopecek, J., P. Kopeckova, et al. (2000). "HPMA copolymer-anticancer drug conjugates: 
design, activity, and mechanism of action." European Journal of Pharmaceutics 
and Biopharmaceutics 50(1): 61-81. 
Kost, J. and R. Langer (2001). "Responsive polymeric delivery systems." Advanced Drug 
Delivery Reviews 46(1-3): 125-148. 
Kowalczuk, M., G. Adamus, et al. (1994). "Synthesis of New Graft Polymers Via 
Anionic Grafting of Beta-Butyrolactone on Poly(Methyl Methacrylate)." 
Macromolecules 27(2): 572-575. 
Kwak, J. C. T. (1998). Polymer-surfactant systems. New York, M. Dekker. 
Kwart, H. and I. Burchuk (1952). "Isomerism and Adduct Stability in the Diels Alder 
Reaction .1. The Adducts of Furan and Maleimide." Journal of the American 
Chemical Society 74(12): 3094-3097. 
Langer, R. (1998). "Drug delivery and targeting." Nature 392(6679): 5-10. 
Langer, R. (2003). "Controlled release (of peptides and proteins) and tissue engineering." 
Biopolymers 71(3): 284-284. 
Lavasanifar, A., J. Samuel, et al. (2002). "Poly(ethylene oxide)-block-poly(L-amino acid) 
micelles for drug delivery." Advanced Drug Delivery Reviews 54(2): 169-190. 
Lee, E. S., Z. Gao, et al. (2008). "Recent progress in tumor pH targeting 
nanotechnology." Journal of Controlled Release 132(3): 164-170. 
Lee, E. S., K. Na, et al. (2005). "Doxorubicin loaded pH-sensitive polymeric micelles for 
reversal of resistant MCF-7 tumor." Journal of Controlled Release 103(2): 405-
418. 
Lee, J. H., H. B. Lee, et al. (1995). "Blood Compatibility of Polyethylene Oxide 
Surfaces." Progress in Polymer Science 20(6): 1043-1079. 
Lensen, D., D. M. Vriezema, et al. (2008). "Polymeric microcapsules for synthetic 
applications." Macromolecular Bioscience 8(11): 991-1005. 
Li, C. and S. Wallace (2008). "Polymer-drug conjugates: Recent development in clinical 
oncology." Advanced Drug Delivery Reviews 60(8): 886-898. 
Li, S. D. and L. Huang (2008). "Pharmacokinetics and biodistribution of nanoparticles." 
Molecular Pharmaceutics 5(4): 496-504. 
Love, J. A., J. P. Morgan, et al. (2002). "A practical and highly active ruthenium-based 
catalyst that effects the cross metathesis of acrylonitrile." Angewandte Chemie-
International Edition 41(21): 4035-4037. 
Lynn, D. M., B. Mohr, et al. (1998). "Living ring-opening metathesis polymerization in 
water." Journal of the American Chemical Society 120(7): 1627-1628. 
  191 
Lynn, D. M., B. Mohr, et al. (2000). "Water-soluble ruthenium alkylidenes: Synthesis, 
characterization, and application to olefin metathesis in protic solvents." Journal 
of the American Chemical Society 122(28): 6601-6609. 
Ma, H. M., R. H. Davis, et al. (2000). "A novel sequential photoinduced living graft 
polymerization." Macromolecules 33(2): 331-335. 
Macdonald, R. C., R. I. Macdonald, et al. (1991). "Small-Volume Extrusion Apparatus 
for Preparation of Large, Unilamellar Vesicles." Biochimica Et Biophysica Acta 
1061(2): 297-303. 
Maeda, H., J. Wu, et al. (2000). "Tumor vascular permeability and the EPR effect in 
macromolecular therapeutics: a review." Journal of Controlled Release 65(1-2): 
271-284. 
Mark, P. R., N. S. Murthy, et al. (2008). "Microphase separated structures in the solid and 
molten states of double-crystal graft copolymers of polyethylene and 
poly(ethylene oxide)." Polymer 49(13-14): 3116-3124. 
Matsumura, Y. and H. Maeda (1986). "A New Concept for Macromolecular Therapeutics 
in Cancer-Chemotherapy - Mechanism of Tumoritropic Accumulation of Proteins 
and the Antitumor Agent Smancs." Cancer Research 46(12): 6387-6392. 
Maulucci, G., M. De Spirito, et al. (2005). "Particle size distribution in DMPC vesicles 
solutions undergoing different sonication times." Biophysical Journal 88(5): 
3545-3550. 
Maynard, H. D., S. Y. Okada, et al. (2001). "Inhibition of cell adhesion to fibronectin by 
oligopeptide-substituted polynorbornenes." Journal of the American Chemical 
Society 123(7): 1275-1279. 
Metters, A. T., K. S. Anseth, et al. (2000). "Fundamental studies of a novel, 
biodegradable PEG-b-PLA hydrogel." Polymer 41(11): 3993-4004. 
Mohr, B., D. M. Lynn, et al. (1996). "Synthesis of water-soluble, aliphatic phosphines 
and their application to well-defined ruthenium olefin metathesis catalysts." 
Organometallics 15(20): 4317-4325. 
Mross, K., B. Niemann, et al. (2004). "Pharmacokinetics of liposomal doxorubicin (TLC-
D99 ; Myocet) in patients with solid tumors: an open-label, single-dose study." 
Cancer Chemotherapy and Pharmacology 54(6): 514-524. 
Myers, S. B. and R. A. Register (2008). "Synthesis of narrow-distribution 
polycyclopentene using a ruthenium ring-opening metathesis initiator." Polymer 
49(4): 877-882. 
Nagasaki, Y., K. Yasugi, et al. (2001). "Sugar-installed block copolymer micelles: Their 
preparation and specific interaction with lectin molecules." Biomacromolecules 
2(4): 1067-1070. 
Nagayasu, A., K. Uchiyama, et al. (1999). "The size of liposomes: a factor which affects 
their targeting efficiency to tumors and therapeutic activity of liposomal antitumor 
drugs." Advanced Drug Delivery Reviews 40(1-2): 75-87. 
Nardin, C., T. Hirt, et al. (2000). "Polymerized ABA triblock copolymer vesicles." 
Langmuir 16(3): 1035-1041. 
Nayar, R., M. J. Hope, et al. (1989). "Generation of Large Unilamellar Vesicles from 
Long-Chain Saturated Phosphatidylcholines by Extrusion Technique." Biochimica 
Et Biophysica Acta 986(2): 200-206. 
  192 
Norton, R. L. and T. J. Mccarthy (1989). "Omega-Norbornenyl Polystyrene - an Olefin 
Metathesis Polymerizable Macromonomer." Macromolecules 22(3): 1022-1025. 
Novak, B. M. and R. H. Grubbs (1988). "Catalytic Organometallic Chemistry in Water - 
the Aqueous Ring-Opening Metathesis Polymerization of 7-Oxanorbornene 
Derivatives." Journal of the American Chemical Society 110(22): 7542-7543. 
O'donnell, P. M., K. Brzezinska, et al. (2001). ""Perfect comb" ADMET graft 
copolymers." Macromolecules 34(20): 6845-6849. 
Ojugo, A. S., P. M. McSheehy, et al. (1999). "Measurement of the extracellular pH of 
solid tumours in mice by magnetic resonance spectroscopy: a comparison of 
exogenous (19)F and (31)P probes." NMR in Biomedicine 12(8): 495-504. 
Papahadjopoulos, D. and J. C. Watkins (1967). "Phospholipid Model Membranes .2. 
Permeability Properties of Hydrated Liquid Crystals." Biochimica Et Biophysica 
Acta 135(4): 639-652. 
Park, K. (1997). Controlled drug delivery : challenges and strategies. Washington, DC, 
American Chemical Society. 
Park, M. K., S. X. Deng, et al. (2005). "Sustained release control via photo-cross-linking 
of polyelectrolyte layer-by-layer hollow capsules." Langmuir 21(12): 5272-5277. 
Parrish, B., R. B. Breitenkamp, et al. (2005). "PEG- and peptide-grafted aliphatic 
polyesters by click chemistry." Journal of the American Chemical Society 
127(20): 7404-7410. 
Parrish, B. and T. Emrick (2007). "Soluble camptothecin derivatives prepared by click 
cycloaddition chemistry on functional aliphatic polyesters." Bioconjugate 
Chemistry 18(1): 263-7. 
Patty, P. J. and B. J. Frisken (2003). "The pressure-dependence of the size of extruded 
vesicles." Biophysical Journal 85(2): 996-1004. 
Pavanetto, F., I. Genta, et al. (1993). "Evaluation of Spray-Drying as a Method for 
Polylactide and Polylactide-Co-Glycolide Microsphere Preparation." Journal of 
Microencapsulation 10(4): 487-497. 
Peppas, N. A. (1991). "Physiologically Responsive Hydrogels." Journal of Bioactive and 
Compatible Polymers 6(3): 241-246. 
Peppas, N. A. and J. Klier (1991). "Controlled Release by Using Poly (Methacrylic Acid-
G-Ethylene Glycol) Hydrogels." Journal of Controlled Release 16(1-2): 203-214. 
Preishuber-Pflugl, P., P. Buchacher, et al. (1998). "New features of ROMP by 
heterogenization of molybdenum carbene complexes." Journal of Molecular 
Catalysis A-Chemical 133(1-2): 151-158. 
Quattrin, T. (2006). "Inhaled insulin: a novel and non-invasive way for insulin 
administration?" Current Drug Safety 1(2): 151-8. 
Randall, M. L., J. A. Tallarico, et al. (1995). "Selective Ring-Opening Cross-Metathesis - 
Short Syntheses of Multifidene and Viridiene." Journal of the American Chemical 
Society 117(37): 9610-9611. 
Rankin, D. A., S. J. P'Pool, et al. (2007). "The controlled homogeneous organic solution 
polymerization of new hydrophilic cationic exo-7-oxa-norbornenes via ROMP 
with RuCl2(PCY3)(2)CHPh in a novel 2,2,2-trifluoroethanol/methylene chloride 
solvent mixture." Journal of Polymer Science Part A-Polymer Chemistry 45(11): 
2113-2128. 
  193 
Ratner, B. D. and S. J. Bryant (2004). "Biomaterials: Where we have been and where we 
are going." Annual Review of Biomedical Engineering 6: 41-75. 
Rigler, P. and W. Meier (2006). "Encapsulation of fluorescent molecules by 
functionalized polymeric nanocontainers: Investigation by confocal fluorescence 
Imaging and fluorescence correlation Spectroscopy." Journal of the American 
Chemical Society 128(1): 367-373. 
Rinehart, R. E. and H. P. Smith (1965). "Emulsion Polymerization of Norbornene Ring 
System Catalyzed by Noble Metal Compounds." Journal of Polymer Science Part 
B-Polymer Letters 3(12): 1049. 
Ringsdorf, H. (1975). "Structure and Properties of Pharmacologically Active Polymers." 
Journal of Polymer Science Part C-Polymer Symposium (51): 135-153. 
Roy, D., J. T. Guthrie, et al. (2005). "Graft polymerization: Grafting poly(styrene) from 
cellulose via reversible addition-fragmentation chain transfer (RAFT) 
polymerization." Macromolecules 38(25): 10363-10372. 
Ruoslahti, E. (2003). "The RGD story: a personal account." Matrix Biology 22(6): 459-
65. 
Safra, T., F. Muggia, et al. (2000). "Pegylated liposomal doxorubicin (doxil): Reduced 
clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 
mg/m(2)." Annals of Oncology 11(8): 1029-1033. 
Sanford, M. S., J. A. Love, et al. (2001). "A versatile precursor for the synthesis of new 
ruthenium olefin metathesis catalysts." Organometallics 20(25): 5314-5318. 
Sat, Y. N., M. Bibby, et al. (1999). "Effect of tumour size and tumour type on passive 
tumour accumulation of polymeric anticancer agents." British Journal of Cancer 
81(4): 583-583. 
Savic, R., L. B. Luo, et al. (2003). "Micellar nanocontainers distribute to defined 
cytoplasmic organelles." Science 300(5619): 615-618. 
Schacht, E., V. Toncheva, et al. (2006). "Polyacetal and poly(ortho ester)-poly(ethylene 
glycol) graft copolymer thermogels: Preparation, hydrolysis and FITC-BSA 
release studies." Journal of Controlled Release 116(2): 219-225. 
Schitter, R. M. E., D. Jocham, et al. (2000). "Novel routes to polyelectrolytes and reactive 
polymers via ROMP." Journal of Applied Polymer Science 78(1): 47-60. 
Schleyer, P. V., J. E. Williams, et al. (1970). "Evaluation of Strain in Hydrocarbons - 
Strain in Adamantane and Its Origin." Journal of the American Chemical Society 
92(8): 2377-2386. 
Scholl, M., S. Ding, et al. (1999). "Synthesis and activity of a new generation of 
ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-
dihydroimidazol-2-ylidene ligands." Organic Letters 1(6): 953-956. 
Schrock, R. R., J. S. Murdzek, et al. (1990). "Synthesis of Molybdenum Imido 
Alkylidene Complexes and Some Reactions Involving Acyclic Olefins." Journal 
of the American Chemical Society 112(10): 3875-3886. 
Schwab, P., R. H. Grubbs, et al. (1996). "Synthesis and applications of 
RuCl2(=CHR')(PR(3))(2): The influence of the alkylidene moiety on metathesis 
activity." Journal of the American Chemical Society 118(1): 100-110. 
Scott, K. (2003). Handbook of Industrial Membranes. Oxford, Elsevier. 
  194 
Shoichet, M. S., S. R. Winn, et al. (1994). "Poly(Ethylene Oxide) Grafted Thermoplastic 
Membranes for Use as Cellular Hybrid Bioartificial Organs in the Central-
Nervous-System." Biotechnology and Bioengineering 43(7): 563-572. 
Shuai, X. T., H. Ai, et al. (2004). "Micellar carriers based on block copolymers of poly(e-
caprolactone) and poly(ethylene glycol) for doxorubicin delivery." Journal of 
Controlled Release 98(3): 415-426. 
Shum, H. C., J. W. Kim, et al. (2008). "Microfluidic fabrication of monodisperse 
biocompatible and biodegradable polymersomes with controlled permeability." 
Journal of the American Chemical Society 130(29): 9543-9549. 
Siepmann, J., N. Faisant, et al. (2004). "Effect of the size of biodegradable microparticles 
on drug release: experiment and theory." Journal of Controlled Release 96(1): 
123-134. 
Skaff, H. and T. Emrick (2003). "The use of 4-substituted pyridines to afford 
amphiphilic, pegylated cadmium selenide nanoparticles." Chemical 
Communications (1): 52-53. 
Skaff, H., Y. Lin, et al. (2005). "Crosslinked capsules of quantum dots by interfacial 
assembly and ligand crosslinking." Advanced Materials 17(17): 2082-+. 
Strong, L. E. and L. L. Kiessling (1999). "A general synthetic route to defined, 
biologically active multivalent arrays." Journal of the American Chemical Society 
121(26): 6193-6196. 
Sukhorukov, G. B., A. A. Antipov, et al. (2001). "pH-controlled macromolecule 
encapsulation in and release from polyelectrolyte multilayer nanocapsules." 
Macromolecular Rapid Communications 22(1): 44-46. 
Sukhorukov, G. B., E. Donath, et al. (1998). "Stepwise polyelectrolyte assembly on 
particle surfaces: a novel approach to colloid design." Polymers for Advanced 
Technologies 9(10-11): 759-767. 
Szleifer, I. (1997). "Polymers and proteins: Interactions at interfaces." Current Opinion in 
Solid State & Materials Science 2(3): 337-344. 
Tangirala, R., R. Revanur, et al. (2007). "Sizing nanoparticle-covered droplets by 
extrusion through track-etch membranes." Langmuir 23(3): 965-969. 
Thom, V., K. Jankova, et al. (1998). "Synthesis of photoreactive alpha-4-azidobenzoyl-
omega-methoxypoly(ethyleneglycol)s and their end-on photo-grafting onto 
polysulfone ultrafiltration membranes." Macromolecular Chemistry and Physics 
199(12): 2723-2729. 
Thomas, P. A., T. Padmaja, et al. (1997). "Polyanhydride blend microspheres: Novel 
carriers for the controlled release of macromolecular drugs." Journal of 
Controlled Release 43(2-3): 273-281. 
Thorn-Csanyi, E. and K. Ruhland (1999). "Quantitative description of the metathesis 
polymerization depolymerization equilibrium in the 1,4-polybutadiene system, 1 - 
Influence of feed concentration and temperature." Macromolecular Chemistry and 
Physics 200(7): 1662-1671. 
Thorn-Csanyi, E. and K. Ruhland (1999). "Quantitative description of the metathesis 
polymerization/depolymerization equilibrium in the 1,4-polybutadiene system, 2 - 
Unusual behaviour at lower temperature." Macromolecular Chemistry and 
Physics 200(10): 2245-2249. 
  195 
Thorn-Csanyi, E., J. Hammer, et al. (1995). "Formation and Degradation of 1,4-
Polybutadiene Via Metathesis - New Results Concerning Cyclic Oligomers." 
Macromolecular Chemistry and Physics 196(4): 1043-1050. 
Tian, Y., L. Bromberg, et al. (2007). "Complexation and release of doxorubicin from its 
complexes with pluronic P85-b-poly(acrylic acid) block copolymers." Journal of 
Controlled Release 121(3): 137-145. 
Tiarks, F., K. Landfester, et al. (2001). "Preparation of polymeric nanocapsules by 
miniemulsion polymerization." Langmuir 17(3): 908-918. 
Tomalia, D. A., H. Baker, et al. (1985). "A New Class of Polymers - Starburst-Dendritic 
Macromolecules." Polymer Journal 17(1): 117-132. 
Tong, W., C. Gao, et al. (2005). "Manipulating the Properties of Polyelectrolyte 
Microcapsules by Glutaraldehyde Cross-Linking." Chemistry of Materials 17(18): 
4610-4616. 
Trnka, T. M. and R. H. Grubbs (2001). "The development of L2X2Ru = CHR olefin 
metathesis catalysts: An organometallic success story." Accounts of Chemical 
Research 34(1): 18-29. 
Trzaska, S. T., L. B. W. Lee, et al. (2000). "Synthesis of narrow-distribution "perfect" 
polyethylene and its block copolymers by polymerization of cyclopentene." 
Macromolecules 33(25): 9215-9221. 
Ulbricht, M. and H. G. Hicke (1993). "Photomodification of Ultrafiltration Membranes 
.1. Photochemical Modification of Polyacrylonitrile Ultrafiltration Membranes 
with Aryl Azides." Angewandte Makromolekulare Chemie 210: 69-95. 
Ulbricht, M. and H. G. Hicke (1993). "Photomodification of Ultrafiltration Membranes 
.2. Ultrafiltration Properties of Polyacrylonitrile Membranes Photochemically 
Modified with Aryl Azides." Angewandte Makromolekulare Chemie 210: 97-117. 
Ulbricht, M., H. Matuschewski, et al. (1996). "Photo-induced graft polymerization 
surface modifications for the preparation of hydrophilic and low-protein-
adsorbing ultrafiltration membranes." Journal of Membrane Science 115(1): 31-
47. 
Vasey, P. A., S. B. Kaye, et al. (1999). "Phase I clinical and pharmacokinetic study of 
PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First 
member of a new class of chemotherapeutic agents - Drug-polymer conjugates." 
Clinical Cancer Research 5(1): 83-94. 
Vazquez-Dorbatt, V. and H. D. Maynard (2006). "Biotinylated glycopolymers 
synthesized by atom transfer radical polymerization." Biomacromolecules 7(8): 
2297-302. 
Wang, Y. J., V. Bansal, et al. (2008). "Templated synthesis of single-component polymer 
capsules and their application in drug delivery." Nano Letters 8(6): 1741-1745. 
Watson, K. J., D. R. Anderson, et al. (2001). "Toward polymeric anticancer drug 
cocktails from ring-opening metathesis polymerization." Macromolecules 34(11): 
3507-3509. 
Willert, H. G., G. Buchhorn, et al. (1991). Ultra-high molecular weight polyethylene as 
biomaterial in orthopedic surgery. Toronto ; Lewiston, NY, Hogrefe & Huber 
Publishers. 
  196 
Wu, M. L., S. A. O'Neill, et al. (2000). "Synthesis of nanometer-sized hollow polymer 
capsules from alkanethiol-coated gold particles." Chemical Communications (9): 
775-776. 
Yang, F., C. G. Williams, et al. (2005). "The effect of incorporating RGD adhesive 
peptide in polyethylene glycol diacrylate hydrogel on osteogenesis of bone 
marrow stromal cells." Biomaterials 26(30): 5991-5998. 
Zelikin, A. N., J. F. Quinn, et al. (2006). "Disulfide cross-linked polymer capsules: En 
route to biodeconstructible systems." Biomacromolecules 7(1): 27-30. 
Zeman, L. J., Zydney, A. L. (1996). Microfiltration and Ultrafiltration Principles and 
Applications. New York, Marcel Dekker. 
Zhang, Q., E. E. Remsen, et al. (2000). "Shell cross-linked nanoparticles containing 
hydrolytically degradable, crystalline core domains." Journal of the American 
Chemical Society 122(15): 3642-3651. 
Zhang, S. (2002). "Emerging biological materials through molecular self-assembly." 
Biotechnology Advances 20(5-6): 321-39. 
 
 
 
